| Excerpt | Reference |
|---|
| "CT staging of bladder neoplasms is a highly accurate procedure with a proven accuracy rate of 81% and a potential accuracy rate probably above 90%." | ( Bryan, PJ; Cohen, WN; Kraus, D; Schoenrock, G; Seidelmann, FE; Temes, SP, 1978) |
| "Bladder cancer is a potentially preventable disease and an important one, as indicated by the total number of cases and the extent of morbidity and death attributable to it around the world." | ( Cohen, SM; Johansson, SL, 1992) |
| "A case of cancer of the bladder is reported in a patient treated 5 years previously with cyclophosphamide for membranoproliferative glomerulonephritis." | ( Court, BH; Culine, S; Droz, JP; Ghosn, M; Hayat, M; Lupera, H; Perrin, JL, 1990) |
| "The treatment of bladder cancer is one of the most active areas of clinical cancer research." | ( Torti, FM, 1987) |
| "The treatment of bladder cancer is in a state of evolution." | ( Bosl, GJ; Nanus, DM, 1989) |
| "Then, the risk of bladder tumors is estimated to be between 0." | ( Gaylor, DW; Kadlubar, FF; West, RW, 1988) |
| "Although metastatic bladder cancer is difficult to treat effectively, chemotherapy combinations and schedules have emerged recently that can result in long-lasting complete responses in some patients." | ( Hrushesky, WJ; Roemeling, RV, 1986) |
| "The incidence of bladder cancer is unusually high in aluminium smelter workers." | ( Cordier, S; Gingras, S; Thériault, G; Tremblay, C, 1984) |
| "The incidence of bladder cancer is slowly rising, which may be due in part to the increasing use of chemicals in every phase of our modern society." | ( Soloway, MS, 1983) |
| "Most superficial bladder tumors are best treated by transurethral resection." | ( Englander, L; Huben, RP; McGill, W; Pontes, JE; Wajsman, Z, 1983) |
| "Chemotherapy for bladder cancer is administered either in an adjuvant setting or in patients with metastatic disease, most of whom have been treated already with cystectomy and/or radiation." | ( Dougherty, WE; Lynch, JH; Maxted, WC, 1984) |
| "The BBN model of bladder cancer is an excellent model of human urinary bladder cancer and has already led to a greater knowledge of its pathogenesis." | ( Fukushima, S; Hasegawa, R; Imaida, K; Ito, N; Nakanishi, K; Shirai, T, 1983) |
| "Bladder cancer is a chemosensitive tumour, however, there is no effective therapy for patients with metastatic disease who failed to respond or relapsed after prior treatment with cisplatin-based chemotherapy." | ( Aitken, SE; Huan, SD; Stewart, DJ, 1995) |
| "Advanced bilharzial bladder cancer is relatively sensitive to combination chemotherapy, but complete remission and prolonged survival is rare in this subgroup of patients with advanced disease." | ( Abu Rabia, A; el-Attar, I; el-Said, A; Gaafar, R; Gad el-Mawla, N; Hamza, MR; Khaled, HM; Magrath, I, 1996) |
| "Bladder cancer is associated with smoking." | ( Cottell, DC; de Feijter-Rupp, HL; Hayashi, T; Lyng, FM; Mothersill, C; Murphy, DM; O'Malley, K; Seymour, CB; Trosko, JE, 1996) |
| "In Bombay, bladder cancer is very uncommon in the first three decades of life; but after the age of 30, the incidence rates increase with age, in log-linear fashion, in both sexes." | ( Jussawalla, DJ; Yeole, BB, 1997) |
| "Many bladder cancers are indolent, and since there are no biomarkers to predict progression, the prognosis is problematic." | ( Butler, MA; Cheever, K; DeBord, DG; Kanitz, MH; Reid, T; Savage, RE; Snawder, J; Swaminathan, S; Werren, D, 1998) |
| "Superficial bladder cancer is characterized by a high incidence of recurrence and a low risk of progression." | ( Grossman, HB, 1998) |
| "Bladder cancer is strongly related to tobacco use and is estimated to cause 54,500 new cancer cases and 11,700 deaths in the United States in 1998." | ( Grossman, HB; Lerner, SP; Lippman, SM; Sabichi, AL, 1998) |
| "T1G3 superficial bladder cancer is considered to be at high risk for progression, and in some institutions early cystectomy is advocated." | ( Bono, AV; Lovisolo, JA; Saredi, G, 2000) |
| "Close to 75% of all bladder tumors are confined to the urothelium (stage Ta, or carcinoma in situ), and nearly 30% of papillary tumors invade the lamina propria (stage T1)." | ( Baselli, EC; Greenberg, RE, 2000) |
| "Bladder cancer is a frequently occurring tumour in Spain and usually affects elderly patients with renal impairment." | ( Carles, J; Domènech, M; Guasch, I; Ibeas, R; Nogué, M; Pérez, C; Saigí, E; Villadiego, K, 2000) |
| "Recurrent bladder cancer is due to tumor cell implantation, incomplete resection, and multicentric neoplastic changes throughout the bladder." | ( Frimberger, D; Hofstetter, A; Zaak, D, 2000) |
| "Superficial bladder cancer is a major target for chemoprevention." | ( Clifford, JL; Kelloff, GJ; Lippman, SM; Lotan, R; Sabichi, AL; Steele, VE; Yang, X; Zou, C, 2001) |
| "Bladder cancer is a common genitourinary malignancy and carcinoma in situ (CIS) of the bladder exists as a potentially aggressive variant of the superficial form of the disease." | ( Kim, JC; Steinberg, GD, 2001) |
| "Invasive bladder cancer is a chemotherapy-sensitive neoplasm." | ( Malkowicz, SB; Vaughn, DJ, 2001) |
| "Bladder cancer is a common tumor in our population (Spain), usually affecting elderly patients with comorbid diseases and renal impairment." | ( Carles, J; Nogué, M, 2001) |
| "Muscle-invasive bladder cancer is typically an aggressive solid tumor with the propensity for early systemic dissemination." | ( Dreicer, R, 2001) |
| "The curability of bladder cancer is directly related to the pathologic stage of the primary tumor." | ( Sun, W; Vaughn, DJ, 2001) |
| "Bladder cancer is a disease that occurs late in life (> 50% of the patients in Germany are 70 years or older)." | ( Weissbach, L, 2001) |
| "The development of bladder cancer is one such example." | ( McKenzie, GH; Moriarty, HT; Webster, LR, 2002) |
| "The diagnosis of bladder cancer is confirmed by histological analysis of tissue biopsies." | ( Barlandas-Rendón, E; García-Latorre, E; Heinschink, A; Müller, MM, 2002) |
| "Bladder cancer is an urologic common tumor after prostatic carcinoma." | ( Chrétien, Y; Durdux, C; Oudard, S, 2003) |
| "Bladder cancer is one of the most common malignant tumor." | ( Dai, G; Wang, X, 2003) |
| "Bladder cancer is the second most common genitourinary tumour and is a significant cause of morbidity and mortality." | ( Hussain, SA; James, ND, 2003) |
| "Bladder cancer is the fourth most common malignant neoplasm in men and the tenth most common in women." | ( Emerk, K; Mutlu, N; Turkeri, L, 2003) |
| "Bladder cancer is the fourth and eighth most common cancer in men and women in the United States, respectively." | ( Agarwal, C; Agarwal, R; Glode, LM; Shroyer, KR; Singh, RP; Tyagi, AK, 2003) |
| "Bladder cancer is a common disease of the genitourinary tract for which the development of a noninvasive detection technique would have a significant impact on disease management." | ( Barder, T; Getzenberg, RH; Konety, BR; Myers, J; Van Le, TS, 2004) |
| "Bladder cancer is the fourth and eighth most common cancer in men and women in the USA, respectively." | ( Agarwal, C; Agarwal, R; Glode, LM; Harrison, G; Tyagi, A, 2004) |
| "Bladder cancer is an excellent model for testing this approach; however, comprehending the strategy for biomarker selection and analysis is more complicated than is generally appreciated." | ( Hemstreet, GP; Wang, W, 2004) |
| "Bladder cancer is the most common disease among urogenital tumors, and poorly differentiated bladder transitional cell carcinoma (BTCC) tends to recur, progress, and metastasize." | ( Han, H; Li, YH; Liu, ZW; Qin, ZK; Wang, B; Wang, H; Yu, SL; Zhou, FJ, 2004) |
| "Bladder cancer is one of the most important diseases associated with arsenic (As) exposure in view of its high prevalence and mortality rate." | ( Cebrián, ME; Córdova, E; Del Razo, LM; Garrido, E; Hernández-Zavala, A, 2005) |
| "Bladder cancer is a common cancer with high risk of recurrence and mortality." | ( Chang, JS; Kim, JA; Lee, JS; Lee, JY, 2004) |
| "Bladder cancer is a frequent disease and represents the second most common genitourinary neoplasm." | ( Bachmann, A; Hartmann, A; Karl, A; Knüchel, R; Popken, G; Reich, O; Siebels, M; Stepp, H; Stief, C; Zaak, D, 2005) |
| "Bladder cancer is regarded as a promising candidate for innovative therapies in the field of immune and gene therapy." | ( Alimohammadi, M; Hedlund, T; Loskog, A; Malmström, PU; Ninalga, C; Tötterman, TH, 2005) |
| "Bladder cancer is the fifth most common cancer among men and the seventh among women." | ( Adamo, B; Adamo, V; Alafaci, E; Garipoli, C; Magno, C; Maisano, C; Rossello, R; Scandurra, G; Scimone, A; Spitaleri, G, 2005) |
| "Bladder cancer is a relatively common tumor in the urinary system, in which mitomycin C (MMC)-based chemotherapy or combination chemotherapy has been mainly used to treat patients with advanced bladder cancer." | ( Guan, KP; He, LF; Hou, SK; Ren, L; Xu, KX; Yan, Z; Ye, HY, 2005) |
| "Bladder cancer is mostly superficial at first diagnosis." | ( Bhuiyan, ZH; Islam, MA; Shameem, IA, 2006) |
| "Bladder cancer is a malignant disease with exogenous and thus avoidable causative factors." | ( Goebell, PJ; Golka, K; Rettenmeier, AW, 2006) |
| "Nonmuscle-invasive bladder cancer is a common malignancy, standardly treated by transurethral resection and adjuvant intravesical instillations of chemotherapy or immunotherapy." | ( Hendricksen, K; Witjes, JA, 2006) |
| "Bladder cancer is the fifth most common cancer in the Western world and is on the rise." | ( Haas, GP; Jones, K; Landas, S; Shapiro, O; Wang, C, 2006) |
| "Bladder cancer is the fourth most common cancer in men and ninth most common in women." | ( Bai, Y; Dahiya, R; Li, LC; Qin, J; Shen, HF; Wang, YB; Xie, LP; Zheng, XY, 2007) |
| "Urothelial cancer of the bladder is a frequent disease, and urinary cytology often is used as a routine diagnostic tool." | ( Karl, A; Meier, R; Stepp, H; Stief, CG; Tauber, S; Tritschler, S; Zaak, D, 2007) |
| "Bladder cancer is the fourth most common malignant disease worldwide, accounting for 4% of all cancer cases." | ( Chin, WW; Fu, CY; Lau, WK; Ng, BK; Olivo, M; Razul, SG; Tan, PH, 2007) |
| "Non-muscle-invasive bladder cancer is labor intensive and costly to manage." | ( Douglass, J; Witjes, JA, 2007) |
| "Bladder cancer is a frequent disease and represents the second most common genitourinary neoplasm." | ( Burger, M; Karl, A; Knuechel, R; Stepp, H; Stief, C; Tilki, D; Tritschler, S; Zaak, D, 2007) |
| "Bladder cancer is a chemoresponsive disease and should be dealt with in a multimodality approach." | ( Akaza, H; Miyanaga, N, 2007) |
| "Bladder cancer is a heterogeneous and frequent disease." | ( Kolli, PS; Witjes, JA, 2008) |
| "Superficial bladder cancers are usually managed with transurethral resection followed by the intravesical administration of Bacillus Calmette-Guerin which requires major histocompatibility complex (MHC) class I expression on cancer cells." | ( Ashihara, E; Habuchi, T; Kimura, S; Maekawa, T; Maita, S; Sato, K; Takeuchi, M; Tsuchiya, N; Yuasa, T, 2009) |
| "Bladder cancer is the second common cancer of the genitourinary system throughout the world and intravesical chemotherapy is usually used to reduce tumour recurrence and progression." | ( Bahrami, AR; Behnam Rassouli, F; Iranshahi, M; Matin, MM; Mollazadeh, S; Neshati, V; Neshati, Z, 2009) |
| "Bladder cancer is a common but serious malignancy." | ( Hamada, M; Liu, J; Sugiura, N; Takahashi, S; Xing, G; Zhang, P; Zhang, Z, 2008) |
| "Bladder cancer is a disease with a high prevalence due to its recurrence rate." | ( Alvarez Múgica, M; Escaf Bramada, S; Fernández Gómez, JM; García Rodríguez, J; Jalón Monzón, A; Regadera Sejas, FJ, 2008) |
| "Bladder cancer is a potentially curable malignancy but for those patients who present with or develop muscle-invasive disease, there is a high risk of metastases and cancer-related death." | ( Bajorin, DF; Milowsky, MI; Stadler, WM, 2008) |
| "High grade invasive bladder cancer is a leading cause of cancer deaths and treatment options are limited for this type of cancer." | ( Byun, SS; Khandrika, L; Kim, FJ; Koul, HK; Koul, S; Kumar, B; Wilson, S, 2009) |
| "Non-muscle invasive bladder cancer is the most expensive cancer to manage on a per patient basis due to the high recurrence rate, low mortality and the need for long term, often lifelong surveillance." | ( Bunce, CJ; Dindyal, S; Nitkunan, T, 2008) |
| "Bladder cancer is not only a major public health and economically burden for the patients but also a major clinical impact for Thai urologists." | ( Chavasiri, W; Gritsanapan, W; Muangman, V; Supabphol, A; Supabphol, R, 2009) |
| "Bladder cancer is a very common and aggressive tumor entity." | ( Hakenberg, OW; Protzel, C, 2009) |
| "Bladder cancer is the sixth most prevalent malignancy in the United States." | ( Ksheersagar, P; Sharma, P; Sharma, S, 2009) |
| "Urinary bladder cancer is a heterogeneous disease with tumors ranging from papillary noninvasive (stage Ta) to solid muscle infiltrating tumors (stage T2+)." | ( Busch, C; Díaz de Ståhl, T; Dumanski, JP; Komorowski, J; Malmström, PU; Menzel, U; Nord, H; Sandgren, J; Segersten, U; Wester, K, 2010) |
| "Non-muscle invasive bladder cancer is one of the most prevalent and incident neoplastic conditions in the Western world." | ( Oliva Encina, J; Rioja Sanz, C, 2009) |
| "Bladder cancer is one of the common human cancers and also has a very high recurrence rate." | ( Bhattacharya, A; Chen, SC; Geng, F; Li, Y; Paonessa, JD; Tang, L; Wong, MK; Zhang, Y, 2010) |
| "Bladder cancer is the ninth most common malignancy in the world." | ( He, Y; Liu, G; Ma, Y; Tang, W; Zhou, S, 2009) |
| "Urinary bladder cancer is a major epidemiological problem that continues to grow each year." | ( Dalela, D; Goel, A; Kumar, P; Roy, R; Sankhwar, SN; Singh, S; Sonkar, AA; Srivastava, S, 2010) |
| "Bladder cancer is a heterogeneous disease: approximately 75% of its forms are non muscle invasive neoplasms." | ( Bassi, PF; Cappa, E; D'Agostino, D; Filianoti, A; Racioppi, M; Volpe, A, 2010) |
| "Bladder cancer is a major health problem in Egypt as it represents the most common malignancy." | ( Ali, MH; Elhadidy, GS; Hassoba, HM; Mahmoud, MA, 2010) |
| "Aggressive bladder cancer is a major cause of morbidity and mortality." | ( Kim, C; Kim, EY; Kim, JH; Lee, JE; Lee, KM; Seo, JM, 2010) |
| "Bladder cancer is one of the most common malignancies in the world." | ( Chen, RJ; Ho, CT; Wang, YJ, 2010) |
| "Urinary bladder cancer is one of the most common cancers worldwide." | ( Bahrami, AR; Behnam-Rassouli, F; Iranshahi, M; Matin, MM; Mollazadeh, S; Neshati, V, 2010) |
| "Bladder cancer is a highly recurrent cancer after intravesical therapy, so new drugs are needed to treat this cancer." | ( Lin, YW; Liu, YW; Shee, JJ; Shen, CH; Wu, JD; Wu, JY, 2010) |
| "Bladder cancer is the fourth more frequent tumour in men." | ( Cantiani, A; Cicione, A; De Nunzio, C; Franco, G; Leonardo, C; Leonardo, F; Rondoni, M; Tubaro, A, 2011) |
| "Bladder cancer is an urologic common tumor after prostate carcinoma." | ( Denis, F; Durdux, C; Klotz, S; Pointreau, Y, 2010) |
| "Bladder cancer is common worldwide and the fourth most commonly diagnosed malignancy in men in Argentina." | ( Diaz, Mdel P; Osella, AR; Pou, SA, 2011) |
| "Bladder cancer is associated with enhanced inflammation and characterized by deregulated prostanoid metabolism." | ( Daaka, Y; Daurkin, I; Eruslanov, E; Kusmartsev, S; Vieweg, J, 2011) |
| "Bladder cancer is approximately three times more common in men as compared to women." | ( Downes, MJ; Gudas, LJ; Kauffman, EC; Lee, MM; Mongan, NP; Powell, LG; Robinson, BD; Scherr, DS, 2011) |
| "Urinary bladder cancer is two to four times more common among men than among women, a difference in risk not fully explained by established risk factors." | ( Bernstein, L; Castelao, JE; Conti, DV; Cortessis, VK; Davis-Dao, CA; Gago-Dominguez, M; Henderson, KD; Ma, H; Pike, MC; Stern, MC; Sullivan-Halley, J; West, D; Xiang, YB, 2011) |
| "Bladder cancer is one of the most common malignancies and causes hundreds of thousands of deaths worldwide each year." | ( Abrams, J; Wang, G; Wang, L; Xu, XS, 2011) |
| "Bladder cancer is the second most common malignancy of urologic tumors." | ( Bach, T; Gross, AJ; Herrmann, TR; Imkamp, F; Kramer, MW; Kuczyk, MA; Merseburger, AS; Wolters, M, 2011) |
| "Bladder cancer is the ninth most common type of cancer, and its surgery is always followed by chemotherapy to prevent recurrence." | ( Fan, Y; Feng, J; Hou, L; Liu, C; Liu, Z; Xu, Z; Yan, K; Yan, L; Zhang, C; Zheng, B; Zhou, Z, 2011) |
| "Bladder cancer is the second most common malignancy of the genito-urinary system." | ( , 2011) |
| "Bladder cancer is a common urothelial cancer." | ( Chang, CC; Chang, KJ; Chen, CN; Chen, ST; Hsu, WM; Lee, H; Lu, YC; Wang, B, 2011) |
| "Bladder cancer is the most common urological cancer with higher incidence rates in endemic areas of Blackfoot disease (BFD) in southern Taiwan." | ( Chen, SC; Chen, WC; Chu, PY; Chung, TW; Kan, WC; Su, SB; Tan, LB; Tyan, YC; Wang, HY; Yang, MH, 2011) |
| "Bladder cancer is often associated with recurrence and progression to invasive metastatic disease that have palliative therapeutic options." | ( Arora, S; Chen, Y; Dahiya, R; Deng, G; Majid, S; Saini, S; Shahryari, V; Ueno, K; Yamamura, S, 2011) |
| "Bladder cancer is the most common urological cancer with higher incidence rate in the endemic areas of Blackfoot disease (BFD) in southern Taiwan." | ( Chen, SC; Chen, WC; Chung, TW; Jong, SB; Liao, PC; Tyan, YC; Yang, MH; Yang, YH, 2011) |
| "Bladder cancer is one of the most common urogenital malignancies." | ( Eto, M; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tanaka, S; Tatsugami, K; Yokomizo, A, 2012) |
| "Urinary bladder cancer is often a result of exposure to chemical carcinogens such as cigarette smoking." | ( Bae, SC; Kim, J; Kim, SK; Kim, WJ; Lee, OJ; Yun, SJ, 2011) |
| "Non-muscle invasive bladder cancer is the most common type of bladder cancer in Western countries." | ( Abbruzzese, A; Altieri, V; Buonerba, C; Caraglia, M; Di Lorenzo, G; Facchini, G; Ferro, M; Giuberti, G; Perdonà, S; Porto, S; Sperlongano, P; Zappavigna, S, 2012) |
| "Bladder cancer is the most prevalent tumor in the genitourinary tract and the current treatments are not efficient to prevent recurrence and progression of tumor cases." | ( Barrios, CH; Bavaresco, L; Bueno Morrone, F; Cappellari, AR; Fernandes Farias, P; Oliveira Battastini, AM; Rockenbach, L, 2013) |
| "Bladder cancer is one of the few cancers that have been linked to carcinogens in the environment and tobacco smoke." | ( Guttenplan, JB; He, Z; Kosinska, W; Wu, XR; Zhao, ZL, 2012) |
| "Bladder cancer is highly recurrent after intravesical therapy, and most of the deaths from this disease are due to invasive metastasis." | ( Chen, SS; Huang, CC; Lin, PY; Lin, YL; Liu, YW, 2012) |
| "Invasive bladder cancer is a lethal disease for which effective prognostic markers as well as potential therapy targets are still lacking." | ( Chen, K; Li, J; Li, Y; Liao, W; Liu, L; Liu, Z; Song, L; Wu, Y; Yu, C; Zhang, Z; Zhao, X; Zhong, Y; Zhou, F, 2012) |
| "Superficial bladder cancer is often multifocal, has high recurrences after surgical resection and recurs after intravesical live Bacillus Calmette-Guérin." | ( Annels, NE; Coffin, RS; Harrington, KJ; Horvath, A; Melcher, AA; Metcalf, S; Mostafid, H; Pandha, HS; Pencavel, T; Peschard, P; Price, T; Seth, R; Simpson, GR, 2012) |
| "Given that bladder cancer is characterized by initial localized presentation in the vast majority of cases, the paradigm of neoadjuvant therapy may expedite the development of novel systemic agents." | ( Sonpavde, G; Sternberg, CN, 2012) |
| "However, bladder cancer is characterized by chemoresistance." | ( Catto, JW; Drayton, RM, 2012) |
| "In Belgium, bladder cancer is the fifth most common cancer in males (5." | ( Ackaert, K; Ameye, F; Billiet, I; Braeckman, J; Breugelmans, A; Buntinx, F; Darras, J; Dilen, K; Goeman, L; Goossens, ME; Joniau, S; Kellen, E; Tombal, B; Van Bruwaene, S; Van Cleyenbreuge, B; Van der Aa, F; Van Poppel, H; Vekemans, K; Zeegers, MP, 2012) |
| "Bladder cancer is one of the most common tumors of the genitourinary tract; however, the molecular events underlying growth and invasion of the tumor remain unclear." | ( Bo, J; Chen, X; Hao, M; Hou, K; Lu, X; Shen, K; Wang, J; Xu, C; Zheng, J, 2012) |
| "Bladder cancer is the most common neoplasm in the urinary system." | ( Feng, S; Li, X; Liu, Y; Lv, X; Ma, J; Xiao, J; Yang, H; Yang, S; Zhang, Y, 2012) |
| "Although bladder cancer is considered a chemosensitive disease, the prognosis of patients with metastatic disease is still poor with median survival being approximately 12-14 months in good prognosis patients and with cure in only a minority of patients." | ( Calabrò, F; Sternberg, CN, 2012) |
| "Bladder cancer is one of the most common urogenital malignancies." | ( Hirata, T; Huh, NH; Kaku, H; Kobayashi, Y; Kumon, H; Nasu, Y; Sakaguchi, M; Takei, K; Watanabe, M; Yamada, H, 2012) |
| "Diagnosis of bladder cancer is done by cystoscopy and cytology." | ( Eissa, S; El-Ahmady, O; Esmat, M; Mansour, A; Shehata, H, 2012) |
| "Bladder cancer is a common malignancy worldwide." | ( Brassesco, MS; da Silva, GN; de Oliveira, HF; de Oliveira, JC; Morales, AG; Pezuk, JA; Scrideli, CA; Tone, LG; Umezawa, K; Valera, ET, 2012) |
| "Muscle-invasive bladder cancer is associated with a high frequency of metastasis, and bone is the most common metastatic site outside the pelvis." | ( Chen, Y; Fan, J; He, D; Hsieh, JT; Li, L; Ning, Z; Wang, X; Wu, K; Zeng, J; Zhang, L; Zhang, T; Zhou, J, 2012) |
| "Bladder cancer is an uncommon disease, transitional tumors being the only histological type observed." | ( Khuraijam, S; Kipgen, P; Laishram, RS; Laishram, S; Sharma, DC, 2012) |
| "Bladder cancer is the fourth most common cancer in males and the ninth most common in females." | ( Bai, Y; Kong, D; Lin, Y; Mao, Q; Qin, J; Wang, Y; Xie, L; Yang, K; Zheng, X, 2012) |
| "Bladder cancer is the fifth most common type of cancer in the USA, with over 70,000 new cases diagnosed each year." | ( Hoffman, KL; Lerner, SP; Smith, CL, 2013) |
| "Bladder cancer is one of the leading lethal cancers worldwide." | ( Bonney, P; Knapp, DW; Liu, L; Nagana Gowda, GA; Raftery, D; Stewart, J; Wei, S; Zhang, J, 2012) |
| "Bladder cancer is the fifth most common cancer in the United States, and identifying genetic markers that may predict susceptibility in high-risk population is always needed." | ( Aldousari, S; Dinney, CP; Huang, M; Kamat, AM; Wei, H; Wu, X; Ye, Y, 2012) |
| "Bladder cancer is the most common cancer in the urological tract." | ( He, B; Ren, J; Tang, W; Tang, Z; Xiao, X; Yin, X; Yu, B, 2013) |
| "Non-muscle-invasive bladder cancer is characterized by frequent recurrences requiring repeated transurethral resections and carries a risk of progression to muscle-invasive disease." | ( Dekel, Y; Freifeld, Y; Stein, A, 2013) |
| "Urinary bladder cancer is one of the most common cancers worldwide, with the highest incidence in industrialized countries." | ( Cunha, MF; Fernandes, JC; Garrido, P; Parada, B; Pintado, ME; Reis, F; Santos-Silva, A; Sereno, J, 2012) |
| "Bladder cancer is the most common malignant urological disease in China." | ( Fu, Q; Gao, JY; Gao, XP; Lei, YH; Li, JQ; Li, YM; Shao, C; Shi, CH; Shi, JG; Wang, H; Wang, JY; Wang, Y; Xu, P; Xue, W; Yuan, JL; Zhang, W; Zhang, YT, 2013) |
| "Human urinary bladder cancer is the fifth most common cancer in the United States, and the long-term disease-free survival in patients is still suboptimal with current chemotherapeutic regimens." | ( Choudhary, S; Sood, S; Wang, HC, 2013) |
| "Bladder cancer is the most common tumor of the urinary tract, with a worldwide incidence of 8." | ( Ambrosini, E; Frea, B; Giona, S; Gontero, P; Gurioli, A; Oderda, M; Peraldo, F; Soria, F, 2013) |
| "Bladder cancer is a common urological malignancy with high recurrence rate, which may be reduced by chemoprevention." | ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Muscle-invasive bladder cancer is associated with a high frequency of metastasis, and fewer therapies substantially prolong survival." | ( Chen, Y; Fan, J; Gao, Y; Guo, P; He, D; Li, L; Ning, Z; Wang, B; Wang, X; Wu, K; Zeng, J; Zhang, L; Zhang, T; Zhou, J, 2013) |
| "Bladder cancer is the second cause of death for urological tumors in man." | ( Belgorosky, D; Colombo, L; Eiján, AM; Langle, Y; Prack Mc Cormick, B; Sandes, E, 2014) |
| "Urothelial bladder cancer is the ninth most common cancer." | ( Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F, 2013) |
| "Bladder cancer is one of the most prevalent genitourinary malignancies." | ( Barrios, CH; Battastini, AM; Bertola, G; Dietrich, F; Figueiró, F; Gerhardt, D; Moreira Fonseca, JC; Morrone, FB; Salbego, CG; Zanotto-Filho, A, 2014) |
| "Bladder cancer is a common cancer worldwide." | ( Dancik, GM; Theodorescu, D, 2014) |
| "Human urinary bladder cancer is the fifth most common cancer, with a worldwide estimate of about two million patients." | ( Cho, BW; Choi, YH; Darvin, P; Joung, YH; Kang, DY; Kim, HS; Kim, SY; Lee, HK; Na, YM; Park, JH; Park, KD; Sp, N; Yang, YM; Yoo, YB, 2014) |
| "Metastatic bladder cancer is a serious condition with a 5-year survival rate of approximately 14 %, a rate that has remained unchanged for almost three decades." | ( Andresen, CJ; Bagi, CM; Cirone, P; Eswaraka, JR; Lappin, PB, 2014) |
| "Bladder cancer is one of the few cancers that have been linked to carcinogens in the environment and tobacco smoke." | ( Scherr, DS, 2014) |
| "Bladder cancer is the second most prevalent malignancy in the genitourinary tract and remains a therapeutic challenge." | ( Battastini, AM; Bergamin, LS; da Cunha, FM; Dietrich, F; Figueiró, F; Kaiser, S; Morrone, FB; Ortega, GG; Rockenbach, L, 2014) |
| "Bladder cancer is among the most aggressive human malignant carcinoma and always showed resistance to traditional chemotherapy based on DNA damaging drugs." | ( Ding, D; Liu, Z; Shan, L; Zhang, S; Zhang, X, 2014) |
| "Human bladder cancer is an aggressive tumor which frequently resists chemotherapy." | ( Li, X; Zhao, B, 2014) |
| "Nonmuscle invasive bladder cancer is characterized by a high recurrence rate." | ( Arends, TJ; van der Heijden, AG; Witjes, JA, 2014) |
| "Bladder cancer is the ninth most common cancer in the world; fewer than 15% of transitional-cell carcinoma patients survive 2 years if left untreated." | ( Dong, P; Han, H; Jiang, L; Li, Y; Liu, Z; Qin, Z; Yao, K; Yao, M; Zhang, Z; Zhou, F, 2014) |
| "Bladder cancer is associated with high rates of recurrence making tertiary chemoprevention an attractive intervention strategy." | ( Brown, K; Higgins, JA; Jones, GD; Zainol, M, 2014) |
| "Bladder cancer is a major public health problem worldwide, with relatively high morbidity." | ( Chen, T; Jiang, X; Xi, Z; Yan, S; Yang, X, 2014) |
| "Bladder cancer is a significant disease, the rates of which have increased over the few last years." | ( Feki-Tounsi, M; Hamza-Chaffai, A, 2014) |
| "Bladder cancer is highly recurrent following specific transurethral resection and intravesical chemotherapy, which has prompted continuing efforts to develop novel therapeutic agents and early-stage diagnostic tools." | ( Chan, HL; Chen, YY; Chuang, JJ; Dai, YC; Lin, WH; Lin, YL; Liu, YW, 2014) |
| "Bladder cancer is one of the causes of cancer‑related death and has a high mortality rate due to its metastatic ability." | ( Hseu, YC; Hsu, LS; Huang, YC; Kuo, CC; Liao, AC; Liu, JY; Yeh, CW, 2014) |
| "Bladder cancer is the most common malignant tumor of the urinary tract and remains one of the major causes of cancer death worldwide." | ( Wang, ZZ; Xue, J; Zuo, W, 2014) |
| "Bladder cancer is the sixth most common cancer in humans." | ( Batourina, E; Cordon-Cardo, C; Dan, H; Dunlop, M; Mansukhani, M; Mendelsohn, C; Molotkov, A; Oyon, D; Schneider, K; Van Batavia, J; Wu, XR; Yamany, T, 2014) |
| "Bladder cancer is the fourth most commonly diagnosed cancer in men and eighth leading cause of cancer-related death in the US." | ( Glenn, ST; Hu, Q; Johnson, CS; Liu, S; Luo, W; Ma, Y; Pratt, RN; Trump, DL, 2015) |
| "Non-muscle invasive bladder cancer is treated with intravesical chemotherapy (IVC) after transurethral resection (TUR) to reduce the probability of recurrence." | ( Endo, H; Inoue, M; Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, H; Yoshida, T, 2015) |
| "Bladder cancer is a significant health problem in rural areas of Africa and the Middle East where Schistosoma haematobium is prevalent, supporting an association between malignant transformation and infection by this blood fluke." | ( Brindley, PJ; Correia da Costa, JM; Fernandes, E; Ferreira, JA; Lima, L; Lopes, C; Parreira, B; Peixoto, A; Santos, J; Santos, LL; Tavares, A, 2014) |
| "Bladder cancer is a disease of the elderly." | ( Chau, C; Crabb, SJ; Geldart, T; Wheater, M, 2015) |
| "Bladder cancer is among the five most common malignancies worldwide." | ( Abou Farha, MO; Gaballah, HH; Shafik, NM; Wasfy, RE, 2015) |
| "Bladder cancer is a highly recurrent disease in need of novel, durable treatment strategies." | ( Katz, MD; Koppolu, BP; Kurtz, SL; Ravindranathan, S; Smith, SG; Yang, L; Zaharoff, DA, 2015) |
| "Bladder cancer is the most expensive cancer to treat from diagnosis to death." | ( Greene, PS; Johnson, DC; Nielsen, ME, 2015) |
| "Bladder cancer is the most common malignancy in urinary system and the ninth most common malignancy in the world." | ( Chen, JX; Chen, LW; Huang, B; Liao, J; Mao, XP; Qiu, SP; Zhang, LS; Zhou, SY, 2015) |
| "Bladder cancer is a common malignancy worldwide." | ( Fang, KM; Huang, CF; Huang, KT; Lai, CH; Lee, KI; Liu, SH; Lu, TH; Su, CC; Su, YC; Wu, CC; Yen, CC, 2015) |
| "Urinary bladder cancer is one of the most fatal and expensive diseases of industrialized world." | ( Anastasiadou, E; Balafas, E; Basogianni, AS; Konstantakou, EG; Kostomitsopoulos, N; Paronis, E; Stravopodis, DJ; Syrigos, KN; Velentzas, AD; Voutsinas, GE, 2015) |
| "Bladder cancer is the second most common urological malignancy around the world and is by far the most frequent urological malignancy in China." | ( Chen, S; Fu, X; Li, Y; Pang, X; Qi, H; Tan, W, 2016) |
| "Bladder cancer is a common malignant tumor with a very high recurrence rate after surgery." | ( Ren, L; Wang, J; Yang, X; Zhang, H; Zhao, L, 2016) |
| "Bladder cancer is a common malignancy for which regional or metastatic disease is identified at diagnosis." | ( Jinesh, GG; Kamat, AM; Mmeje, CO; Takeuchi, H; Taoka, R, 2015) |
| "Bladder cancer is the health end point used by the United States Environmental Protection Agency (EPA) in its benefits analysis for regulating disinfection byproducts in drinking water." | ( Chen, J; Elovitz, MS; Letkiewicz, FJ; Messner, M; Pegram, RA; Pepping, TJ; Regli, S; Richardson, SD; Wright, JM, 2015) |
| "Bladder cancer is one of the most commonly diagnosed urological malignancies." | ( Cao, JW; Chen, L; Cui, XG; Gao, Y; Hong, Y; Huang, H; Huang, Y; Li, L; Pan, XW; Ren, JZ; Xu, DF, 2016) |
| "Albeit bladder cancer is one of the most common malignancies worldwide, it has been rarely reported among HIV-infected patients." | ( Chawki, S; Desgrandchamps, F; Molina, JM; Mongiat-Artus, P; Montlahuc, C; Ploussard, G; Verine, J, 2015) |
| "Bladder cancer is the ninth most common cancer around the world, and is a severe urological cancer irrespective of sex." | ( Chia, CH; Chiu, KY; Hsu, SL; Tzeng, YM; Wu, CC, 2016) |
| "Bladder cancer is one of the leading causes of cancer-related death in the world." | ( Deng, QF; Geng, H; Liang, ZF; Sun, X; Wang, Y; Xie, DD; Yu, DX; Zhang, ZQ; Zhao, L; Zhong, CY, 2016) |
| "Bladder cancer is a common type of cancer with an estimated incidence of more than 70,000 patients and had a mortality of 16,000 patients in the US in 2015." | ( Boegemann, M; Krabbe, LM; Schlack, K; Schrader, AJ; Steinestel, J, 2016) |
| "Bladder cancer is a major cause of cancer-related mortality, with an estimated 74,000 new cases and 16,000 deaths in the United States in 2015." | ( Buonerba, C; De Placido, S; Di Lorenzo, G; Pagliuca, M; Perillo, T; Verde, A; Zarrella, A, 2016) |
| "Bladder cancer is a common genitourinary malignant disease worldwide." | ( Deng, QF; Liang, ZF; Sun, X; Yu, DX; Zhang, ZQ; Zhong, CY, 2016) |
| "Bladder cancer is the most prevalent malignancy of the urinary tract and is associated with significant morbidity and mortality." | ( Khajeh, NR; Khoyilar, C; Spradling, K; Wu, Y; Youssef, RF; Zi, X, 2018) |
| "Bladder cancer is a significant clinical and economic problem." | ( Chang, IH; Chi, BH; Choi, SS; Kim, KD; Kim, SU; Lee, HJ; Lee, SR, 2016) |
| "Bladder cancer is observed worldwide having been associated with a host of environmental and lifestyle risk factors." | ( Demeter, J; Grabnar, M; Hinds, TD; McBeth, L; Nestor-Kalinoski, A; Nwaneri, AC, 2016) |
| "Bladder cancer is the most common malignancy of the urinary system and is also one of the 10 most common cancers of the human body." | ( Che, X; Chen, F; Chen, X; Li, X; Song, X; Wang, J; Wang, L; Wang, Q; Wang, X; Yang, D; Zhang, Z; Zheng, W, 2016) |
| "Bladder cancer is common and widespread, and its incidence is increasing." | ( Cui, Y; Liu, J; Luo, F; Luo, J; Pang, J; Su, X; Wang, W; Yan, S; Yang, X; Zhang, F, 2016) |
| "Bladder cancer is one of the causes of cancer‑related death and has a high mortality rate." | ( Cao, Y; Chen, H; Gu, Y; He, Y; Hou, Y; Lu, L; Wu, L; Wu, X; Zhu, W, 2016) |
| "Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally." | ( Choi, W; Efstathiou, JA; Guo, CC; Hahn, NM; Kamat, AM; Kassouf, W; Lerner, SP; Lotan, Y; Malmström, PU, 2016) |
| "Urinary bladder cancer is a common malignancy in the West and ranks as the 7th most common cancer in our region of Kashmir, India." | ( Hussain, A; Khan, MS; Pandith, AA; Shah, ZA; Siddiqi, MA; Wani, MS, 2016) |
| "Bladder cancer is one of the most frequent cancers among males, and its poor survival rate reflects problems with aggressiveness and chemo-resistance." | ( Chen, HY; Cheng, HL; Chueh, PJ; Jhuang, FH; Lee, YH; Lin, MH, 2016) |
| "Bladder cancer is the second most common urological malignancy in the world." | ( Derré, L; Domingos-Pereira, S; Gharbi, D; Hojeij, R; Jichlinski, P; Nardelli-Haefliger, D; Nkosi, M; Schiller, JT, 2016) |
| "Bladder cancer is the second commonest urinary tract malignancy with 70-80 % being non-muscle invasive (NMIBC) at diagnosis." | ( Bach, C; Heer, R; Johnson, MI; Persad, R; Veeratterapillay, R, 2016) |
| "Urinary bladder cancer is one of the most frequent cancers worldwide." | ( Lan, Y; Lin, M; Liu, D, 2016) |
| "Bladder cancer is among the five most common cancers diagnosed in the Western world and causes significant mortality and morbidity rates in affected patients." | ( Clozel, T; Elemento, O; Erdem, Z; Hassler, MR; Krzywinski, M; Robinson, BD; Shariat, SF; Xylinas, E; Zhuang, D, 2016) |
| "Bladder cancer is the fifth most common in incidence and one of the most expensive cancers to treat." | ( Adochite, RC; Amin, A; Andreev, GO; Andreev, OA; Brito, JM; Crawford, T; Engelman, DM; Golijanin, D; Golijanin, J; Moshnikova, A; Reshetnyak, YK; Tran, TY, 2016) |
| "Bladder cancer is very common and most cases are diagnosed as nonmuscle invasive disease, which is characterized by its propensity to recur and progress." | ( Celestino, F; De Carlo, F; Di Stasi, SM; Pagliarulo, V; Verri, C, 2016) |
| "Bladder cancer is one of the leading causes of death in Europe and the United States." | ( Bastaros, JM; Carles, J; de Castro, AM; Maldonado, X; Morales-Barrera, R; Morote, J; Racca, F; Suárez, C; Valverde, C, 2016) |
| "Bladder cancer is the second most common cancer of the genitourinary tract, and it has a high rate of recurrence." | ( Jang, J; Jeon, H; Lee, J; Lee, MS; Lee, S; Park, J; Yoo, SM, 2016) |
| "Bladder cancer is the most general malignant cancer in genitourinary system, more than 90% of BCs are bladder transitional cell carcinomas (BTCC)." | ( Guo, Y; Shang, C; Song, Y; Zhang, H, 2017) |
| "Bladder cancer is the most common malignancy of the urinary tract for which the accurate measurement of minimal residual disease is critical to treatment and determining prognosis." | ( Ding, C; Fan, J; Guan, Z; Liu, L; Wang, L; Wang, R; Wang, W; Wang, X; Wu, K, 2017) |
| "Advanced bladder cancer is treated mainly with gemcitabine and cisplatin, but most patients eventually become resistance." | ( Deguchi, T; Fujita, Y; Horie, K; Ito, M; Kameyama, K; Kato, T; Kawakami, K; Kojima, T; Miyazaki, T; Mizutani, K, 2017) |
| "Rat bladder cancer is nearly always papillary non-invasive urothelial carcinoma (UC)." | ( Fujioka, M; Gi, M; Hirayama, Y; Kakehashi, A; Kato, M; Koyama, Y; Nakatani, T; Tachibana, H; Tamada, S; Wanibuchi, H; Yamano, S, 2017) |
| "Worldwide, Bladder cancer is the most frequent male malignancy." | ( Abbar, M; Al Bouzidi, A; Ameur, A; Ameziane El Hassani, R; Attaleb, M; Dakka, N; El Mzibri, M; Hadami, K, 2016) |
| "1) Bladder cancer is one of the most frequent malignancies in the urinary system." | ( Cao, W; Chen, W; Guo, H; Hu, Y; Lian, H; Lin, T; Liu, G; Wu, J; Yuan, A; Zhang, C; Zhang, Q; Zhang, S; Zhao, X; Zhuang, J, 2017) |
| "Bladder cancer is the most commonly malignant tumor in the urogenital tract, only next to prostate cancer with a higher incidence in China." | ( Chen, GX; Deng, N; Pan, ZJ; Zou, ZH, 2017) |
| "Muscle-invasive bladder cancer is an aggressive disease associated with high morbidity and mortality." | ( Khan, MS; Lobo, N; Mount, C; Nair, R; Omar, K; Thurairaja, R, 2017) |
| "Bladder cancer is a neoplasm originated from bladder epithelial cells." | ( Cao, HL; Chang, Z; Liu, ZJ, 2017) |
| "Bladder cancer is among the most common and aggressive human malignant carcinomas, thus targeting and removal of bladder cancer cells is still a challenge." | ( Jerman, UD; Kreft, ME; Veranič, P; Višnjar, T, 2017) |
| "Bladder cancer is the second most common urological malignant disease." | ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018) |
| "Bladder cancer is nowadays a common tumor." | ( Caramés Masana, F; de Reijke, TM, 2017) |
| "Metastatic bladder cancer is an aggressive malignancy with a poor prognosis when presenting with advanced stage." | ( Hamilou, Z; Lavaud, P; Loriot, Y, 2018) |
| "Non-muscle invasive bladder cancer is one of the most common tumors of the urinary tract." | ( Ishi, K; Ishizuka, M; Kudo, N; Morishita, K; Nakamura, K; Nakayama, SMM; Ohta, H; Sasaki, N; Takiguchi, M, 2017) |
| "Bladder cancer is the 7th cause of death from cancer in men and 10th in women." | ( Bellera, C; Cazeau, AL; Goberna, A; Houédé, N; Joly, F; Lortal, B; Mahammedi, H; Mourey, L; Pfister, C; Pourquier, P; Pulido, M; Roubaud, G; Vedrine, L, 2018) |
| "Prostate and bladder cancers are the most commonly detected cancers in men, and are related to cancer death in males." | ( Durán, N; Seabra, AB, 2018) |
| "Diagnosis of bladder cancer is based on urine cytology and white-light cystoscopy (WLC) performed for patients with suspected bladder mass and÷or hematuria." | ( Drăgoescu, NAM; Drăgoescu, PO; Drocaş, AI; Meşină, C; Mititelu, CD; Mitroi, G; Mohamed, G; Pănuş, A; Stănculescu, AD; Tomescu, PI; Tudorache, Ş, 2017) |
| "Bladder cancer is known as the world's ninth most prevalent cancer in 2012." | ( Chen, SC; Huang, HP; Liao, CC; Wang, CJ, 2018) |
| "Urothelial bladder cancer is a very prevalent disease." | ( Martínez-Piñeiro, L; Rios González, E, 2018) |
| "Bladder cancer is one of the most common malignant tumors of the urinary system characterized by a high recurrence rate after treatment." | ( Gong, BS; Li, LJ; Qiu, MX; Wang, Y, 2018) |
| "Non-muscle invasive bladder cancer is one of the most frequent forms of cancer." | ( Apfelthaler, C; Ciola, R; Gabor, F; Skoll, K; Wirth, M, 2018) |
| "Bladder cancer is responsible for more than 130,000 deaths annually worldwide." | ( Baloğlu, E; Çalışkan, Ç; Erzurumlu, Y; Karavana, SY; Özdemir, Dİ; Şen, S; Şenyiğit, ZA; Sevin, G, 2018) |
| "Because its role in bladder cancer is unknown, we investigated whether miR-374a affects the progression of bladder cancer and studied the underlying mechanism." | ( Chen, X; Gu, X; Jia, C; Jin, X, 2018) |
| "Bladder cancer is a significant health burden due to its high prevalence, risk of mortality, morbidity, and high cost of medical care." | ( Abbaoui, B; Clinton, SK; Lucas, CR; Mortazavi, A; Riedl, KM, 2018) |
| "Bladder cancer is currently considered the most common malignancy of the urinary tract." | ( Li, K; Tan, M; Xia, S; Xu, D; Xu, Y; Xu, Z, 2019) |
| "Bladder cancer is the most prevalent genitourinary malignant disorder worldwide." | ( Gao, L; Ge, B; Long, YF; Lu, YL; Shi, WJ; Teng, RB; Xu, FM; Zhang, S; Zhao, DK, 2018) |
| "In particular, bladder cancer is the ninth most common cancer worldwide and presents a high survival rate but serious recurrence levels, demanding an improvement in the existent therapies." | ( Carrascosa, R; Hortelão, AC; Murillo-Cremaes, N; Patiño, T; Sánchez, S, 2019) |
| "Bladder cancer is the 2nd most common reason for human genitourinary cancer-associated mortality." | ( Chen, F; Fu, YR; Luo, Y; Yi, YF, 2019) |
| "Advanced bladder cancer is a common disease characterized by a frequent onset of resistance to cisplatin-based therapy." | ( Barrera, G; Cavalli, R; Cucci, MA; Daga, M; Dianzani, C; Ferrara, B; Grattarola, M; Pizzimenti, S; Scariot, V; Trotta, F, 2019) |
| "Bladder cancer is one of the most common malignant diseases in the urinary system, with poor survival after metastasis." | ( Cheng, F; Fan, J; Jin, Y; Li, H; Li, Q; Liang, P; Ma, Z; Wu, Y; Zhou, Z, 2019) |
| "Bladder cancer is a significant health issue across the United States of America (USA)." | ( Amin, RW; Guttmann, RP; Stafford, B, 2019) |
| "Bladder cancer is the 13th leading cause of cancer death worldwide, and its mortality rate is highly associated with the motility of the malignant cells." | ( Lee, YH; Tuyet, PT, 2019) |
| "Bladder cancer is the fourth common cancer among men and more than 70% of the bladder cancer is nonmuscle invasive bladder cancer (NMIBC)." | ( Jung, YD; Kang, TW; Lian, S; Xia, Y; Zhang, C, 2019) |
| "Bladder cancer is a "Warburg-like" tumor characterized by a reliance on aerobic glycolysis and expression of pyruvate kinase M2 (PKM2)." | ( Abbott, E; Anant, S; Didde, R; Hamilton-Reeves, J; Holzbeierlein, JM; Kaushik, G; Lee, EK; Liu, W; Martin, P; Pirani, K; Taylor, JA; Woolbright, BL, 2019) |
| "Bladder cancer is a heterogeneous disease." | ( Bivalacqua, TJ; Fujita, K; Kates, M; McConkey, DJ; Yoshida, T, 2019) |
| "Bladder cancer is one of the most common urogenital tumors." | ( Buğday, MS; Öksüz, E, 2019) |
| "Bladder cancer is the sixth most common cancer in the United States, and it exhibits an alarming 70% recurrence rate." | ( Aguilar, RC; Collier, J; Dhawan, D; Edwards, DF; Elzey, BD; Jack, S; Kaimakliotis, H; Kischuk, EM; Knapp, DW; Koch, M; Loftis, AR; Lu, M; Madhivanan, K; McCluskey, A; Pentelute, B; Rabideau, A; Ramadesikan, S; Ratliff, TL; Santos, M; Subramanian, S; Truex, N, 2020) |
| "Bladder cancer is a common urinary tract tumor in clinic, and its morbidity and mortality are always high." | ( Guo, M; Hou, Y; Li, B; Liu, H; Liu, S; Liu, Y; Qiu, H; Tao, K; Wang, L; Zhang, H; Zhang, M; Zhang, X, 2019) |
| "BACKGROUND Bladder cancer is a very common urological cancer globally, and cisplatin- or gemcitabine-based chemotherapy is essential for advanced bladder cancer patients." | ( He, W; Hu, X; Li, Y; Wang, L; Zu, X, 2019) |
| "Bladder cancer is the ninth most common cancer worldwide." | ( Balalaeva, I; Campbell, D; Care, A; Gillatt, D; Guryev, E; Liang, L; Polikarpov, D; Sunna, A; Walsh, B; Zvyagin, A, 2019) |
| "Bladder cancer is the fourth most common cancer in men and eleventh most common in women." | ( Boehm, D; Mazur, J; Samaddar, S; Thompson, DH, 2019) |
| "Bladder cancer is a common malignant tumor in the urinary system, and its drug-resistant recurrence has become a major problem in clinical treatment." | ( Gao, X; Zhang, S, 2019) |
| "Bladder cancer is one of the most frequently occurring malignant tumors in the urinary system." | ( Cai, Y; Fan, M; Hu, Z; Huang, S; Jin, X; Liu, J; Wang, F; Wu, H; Yu, R; Zhang, Y; Zhou, X, 2020) |
| "Although bladder cancer is commonly chemosensitive to standard first-line therapy, the acquisition of the resistance to cisplatin (DDP)-based therapeutic regimens remains a huge challenge." | ( Cao, L; Chen, J; Li, Y; Li, Z, 2020) |
| "Bladder cancer is the eleventh most commonly diagnosed cancer worldwide." | ( Bracale, U; Buonopane, R; Califano, G; Capece, M; Creta, M; Crocetto, F; Di Meo, S; Fusco, F; Imbimbo, C; Imperatore, V; La Rocca, R; Longo, N; Mirone, V; Napolitano, L; Palmieri, A; Sodo, M; Spirito, L; Verze, P, 2020) |
| "Bladder cancer is the fifth most common disease in the United States, and the treatment and alternatives for patients have not changed in the last decades." | ( de Jesus, MB; Durán, N; Fávaro, WJ; Ferreira, LAB; Garcia-Fossa, F; Radaic, A, 2020) |
| "Bladder cancer is one of the most common urologic malignancies, which is more frequent in men than in women." | ( Geanta, M; Gheorghe, DC; Jinga, V; Sima, CS; Stefan-van Staden, RI, 2020) |
| "Bladder cancer is diagnosed by the use of several biomarkers, including survivin." | ( Aghaie, T; Jazayeri, MH; Manian, M; Nedaeinia, R; Nickho, H, 2020) |
| "Bladder cancer is a threat to human health worldwide." | ( Dong, B; Fu, X; Han, B; Luo, Y; Men, H; Meng, M; Tian, S; Yuan, L; Zhang, F; Zhang, S, 2020) |
| "Bladder cancer is the most common malignancy involving the urinary system." | ( Alić, J; Fajkić, A; Lepara, O; Lepara, Z; Rebić, D; Spahović, H, 2020) |
| "Bladder cancer is a lethal human malignancy." | ( Cheng, L; Huang, H; Lin, J; Wang, H; Wang, Z; Zhuo, D, 2020) |
| "Bladder cancer is an increasingly common malignancy, and muscle invasive bladder cancer is associated with particularly high rates of morbidity and mortality." | ( DeGraff, DJ; Raman, JD; Torab, P; Warrick, JI; Wong, PK; Yamashita, H; Yan, Y, 2020) |
| "Bladder cancer is one of the most aggressive urothelial tumors." | ( Li, Y; Wang, Y; Wu, S; Wu, Z; Xia, W; Xing, N; Yang, W, 2020) |
| "Bladder cancer is common and has one of the highest recurrence rates." | ( Belcher, S; Brown, MP; Chan, KM; Chong, M; Di Fiore, A; Gleadle, JM; Grochowski, A; Jay, A; Kashani, MN; Li, J; MacGregor, M; McNicholas, K; Michl, TD; Ostrikov, K; Robb, S; Safizadeh Shirazi, H; Staudacher, AH; Vasilev, K; Zhalgasbaikyzy, A, 2021) |
| "Bladder cancer is one of the most common malignant tumors in the urinary system with high mortality and morbidity." | ( Gu, S; Li, S; Liu, J; Wang, G; Xiao, H; Yu, C; Zhang, P; Zhang, Y, 2021) |
| "Bladder cancer is one of the major tumors for men in the world, in which therapy the combination of cisplatin and gemcitabine is still fist-line applied to treat with advanced or metastatic bladder cancer." | ( Chen, F; Gou, S; Wang, X, 2021) |
| "Bladder cancer is an aggressive and lethal disease." | ( Apolo, AB; Ghatalia, P; Girardi, DM; Iyer, G; Singh, P; Sridhar, SS, 2023) |
| "Bladder cancer is a frequent, chemosensitive disease and has shown good outcomes on several chemotherapy regimens over last 60 years." | ( Loizaga Iriarte, A; Martín Bazaco, J; Rabade Ferreiro, A; Senarriaga Ruiz de la Illa, N; Unda Urzaiz, M; Zubiaur Libano, C, 2020) |
| "The MDR of bladder cancer is closely related to membranous ABCC2, cytoplasmic DCK, and TKs expression." | ( Cho, CJ; Ho, JY; Wu, CL; Yang, CW; Yu, CP; Yu, DS, 2021) |
| "Bladder cancer is one of the most prevalent deadly diseases worldwide." | ( Assalini, C; Busti, S; Campioni, G; Ducci, G; Pasquale, V; Sacco, E; Vago, R; Vanoni, M; Ventrici, A, 2020) |
| "Bladder cancer is one of the most common cancers in Europe and is mostly found in men." | ( Drabik, A; Hackemer, P; Małkiewicz, B; Menzel, F; Tupikowski, K; Zdrojowy, R, 2021) |
| "Bladder cancer is the ninth most common cancer worldwide, and the third most common cancer in Lebanon." | ( Abou-Kheir, W; El-Hajj, A; Labban, M; Mukherji, D; Najdi, J; Tabbarah, A, 2021) |
| "Bladder cancer is among the most prevalent cancers worldwide." | ( Arora, S; Brown, L; Cai, EY; Corey, E; Garcia, J; Hsieh, AC; Lakely, B; Lam, HM; Lee, JK; Liu, Y; Montgomery, B; Nguyen, HM; Vakar-Lopez, F; Wong, A; Wright, JL, 2021) |
| "Bladder cancer is a common tumor type of the urinary system, which has high levels of morbidity and mortality." | ( Jia, M; Li, D; Li, H; Li, J; Li, X; Lin, P; Mo, L; Qiu, W; Su, B; Wang, D; Xu, L; Yang, B; Ying, J; Zhou, Z, 2021) |
| "Bladder cancer is a clinically heterogeneous disease with a poor prognosis." | ( Diao, HJ; Fan, RZ; Gan, L; Huang, JL; Li, W; Sang, J; Tang, GH; Yin, S; Zou, MF, 2021) |
| "Bladder cancer is one of the most common malignancy in the urinary tract with high recurrence and drug resistance in clinics." | ( Hu, J; Lei, Q; Li, Y; Ou, T; Sun, H; Wang, G; Wang, S; Wu, K; Wu, S; Yang, Z, 2021) |
| "Bladder cancer is a menace to global health worldwide due to its high recurrence rate and its progression to invasive muscular complications." | ( Chen, M; Qi, L; Xu, X; Zuo, Y, 2021) |
| "Bladder cancer is the 10th most common cancer worldwide." | ( Allison, SJ; Burns, JE; Hurst, CD; Knowles, MA; Phillips, RM, 2021) |
| "Bladder cancer is the most common malignancy of the urinary tract and arising from the epithelial lining of the urinary bladder." | ( Cha, TL; Cheng, YC; Ho, CT; Kao, CC; Lin, YC; Sun, GH; Wang, HK; Way, TD; Wu, ST; Yang, MH, 2021) |
| "While bladder cancer is the fourth most common type of cancer all over the world, there is little evidence of the advancing changes in oxidative/nitrative stress during the progression of bladder cancer." | ( Bijak, M; Kowal, P; Marchewka, Z; Saluk-Bijak, J; Sawicka, E; Szymańska, B; Wigner, P, 2021) |
| "Bladder cancer is one of the most severe genitourinary cancers, causing high morbidity worldwide." | ( Chen, G; Deng, Y; Ding, B; Duan, S; Kuang, J; Liu, Y; Lou, W; Lu, X; Wang, C; Zhang, Y, 2021) |
| "Non-muscle-invasive bladder cancer is one of the most common malignancies." | ( Apolo, AB; Bellmunt, J; Girardi, DM; Hahn, NM; Nadal, R, 2023) |
| "Bladder cancer is one of the most common cancer types and better treatments are needed." | ( Drewa, T; Fekner, Z; Jundziłł, A; Kazimierski, Ł; Kloskowski, T; Krzeszowiak, K; Pokrywczyńska, M; Szeliski, K, 2021) |
| "Urinary bladder cancer is a common cancer worldwide." | ( Chan, RC; Kong, AW; Ng, CF; Teoh, JY; To, KF; Tse, RT; Wong, CY; Zhao, H, 2022) |
| "Bladder cancer is a highly heterogeneous and aggressive malignancy with a poor prognosis." | ( Gou, X; He, W; Kuang, Y; Li, T; Ren, K; Wei, Z; Xu, N; Xu, Y; Yin, H; Yu, H; Yuan, F; Zhang, C; Zhu, X, 2022) |
| "Bladder cancer is the second most common genitourinary malignancy and the eleventh most common cancer worldwide." | ( Lin, P; Mu, L; Xiao, L; Xu, C; Yang, X, 2022) |
| "Bladder cancer is common worldwide, with most patients presenting with nonmuscle invasive disease." | ( Guo, J; Huang, Q; Huo, F; Jia, R; Li, PC; Theodorescu, D; Wang, J; Wang, Y; Yan, C; Yang, J; Yu, H; Zhang, Y, 2022) |
| "Bladder cancer is the fourth most common malignancy in males." | ( Abdul Sani, SF; Bradley, DA; Jamil, AHBA; Kamri, NINB; Kanmalar, M; Kuppusamy, S; Mun, KS; Said, NABM, 2022) |
| "Bladder cancer is a malignant tumor characterized by high recurrence and persistence due to the limited therapies that are currently available." | ( Ji, Y; Shen, Y; Tang, L; Yang, M; Ye, H; Yuan, L; Zhang, D; Zhu, X, 2022) |
| "Bladder cancer is one of the most common malignancies but the corresponding diagnostic methods are either invasive or limited in specificity and/or sensitivity." | ( Fang, Q; Hu, J; Nie, Q; Wang, C; Zhang, X; Zhou, S, 2022) |
| "Bladder cancer is the second most common of urological malignancies." | ( Özler, S; Pazarci, P, 2022) |
| "Bladder cancer is a common disease worldwide with most patients presenting with the non-muscle-invasive form (NMIBC) at initial diagnosis." | ( Cao, Q; Huang, Q; Huo, F; Jia, R; Li, P; Lv, Q; Theodorescu, D; Wang, ZA; Yan, C; Zhang, Y, 2022) |
| "Urothelial bladder cancer is rapidly spreading across Western countries, and therapy has shown little-to-moderate effects on bladder cancer." | ( Annseles Rajula, S; Bharath Kumar, V; Chen, MC; Chen, RJ; Day, CH; Hsu, CH; Huang, CY; Li, CC; Viswanadha, VP; Wang, TF, 2022) |
| "Bladder cancer is known to inhibit the immune cells (T cells) from attacking it, which is an important way in which the body controls cancer cells." | ( Chen, SH; Efstathiou, E; Esnaola, NF; Farach, A; Guzman, J; Lim, K; Satkunasivam, R; Sonpavde, GP; Teh, BS; Wallis, CJ; Zhang, J, 2022) |
| "Bladder cancer is the tenth most common cancer worldwide, with Europe having the highest incidence rates." | ( Mesquita, A; Silva, DJ, 2022) |
| "Bladder cancer is a common malignancy in the urinary system." | ( Chen, P; Hong, Z; Li, T; Lin, R; Wei, Y; Wu, X; Xu, Q; Zeng, R, 2022) |
| "Bladder cancer is a common urinary system tumor." | ( Chi, BJ; Quan, LL; Sun, Y; Wang, SQ; Wei, B; Zhao, JT, 2022) |
| "Bladder cancer is a common malignant disease in developed countries." | ( Chu-Su, Y; Horita, S; Iizuka, J; Ishizuka, T; Nagashima, Y; Takagi, T; Tanabe, K; Toguchi, M; Tokuoka, Y; Yokoyama, T, 2022) |
| "Bladder cancer is the 13th most common cause of cancer death with the highest lifetime cost for treatment of all cancers." | ( Buosi, K; Garcia-Perdomo, HA; Jalalizadeh, M; Reis, LO; Yadollahvandmiandoab, R, 2022) |
| "Bladder cancer is the first cancer for which PDT was clinically approved in 1993." | ( Foster, BA; Giram, P; Rahman, KMM; You, Y, 2023) |
| "Bladder cancer is still a burden on the world of oncology medicine, which every year affects about 3." | ( Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP, 2022) |
| "Bladder cancer is the 10th most common cancer in the world and has a high risk of recurrence and metastasis." | ( Binda, C; Couderc, B; Lluel, P; Lucas, A; Mialet-Perez, J; Parini, A; Resta, J; Riant, E; Roumiguié, M; Santin, Y, 2022) |
| "Bladder cancer is the most common malignancy of the urinary system, and accounts for 3% of newly diagnosed tumors." | ( Gao, Y; Huang, Y; Wu, J; Xiao, X; Xiong, Z; Yang, J; Yang, X, 2023) |
| "Bladder cancer is one of the most common malignancies of the male genitourinary urinary system." | ( Bao, BY; Chang, HH; Chen, JK; Chen, YR; Cheng, WC; Chuu, CP; Huang, SP; Ke, CC; Lee, CH; Li, CY; Liu, PL; Su, CC; Wang, SC; Wu, HE; Yeh, HC, 2022) |
| "Bladder cancer is one of the most common malignancies of the male genitourinary urinary system." | ( Bao, BY; Chang, HH; Chen, JK; Chen, YR; Cheng, WC; Chuu, CP; Huang, SP; Ke, CC; Lee, CH; Li, CY; Liu, PL; Su, CC; Wang, SC; Wu, HE; Yeh, HC, 2022) |
| "Bladder cancer is one of the most common malignancies of the male genitourinary urinary system." | ( Bao, BY; Chang, HH; Chen, JK; Chen, YR; Cheng, WC; Chuu, CP; Huang, SP; Ke, CC; Lee, CH; Li, CY; Liu, PL; Su, CC; Wang, SC; Wu, HE; Yeh, HC, 2022) |
| "Bladder cancer is one of the most common malignancies in the world." | ( Chen, W; Deng, F; Fan, Q; Han, C; Li, D; Li, F; Mo, Q; Tan, W; Zhang, H; Zhao, X; Zheng, Z; Zhu, Y, 2023) |
| "Bladder cancer is a major and fatal urological disease." | ( Abe, T; Hashimoto, S; Hirohashi, Y; Hori, K; Isono, M; Iwabuchi, S; Kanaseki, T; Kubo, T; Minowa, T; Miyata, H; Mizue, Y; Murai, A; Murata, K; Nakatsugawa, M; Sasaki, K; Shinohara, N; Tokita, S; Torigoe, T; Tsukahara, T; Yamada, S; Yanagawa, J, 2023) |
| "Bladder cancer is a highly prevalent tumor, requiring the urgent development of novel therapies, especially for locally advanced and metastatic disease." | ( Corral, S; Del Pozo, N; Hilberg, F; Marqués, M; Martínez de Villarreal, J; Real, FX; Sánchez-Díaz, M; Schweifer, N; Zagorac, I, 2023) |
| "Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies." | ( Ambite, I; Babjuk, M; Cavalera, M; Chaudhuri, A; Esmaeili, P; Hien, TT; Sabari, S; Svanborg, C; Wan, MLY, 2023) |
| "Bladder cancer is the most common tumor of the urinary system, with a high incidence in the male population." | ( Biagini, A; Caglioti, C; Claps, F; Fioretti, B; Gentile, R; Palazzetti, F; Pastore, AL; Perotti, A; Sallicandro, L; Zucchi, A, 2023) |
| "Bladder cancer is the most common malignancy of the urinary system." | ( Fu, Y; Shi, D; Sun, X; Wei, B; Xia, Z; Xu, Y; Zhu, Y, 2023) |
| "Bladder cancer is the fourth-most-common cancer in males in the U." | ( Armstrong, J; Davis, D; Kogan, M; Lowe, P; Meng, M; Morash, C; Seely, D, 2023) |
| "Bladder cancer is known as one of the top ten most common cancer types worldwide and can be majorly divided into muscles invasive bladder cancer (MIBC) and non-muscles invasive type (NMIBC)." | ( Chiang, CH; Hsu, FT; Tan, ZL; Yang, CJ; Yang, JD, 2023) |
| "Bladder cancer is one of the most common cancers worldwide, with 213 000 deaths reported in 2020." | ( Chen, J; Lai, KP; Qin, X; Wang, P; Zhang, X; Zhou, H, 2023) |
| "Urinary bladder cancer is more common in geriatric population." | ( Baral, BK; Dhakal, GR; Karki, AJ; Poudel, PR; Rajbhandari, M, 2023) |
| "Bladder cancer is the leading urinary tract malignancy." | ( Chang, CC; Hsu, CY; Hu, KC; Lan, TH; Lin, JH; Lu, CH; Yang, WT, 2023) |
| "Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality." | ( Chen, J; Chen, R; Chen, X; Fan, H; Hao, X; Lian, F; Wang, C; Xia, Y; Zhang, C, 2023) |
| "Bladder cancer is one of the most commonly diagnosed genitourinary malignancies." | ( Drakaki, A; Hannigan, C; Hui, G; Isaacs, DJ; Pantuck, AJ; Stefanoudakis, D; Zektser, Y, 2023) |
| "Bladder cancer is one of the most common urological malignancies worldwide." | ( An, L; Chu, C; Li, L; Li, X; Liu, Q; Wang, R; Wang, Y; Wang, Z; Wei, X; Wu, G; Zhang, G, 2023) |
| "Bladder cancer is one of the most common carcinomas in the human urinary system worldwide." | ( Guo, Q; Li, J; Qiu, J; Wang, D; Wu, J; Wu, Q; Xiao, C; Yuan, H, 2023) |
| Excerpt | Reference |
|---|
| "Treatment of superficial low-grade bladder cancer often incorporates intravesical instillations of the alkylating agent thio-TEPA." | ( Daly, JJ; Irwin, RJ; Nieh, PT; Prout, GR, 1979) |
| "A 9-fold increased incidence of bladder cancer was found in the cyclophosphamide-treated group." | ( Fairchild, WV; Gangai, MP; Solomon, HD; Spence, CR, 1979) |
| "18 patients with category T3 bladder cancer were treated with a combination of radical radiotherapy followed after an interval of 1-3 months by pulsed chemotherapy with adriamycin and 5-fluorouracil." | ( Glashan, RW; Houghton, AL; Robinson, MR, 1977) |
| "61 patients with advanced bladder cancer were treated with methotrexate." | ( Bloom, HJ; Hendry, WF; Turner, AG; Williams, GB, 1977) |
| "We describe 25 patients with bladder cancer who received adjuvant chemotherapy with doxorubicin hydrochloride and cyclophosphamide after radical cystectomy." | ( Beckley, S; Merrin, C, 1978) |
| "They depress the relapse of urinary bladder cancer, BC-47, when they are used with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for treatment of rats bearing BC-47." | ( Hozumi, T; Iwaguchi, T; Kitagawa, H; Ozawa, H, 1978) |
| "An increasing incidence of bladder neoplasms temporally associated with chemotherapy, usually cyclophosphamide, is being reported." | ( Pearson, RM; Soloway, MS, 1978) |
| "Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin." | ( Bruce, AW; Eidinger, D; Morales, A, 1976) |
| "52 patients with advanced bladder cancer, no longer controlled by conventional therapy, have been treated by combination chemotherapy with Adriamycin and 5-fluorouracil." | ( Bono, A; Cifuentes-Delatte, L; Glashan, RW; Macaluso, MP; Martínez-Pinéiro, JA; Mulder, JH; Robinson, MR; Smith, PH, 1977) |
| "Of 48 patients with bladder tumors treated with intravesical epodyl 17 have shown a complete remission at some stage of treatment, although several have relapsed later." | ( Bastable, J; Glashan, RW; Richards, B; Robinson, MR; Shetty, MB; Smith, PH, 1977) |
| "We presented 12 patients with invasive bladder cancer treated by the subselective intra-arterial COMPA chemotherapy." | ( Kawai, T; Kobayashi, T; Kokuho, M; Sawano, S; Tachibana, Y; Tsujino, S; Yamauchi, T, 1992) |
| "Seventeen patients with bladder cancer were treated with semiselective intraarterial COMPA chemotherapy." | ( Aizawa, T; Ishibashi, K; Ito, T; Kawai, T; Miki, M; Namiki, K; Ohno, Y; Tsujino, S; Yamamoto, S; Yamauchi, T, 1992) |
| "Urinary bladder cancers following prolonged cyclophosphamide therapy are being increasingly reported." | ( Advani, SH; Gopal, R; Nadkarni, KS; Pathak, AB; Saikia, TK, 1992) |
| "Twenty-three patients with bladder cancer (TCC; 18 patients, SCC; 5 patients) were treated with adjuvant chemotherapy (day 1: methotrexate 20 mg/m2, vincristine 0." | ( Fujii, A; Higuchi, A; Itoh, N; Izumi, T; Murata, Y; Nakagawa, J; Oka, N; Tanaka, H; Yamada, Y, 1992) |
| "In 18 patients with advanced bladder cancer, teniposide was administered intravenously (IV), followed in seven patients by peptichemio or doxorubicin." | ( Ingargiola, GB; Pavone-Macaluso, M; Serretta, V, 1992) |
| "58 patients with advanced bladder cancer were treated with MVEC chemotherapy (methotrexate, vinblastine, epirubicin and cisplatinum)." | ( Bub, P; Eisenberger, F; Rüther, U; Schmidt, A, 1992) |
| "Three patients with locally advanced bladder cancer were given intra-arterial infusion chemotherapy." | ( Akiyama, M; Inoue, Y; Sumiyoshi, Y; Yokota, K, 1992) |
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| "Thirty-three patients with primary bladder cancer (nine stage T1 with multifocal tumors and 24 stage T2-4) were treated with intraarterial infusion chemotherapy including cisplatin, doxorubicin, and [Sar1,Ile8]Angiotensin II(AT II)." | ( Goto, K; Hara, Y; Ishikawa, S; Ishiyama, S; Kikuchi, T; Kobayashi, Y; Morita, T; Takahashi, K; Tozuka, K; Yoshikawa, H, 1992) |
| "In a randomized study, we treated bladder cancer patients with intravesical MMC using 30-min and 60-min dwelling times." | ( De Bruijn, EA; Maes, RA; Sleeboom, HP; Tjaden, UR; van Helsdingen, PJ; van Oosterom, AT, 1992) |
| "Female Wistar rats with bladder tumors underwent intravesical instillation of normal saline (S group) or 50% DMSO (D group) prior to the administration of pirarubicin (tetrahydropyranyl-Adriamycin)." | ( Hashimoto, H; Nishihara, M; Sasaki, M; Tokunaka, S; Yachiku, S, 1992) |
| "A total of 49 bladder cancer patients with tumor stages pT3b, pT4a and/or pelvic lymph node involvement without microscopic or macroscopic evidence of residual tumor was randomized into 2 comparative groups: the chemotherapy group was to receive 3 adjuvant cycles of methotrexate, vinblastine and cisplatin plus doxorubicin (M-VAC) or epirubicin (M-VEC) after radical cystectomy." | ( Gertenbach, U; Hohenfellner, R; Huber, C; Meyenburg, W; Stöckle, M; Thüroff, JW; Voges, G; Wellek, S, 1992) |
| "Fourteen patients with invasive bladder cancer were treated by bilateral internal iliac artery infusion of cisplatin, with or without other anticancer agents, and concurrent radiotherapy." | ( Eiro, I; Kanetsuki, I; Nakajo, M; Onohara, S; Takeshita, T; Uchiyama, N; Yano, T, 1992) |
| "Twenty superficial bladder tumors (T1) treated with intravesical BCG therapy (10 responders and 10 nonresponders) were tested with this panel." | ( Abbou, CC; Boccon-Gibod, L; Chopin, DK; Deslignères, S; Flam, TA; Leleu, C; Steg, A, 1990) |
| "One hundred fifty-five patients with urinary bladder cancer who were not suitable for radical surgery were treated with full-course radiotherapy, 6600 cGy in 9 weeks, split-course." | ( Salminen, E, 1990) |
| "In superficial bladder cancer, topical instillation therapy with interferon is as effective as conventional chemotherapy and has no side effects." | ( Albrecht, W; Hasun, R; Hoeltl, W; Marberger, M, 1991) |
| "Fifteen patients with invasive bladder cancer were treated with selective intra-arterial cisplatin and external beam radiotherapy (30." | ( Akaza, H; Inada, T; Koiso, K; Miyanaga, N; Noguchi, R; Ohara, K; Ohtani, M; Tatsuzaki, H; Tsuji, H; Uchida, K, 1991) |
| "Although down staging of bladder cancer after neoadjuvant therapy are evaluated by CT or ultrasound, these imaging are not reliable." | ( Hoshi, S; Kawamura, S; Nakazumi, H; Ohyama, C; Orikasa, S; Saitoh, S; Satoh, M; Suzuki, K; Tochigi, T; Yoshikawa, K, 1991) |
| "Sixty patients with Ta and T1 bladder cancer were randomized between treatment with resection only and resection and instillations with either Adriamycin or Mitomycin C." | ( Borgström, E; Brolin, J; Gustafson, H; Nyman, C; Tribukait, B; Wijkström, H, 1991) |
| "Although bladder tumors in cyclophosphamide-treated patients are relatively frequent, upper urothelial tumors are rare." | ( Agüera Fernández, L; Berián Polo, JM; de Castro Barbosa, F; Isa Kroon, WA; Robles García, JE; Rosell Costa, D; Sánchez de la Muela, P; Zudaire Bergera, JJ, 1991) |
| "In the first group of 34 superficial bladder tumors, we evaluated the accuracy of cold-cup biopsy in staging the tumor before treatment with the laser (100% for grade and 90% for stage)." | ( Algaba, F; Laguna, P; Salvador, J; Vicente, J, 1991) |
| "Eight patients with bladder cancer and two patients with prostate cancer were given intra-arterial infusion chemotherapy using the reservoir system." | ( Akiyama, M; Sumiyoshi, Y; Yokota, K, 1991) |
| "Eleven patients with advanced bladder cancers (T2-4) were treated by intra-arterial CDDP infusion therapy and intratumoral Pt concentrations were measured." | ( Matsuyama, H; Sakatoku, J; Shimabukuro, T; Wada, T; Yamamoto, N; Yoshihiro, S, 1991) |
| "Patients with T2 grade 3 and T3 bladder cancer were randomised to be treated with radiation alone (NO MISO) or with radiation and misonidazole (PLUS MISO)." | ( Abratt, RP; Craighead, P; Reddi, VB; Sarembock, LA, 1991) |
| "Significant uptake of FDG in localized bladder tumors in rats was shown, with an average tumor-to-blood ratio of 39 at 2 hours after intravenous FDG administration." | ( Grossman, HB; Harney, JV; Hutchins, GD; Kuhl, DE; Liebert, M; Wahl, RL; Wedemeyer, G, 1991) |
| "Thirty patients with advanced bladder cancer received combination chemotherapy with cis-platinum, adriamycin and mitomycin C." | ( Bacoyiannis, C; Hatzichristou, H; Kosmidis, PA, 1990) |
| "34 patients with locally advanced bladder cancer were treated by combined radiotherapy and chemotherapy." | ( Fritsch, E; Frommhold, H; Hellweg, G; Jakse, G; zur Nedden, D, 1990) |
| "A case of cancer of the bladder is reported in a patient treated 5 years previously with cyclophosphamide for membranoproliferative glomerulonephritis." | ( Court, BH; Culine, S; Droz, JP; Ghosn, M; Hayat, M; Lupera, H; Perrin, JL, 1990) |
| "58-year-old male with bladder cancer complicated acute myocardial infarction (aMI) were treated by 5-FU 300 mg/day orally for approximately one and a half months as single drug chemotherapy preoperatively." | ( Hasegawa, K; Ikeuchi, T; Kai, Y; Onodera, Y; Sasaki, H; Ueno, M; Yoshikawa, H, 1990) |
| "Twenty-one bladder tumors that developed between 25 and 50 weeks after BBN administration was begun were evaluated for immunoreactivity with polyclonal or monoclonal antibodies raised against ras p21, for amplification of ras genes by Southern blotting, and for activating point mutations in ras genes by selective oligonucleotide hybridization of products from polymerase chain reaction (PCR)." | ( Enomoto, T; Perantoni, AO; Ward, JM, 1990) |
| "Between 1976 and 1985, 35 patients with bladder cancer were preoperatively treated with intra-arterial doxorubicin (ADM) chemotherapy." | ( Akiyama, M; Sumiyoshi, Y; Uyama, T; Yano, M; Yokota, K, 1990) |
| "The treatment of bladder cancer is one of the most active areas of clinical cancer research." | ( Torti, FM, 1987) |
| "In the treatment of bladder cancer, it is important to distinguish the malignant potential of the tumor." | ( Akaza, H; Aso, Y; Kameyama, S, 1987) |
| "The high recurrence rate of superficial bladder tumors, its frequent association with premalignant tumors, and its evolution into infiltrating tumors in 15% of the cases justify the use of tumoricidal agents as adjuvant therapy." | ( Beneítez Alvarez, M; de Blas Gómez, V; Gallo Rolanía, FJ; Roa Luzuriaga, M, 1989) |
| "The treatment of bladder cancer is in a state of evolution." | ( Bosl, GJ; Nanus, DM, 1989) |
| "In 100 patients suffering from urinary bladder cancer (pTA-4, Nx, M0-1, G0-3) we created an oral tryptophan load administering 5 g of L-type tryptophan." | ( Grimm, U; Knapp, A; Wich, H, 1989) |
| "16 patients with invasive bladder cancer were treated primarily "bladder in place", with chemotherapy." | ( Adjiman, S; Beuzeboc, P; Boccon-Gibod, L; Steg, A, 1989) |
| "Forty-eight patients with urinary bladder neoplasms were examined with magnetic resonance imaging before and after intravenous administration of gadolinium diethylene-triaminepentaacetic acid (DTPA)." | ( Bohndorf, K; Daus, HJ; Guenther, RW; Neuerburg, JM; Sohn, M; Teufl, F, 1989) |
| "Thirty-two patients with advanced bladder cancer received intraarterial infusion of chemotherapy with cis-platin (CDDP)." | ( Fujihiro, S; Kawada, Y; Kuriyama, M; Nagai, T; Nagatani, Y; Shinoda, I; Takahashi, Y; Takeuchi, T; Tamaki, M; Uno, H, 1989) |
| "Locally advanced bladder cancer (clinical stage T2-T4) of 11 patients and ureteral cancer (clinical stage T3) of 3 patients was treated concurrently by CDDP and irradiation." | ( Itatani, H; Utsunomiya, M, 1989) |
| "Twenty patients with bladder cancer were treated with intra-arterial infusion chemotherapy using CDDP and ADM in combination with [Sar1, Ile8] angiotensin II." | ( Goto, K; Hara, Y; Ishikawa, S; Ishiyama, S; Kikuchi, T; Kobayashi, Y; Morita, T; Nakashima, N; Takahashi, K; Tozuka, K, 1989) |
| "Thirty-two patients with infiltrating bladder cancer were treated with transurethral resection followed by one course of alternating chemoradiotherapy before radical cystectomy (group A, 20 patients) or two courses as definitive procedure (group B, 12 patients)." | ( Curotto, A; Giuliani, L; Martorana, G; Merlano, M; Michelotti, A; Orsatti, M; Rosso, R; Scarpati, D; Venturini, M, 1989) |
| "Photodynamic therapy for bladder cancer is an intriguing modality with theoretical potential for successful treatment of visible tumor and areas of carcinoma in situ and dysplasia throughout the bladder mucosa." | ( Rosenberg, SJ; Williams, RD, 1986) |
| "In the treatment of men and women with bladder cancer, the sexual function morbidity of radical cystectomy is described in data from prospective interview studies." | ( Schover, LR, 1987) |
| "Laser treatment of invasive bladder cancer should not be considered an alternative to cystectomy, but may be useful in patients who are not candidates for radical surgery." | ( Smith, JA, 1986) |
| "Urine from patients with bladder cancer before treatment had osmolalities in the range 187 to 852 mOsm." | ( Groos, E; Masters, JR, 1986) |
| "A human bladder cancer cell line was exposed to a range of concentrations of the four drugs commonly used to treat superficial bladder cancer (adriamycin, epodyl, mitomycin-c, thiotepa) for periods of 30, 60 and 120 min." | ( English, PJ; Hepburn, PJ; Masters, JR; Parris, CN; Walker, MC, 1986) |
| "In view of the activity of Cisplatin in bladder cancer a multicentre study of its less toxic analogue Carboplatin was carried out in 48 patients with metastatic transitional cell carcinoma, of whom 30 had received no previous cytotoxic chemotherapy." | ( , 1987) |
| "Although metastatic bladder cancer is difficult to treat effectively, chemotherapy combinations and schedules have emerged recently that can result in long-lasting complete responses in some patients." | ( Hrushesky, WJ; Roemeling, RV, 1986) |
| "Serially transplanted murine bladder cancer was treated with localized capacitive radiofrequency hyperthermia and liposome-delivered methotrexate (MTX)." | ( Anderson, RU; Bassett, JB; Bostwick, D; Tacker, JR, 1988) |
| "Nine patients with locally advanced bladder cancer were examined by CT to evaluate the response of chemotherapy with Cisplatinum/Methotrexate." | ( Fosså, SD; Johannessen, N; Ous, S; Sager, EM, 1988) |
| "In our study, 29 of 150 patients with bladder cancer also had other associated primary malignancies, 10 of which were manifested after intravesical treatment with bacillus Calmette-Guérin (BCG)." | ( Chou, RH; Cottone, R; Heeg, M; Khanna, OP; Mazer, H; Read, J; Rezvan, M; Son, DL; Viek, N, 1988) |
| "In 22 patients with bladder cancer after local chemotherapy and 13 patients after systemic chemotherapy, respectively, multiple biopsy specimens were examined histologically." | ( Ecke, M; Langen, L; Lenz, E; Theuring, F, 1988) |
| "Successful treatment of superficial bladder cancer using nonspecific immunotherapy with Bacillus Calmette-Guerin (BCG) has been well documented." | ( Lamm, DL; Pickett, SH; Rochester, MG; Sarosdy, MF; Stogdill, BJ, 1988) |
| "Ten patients with advanced bladder cancer were treated with intra-arterial infusion therapy." | ( Akazawa, N; Asahi, T; Hayata, S; Okita, K; Takeda, K; Tsugawa, M, 1987) |
| "A case of untreated bladder cancer with an unusual clinical course in a 48-year-old man is reported." | ( Arai, Y; Ishida, A; Pak, K; Tomoyoshi, T, 1987) |
| "One invasive and 4 superficial bladder cancers were treated by local injection of absolute ethanol through an endoscope." | ( Fujioka, T; Hata, M; Ieda, K; Nakajima, F; Nakamura, H; Odajima, K; Takao, M, 1987) |
| "Nine patients with in situ bladder cancer (TIS) were treated by intravesical instillation of epi-doxorubicin (epi-DOX)." | ( Bogdanowicz, JF; Kurth, KH; Maessen, P; Mross, K; Pinedo, HM; van der Vijgh, WJ, 1987) |
| "Urinary bladder tumors were induced in female Wistar rats by oral administration of N-butyl-N-(4-hydroxybutyl) nitrosamine [(BBN) CAS: 3817-11-6]." | ( Kimura, S; Kinoshita, Y; Maekawa, M; Nishio, S; Ozaki, Y; Wada, S, 1987) |
| "Patients with T3 bladder cancer who survived surgery and proved to have P3a, P3b or P4a tumors were randomized to either no further treatment (61 patients) or postoperative total pelvic irradiation (55 patients)." | ( Amer, F; Awwad, HK; Barsoum, M; el Badawy, S; Mocktar, N; Omar, S; Soliman, O; Zaghloul, MS, 1986) |
| "Seven weeks following FANFT treatment, bladder cancers developed in 12% of mice with sutures and FANFT and in 19% of those with sutures, FANFT, and N-acetylcysteine." | ( Chester, JF; Gaissert, HA; Malt, RA; Ross, JS; Weitzman, SA, 1987) |
| "Fifteen patients with non-disseminated bladder cancer (T1:2, T2:2, T3:8, T4:3) were preoperatively treated with intra-arterial doxorubicin chemotherapy in combination with low-dose irradiation." | ( Aga, Y; Fujita, J; Higa, I; Shiotsu, T; Uyama, T; Yamamoto, A, 1987) |
| "Twenty patients with bladder cancer (T1, 3 patients; T2, 6 patients; T3, 8 patients; T4a, 3 patients) were preoperatively treated with intra-arterial doxorubicin chemotherapy in combination with low-dose irradiation." | ( Fujita, J; Higa, I; Kitada, K; Moriwaki, S; Shiotsu, T; Uyama, T; Yokozeki, A, 1987) |
| "Forty-six patients with bladder cancer without distant metastasis (M0) were treated by chemotherapy as an adjuvant after total cystectomy using three protocols (protocol I: adriamycin 50 mg/m2, cyclophosphamide 500 mg/m2, and cis-platinum 50 mg/m2 i." | ( Kinouchi, T; Kiyohara, H; Kotake, T; Kuroda, M; Miki, T; Saiki, S; Usami, M, 1987) |
| "Twenty-two patients with bladder cancer stage T2 or T3NxM0 received preirradiation treatment with cisplatin." | ( Havsteen, H; Rasmussen, F; Strøyer, I; von der Maase, H, 1987) |
| "In the categories T1, T2 and T3NxM0 bladder cancer, diameter not exceeding 5 cm, the treatment in the Rotterdam Radio-Therapy Institute consists of interstitial irradiation with needles containing radioactive material." | ( van der Werf-Messing, BH; Wijnmaalen, A, 1986) |
| "Twenty-one patients with bladder tumors were treated with THP instillation into the bladder." | ( Aso, Y; Hirose, J; Masuda, H; Suzuki, K; Tajima, A, 1986) |
| "Nineteen patients with locally advanced bladder cancer were treated with irradiation and concomitant 5-fluorouracil intravenous infusion with or without bolus mitomycin." | ( Aziz, H; Braverman, A; Choi, K; Laungani, GB; Macchia, R; Rosenthal, J; Rotman, M; Silverstein, M, 1987) |
| "The in vivo chemosensitivity test for bladder cancer, using the human bladder cancer xenografts (BT-8 and BT-11 strains) in nude mice (BALB/c) and the BBN-BT-1 bladder cancer strain in BALB/c hetero-mouse which was induced by peroral long-period administration of N-butyl-N-(4-hydroxybutyl) nitrosamine and transplantable into the subcutaneous of mouse, were examined especially in respect to the difference of chemosensitivity between young and old straining and the prospective propriety for clinical application." | ( Kawai, T; Okada, K; Yamauchi, T; Yoshida, O, 1986) |
| "Eight patients with deeply invasive bladder cancer were treated with cis-DDP alone or in combination with other drugs following radical cystectomy." | ( Hirano, A; Ogawa, T; Ohkawa, T; Shinka, T; Uekado, Y; Watanabe, T; Yamamoto, S; Yoshida, T, 1985) |
| "A reduced incidence of urinary bladder tumors was observed in FANFT-pretreated animals that also received a mixture of cis- and trans-nicotine-N'-oxides." | ( Hoffmann, D; LaVoie, EJ; Mu, B; Rivenson, A; Shigematsu, A, 1985) |
| "Thirty-seven cases of superficial bladder cancer were treated with 4'-epi-adriamycin (EPI) by intravesical instillation to investigate the optimal dosage and treatment schedule." | ( Akagi, T; Matsumura, Y; Nasu, Y; Obama, T; Ohmori, H; Ozaki, Y; Tsushima, T, 1985) |
| "Thus, it appears that the status of bladder cancer can be monitored successfully by an assessment of urinary cytology in the context of long-term treatment and prophylaxis with this agent." | ( Droller, MJ; Erozan, YS, 1985) |
| "For 50 patients with superficial bladder cancer intravesical chemotherapy with THP was performed." | ( Akaza, H; Aso, Y; Koiso, K; Koyanagi, T; Machida, T; Niijima, T; Origasa, S; Rinsho, K; Sakashita, S; Suzuki, K, 1986) |
| "Ten patients with bladder cancer were treated with double channel chemotherapy which included intra-arterial infusion of DDP and concurrent intra-venous infusion of STS, a neutralizing agent against DDP." | ( Fukui, I; Igarashi, K; Sekine, H; Yamada, T; Yokokawa, M; Yosida, T, 1986) |
| "In a population-based study of 2982 bladder cancer patients and 5782 population controls from 10 geographical areas of the US, no excess risk was associated with medications used for tuberculosis treatment or prophylaxis (relative risk (RR) = 0." | ( Fraumeni, JF; Hartge, P; Hoover, RN; Kantor, AF, 1985) |
| "Responses of bladder cancer in ACI rats to combination therapy with an immunomodulator, PSK, and an alkylating agent, carboquone, are reported." | ( Mickey, DD, 1985) |
| "Seventeen patients with stage T3 bladder cancer were treated in a pilot study of initial chemotherapy (four courses of cyclophosphamide, methotrexate and 5-fluorouracil) followed by megavoltage radiotherapy 6000 cGy) to the bladder." | ( Hart, AJ; Kaye, SB; MacFarlane, JR; McHattie, I, 1985) |
| "109 patients with urinary bladder cancer received post TUR treatment with weekly intravesical instillations of Adriamycin for a period of 6 weeks." | ( Flamm, J; Grof, F, 1985) |
| "Twenty one patients with advanced bladder cancer (metastases and/or loco-regional recurrences) were treated by cisplatin-based chemotherapy (cisplatin, adriamycin, cyclo-phosphamide (8 patients), cisplatin, methotrexate (8 patients) and cisplatin and radiotherapy (5 patients)." | ( Boccon-Gibod, L; Cressey-Kanoui, C; Debré, B; Guinet, F; Steg, A, 1985) |
| "Sixty patients with infiltrating bladder cancer were treated by partial cystectomy and iridium radiotherapy between 1977 and 1982." | ( Ardiet, JM; Auque, JR; De Laroche, G; Gérard, JP; Romestaing, P, 1985) |
| "Seventy patients with T2-T4 NX MO bladder cancer were treated with intravenous cisplatin (100 mg/m2 q 3-weekly) followed by radiotherapy and/or cystectomy." | ( Pearson, BS; Raghavan, D, 1985) |
| "37 patients with recurrent Ta/T1 bladder cancer were treated with intravesical adriamycin (80 mg monthly) after complete TUR (1977-1979)." | ( Fosså, SD; Ous, S; Urnes, T, 1985) |
| "In neither study were bladder tumors found in the control rats or in rats treated with lower doses of the compounds." | ( Biava, CG; Ley, HL; Oser, BL; Price, JM; Steinfeld, J; Vogin, EE, 1970) |
| "Eleven patients with invasive bladder cancer were treated with combination chemotherapy consisting of bleomycin (5 mg, i." | ( Fukui, I; Katoh, M; Sekine, H; Takeuchi, S; Washizuka, M; Yamada, T; Yokokawa, M, 1984) |
| "Photodynamic inactivation of bladder cancer cells (MGH-U1) was investigated in order to apply laser therapy to the treatment of bladder cancer." | ( Ishikawa, S; Ishizaka, S; Kanoh, S; Kobayashi, K; Nemoto, R, 1984) |
| "Using a clonogenic assay and the human bladder cancer cell line T24, enhanced cytotoxicity by the combined use of irradiation and 43 degrees C hyperthermia or two anticancer drugs, bleomycin (BLM) and cis-dichlorodiammineplatinum (CDDP), has been investigated in vitro, as well as the size of colonies derived from single survivor cells after treatment." | ( Hisazumi, H; Kumaki, O; Nakajima, K; Ueki, O, 1983) |
| "A 57-year-old woman with inoperable bladder cancer received radiation treatment." | ( Becher, R; Osieka, R; Schmidt, CG; Schütt, P, 1980) |
| "One hundred patients suffering from cancer of the bladder were treated by external beam irradiation, 400 cGy twice a week to a total dose of 4800 cGy." | ( Davillas, N; Katsoyianni, C; Licourinas, M; Papavasiliou, C; Pappas, J; Seretakis, L; Stathopoulos, P; Thanos, A; Theodorou, C; Yiogarakis, D, 1983) |
| "Patients with T2 grade III and T3 bladder cancer were treated in a Phase II trial of radical irradiation plus Misonidazole (MISO)." | ( Abratt, RP; Barnes, DR; Hammond, JA; Sarembok, LA; Tucker, RD; Williams, AM, 1984) |
| "Moreover, malignant bladder tumors in rabbits were successfully treated with this method." | ( Abe, R; Kato, T; Mori, H; Nemoto, R; Shindo, M, 1983) |
| "The therapeutic principles of bladder cancer are reviewed in the fields of surgery, radiation and chemotherapy." | ( Sakatoku, J; Yamamoto, N, 1983) |
| "Most superficial bladder tumors are best treated by transurethral resection." | ( Englander, L; Huben, RP; McGill, W; Pontes, JE; Wajsman, Z, 1983) |
| "Management of the superficial bladder cancer patient consists of two complementary but separate therapeutic goals: treatment of the existing tumor(s) and prevention of tumor recurrence." | ( Lum, BL; Torti, FM, 1984) |
| "The rate of recurring bladder tumors decreased after instillation therapy." | ( Imai, K; Kaburagi, Y; Miki, M; Yamanaka, H, 1983) |
| "The members of National Bladder Cancer Collaborative Group A have found transurethral resection, cisplatin and full dose external beam radiotherapy practical clinically." | ( Coombs, LJ; Einstein, AB; Prout, GR; Shipley, WU; Soloway, MS; Wajsman, Z, 1984) |
| "Chemotherapy for bladder cancer is administered either in an adjuvant setting or in patients with metastatic disease, most of whom have been treated already with cystectomy and/or radiation." | ( Dougherty, WE; Lynch, JH; Maxted, WC, 1984) |
| "Six patients with low-stage bladder cancer received 4 or 12 treatments of CDDP intravesically with an initial complete response in 3 patients." | ( Echols, CK; Hemstreet, GP; McFarland, S; Weems, WL; West, SS, 1984) |
| "Thirty-five patients with superficial bladder tumors were treated with 4'-Epi-Adriamycin." | ( Akagi, T; Matsumura, Y; Nasu, Y; Obama, T; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1984) |
| "Thirty-nine patients with superficial bladder cancer underwent intravesical instillation therapy of Aclacinomycin-A (ACM)." | ( Kubota, Y; Miura, T; Moriyama, M; Noguchi, S; Oshima, H; Sakuramoto, T; Shuin, T, 1984) |
| "Eighteen cases of bladder cancer were treated with intravesical instillation therapy with 60 mg Adriamycin daily." | ( An, HJ; Cho, JH; Kim, SK, 1983) |
| "Twenty patients with bladder cancer were treated by semiselective intra-arterial chemotherapy with Adriamycin." | ( Fujita, J; Moriwaki, S; Uyama, T; Yonezawa, M, 1983) |
| "We treated 25 bladder cancer patients with combined cytotoxic chemotherapy of adriamycin (10--20 mg/day administration on days 1, 2 and 3), carboquone (4 mg/day administration on day 1 of weeks 3, 4 and 5 and 5-Fu (200 mg/day for 5 weeks) or futraful suppositories (750 mg/day for 5 weeks) as one course." | ( Hisazumi, H; Kojima, A; Mikawa, I; Misaki, T; Naitoh, K; Nakamura, T; Nango, C; Saitoh, Y; Tajiri, S; Uchibayashi, T, 1983) |
| "Argon laser phototherapy of bladder cancer is safe and effective but the superficial effects of argon energy limit its use to patients with small tumors or carcinoma in situ." | ( Dixon, JA; Smith, JA, 1984) |
| "The highest dose induced urinary bladder cancer in all rats treated by week 91, decreasing yields being associated with lower dose levels: an incidence of 76." | ( Fukushima, S; Hirose, M; Ito, N; Shirai, T, 1984) |
| "Among patients with bladder tumors, the rate of relapse was 2/11 following pelvic exenteration (anterior, 10; total 1); 5/12 following partial cystectomy or gross tumor excision; and 3/5 following a primary chemotherapy-radiotherapy (PCR) regimen." | ( Gehan, EA; Hays, DM; Lawrence, W; Raney, RB; Soule, EH; Tefft, M, 1982) |
| "Chemotherapy of advanced bladder cancer aims to destroy all the cancer cells in the host." | ( Koiso, K, 1982) |
| "Two cases of advanced bladder cancer were treated with UFT combined with irradiation therapy, and one case was found that cancer cells degenerated severely in the primary lesion pathologically." | ( Asahi, T; Kaneshige, T; Kumon, H; Matsumura, Y; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1982) |
| "The second patient had noninvasive bladder tumors and was treated with intracavitary irradiation elsewhere." | ( Levin, HS; Maatman, TJ; Montague, DK; Novick, AC, 1983) |
| "Human bladder cancer from cystoscopic biopsies and from established cell lines was transplanted into mice that were immune suppressed by thymectomy plus sequential treatment with 1-beta-D-arabinofuranosylcytosine and whole-body irradiation." | ( Armitage, M; Kovnat, A; Tannock, I, 1982) |
| "Multiple, recurrent cancer of the bladder grade I-II (WHO), stage T1 (UICC) was treated with regular intravesical instillation of ethoglucid (Epodyl) in 39 patients." | ( Colleen, S; Ek, A; Hellsten, S; Lindholm, CE, 1980) |
| "Ten patients with superficial low-grade bladder cancer were treated with intra-vesical instillation of doxorubicin hydrochloride (Adriamycin) with low-dose irradiation (total dose of 800 rads), and the therapeutic effect was evaluated clinically and histopathologically." | ( Kagawa, S; Moriwaki, S; Nakamura, S; Uyama, T, 1980) |
| "Five bladder cancer patients, who had undergone M-VAC neo-adjuvant, chemotherapy were select for this study." | ( Kamidono, S; Miyazaki, J; Okada, H, 1994) |
| "Thirteen patients with invasive bladder cancer treated by induction intra-arterial chemotherapy in combination with radiotherapy achieved a complete response (CR)." | ( Hashine, K; Kasahara, K; Sumiyoshi, Y, 1995) |
| "The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug." | ( Agarwal, AK; Baker, GL; Cash, JM; Gallatin, A; Kahl, LE; Kwoh, CK; Medsger, TA; Radis, CD; Stolzer, BL; Wasko, MC, 1995) |
| "Seventy-six patients with bladder cancer Stage T1G3 through T4 N0 M0 were entered in the same chemotherapy regimen (Cisplatin 20 mg/mq and 5-Fluorouracil 200 mg/mq daily for 5 days) alternated with different radiotherapy scheduling, the first 18 patients received two cycles of 20 Gy/10 fractions/12 days each; the second group of 58 patients received two cycles of 25 Gy/10 fractions/12 days each (the last 21 patients received Methotrexate 40 mg/mq instead of 5-Fluorouracil)." | ( Boccardo, F; Canobbio, L; Curotto, A; Franzone, P; Giudici, S; Guarneri, D; Martorana, G; Orsatti, M; Scarpati, D; Venturini, M, 1995) |
| "Forty patients with bladder cancer who underwent radiotherapy with angiotensin II, a hypertensor, and two cycles of arterial infusion of anticancer chemotherapies, including cisplatin 100 mg/body, were randomly assigned to a granisetron group and a non-granisetron group for comparative study of its prophylactic effect on nausea, vomiting and anorexia." | ( Hayashida, S; Hirasawa, T; Mitsui, H; Nasu, T; Shinohara, Y; Uchiyama, K, 1995) |
| "We have used a panel of bladder cancer cell lines to compare the toxicities of Adriamycin and epirubicin, two drugs used intravesically to treat superficial transitional cell cancer (TCC) of the bladder, alone and in combination with lonidamine, an agent known to be active against anthracycline-resistant disease." | ( Coptcoat, M; Masters, JR; Popert, RJ; Zupi, G, 1995) |
| "A 70-year-old man with invasive bladder cancer and multiple pulmonary metastases received 3 courses of systemic M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy, after which the primary tumor and pulmonary metastases diminished in size and number." | ( Goto, K; Hara, Y; Kobayashi, Y; Mochizuki, M; Tokue, A; Tozuka, K, 1994) |
| "P-glycoprotein can be expressed on bladder cancer cells without prior chemotherapy." | ( Flint, A; Grossman, HB; Liebert, M; Noto, L; Park, J; Shinohara, N, 1994) |
| "Forty patients with invasive bladder tumors were consecutively treated and followed between June 1986 and February 1993." | ( Chuchkova, M; Damianov, C; Koleva, P; Terziev, T, 1994) |
| "For management of muscle-invading bladder cancer (clinical stages T2 to T4), combined treatment of definitive radiotherapy (RT) and intraarterial (IA) administration of chemotherapy was carried out for local cure and bladder preservation." | ( Akaza, H; Koiso, K; Miyanaga, N; Ohara, K; Ohtani, M; Okumura, T; Shimazoi, T; Tsuji, H; Tsujii, H; Uchida, K, 1994) |
| "Twenty patients with primary invasive bladder cancer who underwent radical cystectomy received postoperative adjuvant chemotherapy using a CAP (cyclophosphamide, doxorubicin and cisplatin) or modified M-VAC (methotrexate, vinblastine, pirarubicin and cisplatin) regimen." | ( Kotake, T; Kuroda, M, 1994) |
| "The stage of bladder cancer at presentation and at postchemotherapy pathologic staging are independent prognostic factors for long-term survival in patients treated with neoadjuvant chemotherapy." | ( Bajorin, DF; Bosl, GJ; Fair, WR; Herr, HW; Sarkis, A; Scher, HI; Scherr, D; Schultz, PK; Seidman, A; Zhang, ZF, 1994) |
| "Piritrexim may be an effective drug for bladder cancer after progression on MVAC chemotherapy." | ( Benedetto, P; Clendennin, NJ; Collier, M; Feun, LG; Savaraj, N; Waldman, S, 1994) |
| "An analysis by the Nordic Cooperative Bladder Cancer Study Group concerned the possible benefit of neoadjuvant chemotherapy--given before scheduled low-dose irradiation and cystectomy." | ( Fosså, SD; Hannisdahl, E; Hellsten, S; Rintala, E; Sander, S, 1993) |
| "Treatment of superficial bladder cancers by intravesical mitomycin C (MMC) chemotherapy gives a varying and incomplete response." | ( Au, JL; Badalament, RA; Wientjes, MG, 1993) |
| "Twenty-one patients with superficial bladder cancer entered an analysis of single dose (2'R)-4'-O-tetrahydropyranyladriamycin (THP) or adriamycin (ADM) administration." | ( Akebi, N; Johsen, T; Kaku, S; Nasu, Y; Noda, M; Ohmori, H; Saika, T; Takamatsu, M; Tsushima, T; Uno, S, 1993) |
| "Some 68% of bladder tumors will respond to cisplatin-based chemotherapy but only 30% will have a durable response." | ( Chaganti, RS; Fair, WR; Klein, E; Wood, DP, 1993) |
| "Although most bladder cancers associated with prior cyclophosphamide therapy are transitional cell carcinoma, to our knowledge there have been 6 reports of cyclophosphamide-induced squamous cell carcinoma of the bladder." | ( Boyd, SD; Skinner, DG; Skinner, EC; Stein, JP, 1993) |
| "Thirty-eight bladder cancer cases and 43 controls from these factories were included for study of acetylation phenotype, by dapsone administration, and for polymorphisms in the NAT2 gene, by a polymerase chain reaction (PCR)-based test." | ( Bi, W; Broly, F; Caporaso, N; Feng, P; Hayes, RB; Meyer, UA; Rothman, N; Woosley, RL; Yin, S; You, X, 1993) |
| "Patients with invasive bladder cancer, clinical Stages T2-4, NO-2 or NX, MO were treated with pelvic radiotherapy 40 Gy in 4 weeks and cisplatin 100 mg/m2 on days 1 and 22." | ( Asbell, S; Coughlin, C; Hammond, E; Heaney, J; Krall, J; Martz, K; Porter, A; Tester, W; Venner, P, 1993) |
| "The early diagnosis of bladder cancer is central to the effective treatment of the disease." | ( Bahnson, RR; Becich, MJ; Getzenberg, RH; Hakam, A; Konety, BR; Oeler, TA; Quigley, MM, 1996) |
| "The Nordic Cooperative Bladder Cancer Study Group conducted a randomized phase III study to assess the possible benefit of neoadjuvant chemotherapy in patients with bladder cancer undergoing radical cystectomy after short-term radiotherapy." | ( Hannisdal, E; Hellsten, S; Hellström, P; Malmström, PU; Rintala, E; Wahlqvist, R, 1996) |
| "T1G3 bladder cancer (involvement but no invasion of muscle layers) is a "border line" lesion and is not uniformely treated (some Authors choose a "conservative approach with T." | ( Malvestiti, GM; Pozzi, E; Roggia, A, 1996) |
| "The treatment of T1 G3 bladder cancer is still an issue surrounded by much conflict." | ( Baroni, GP; Bottanelli, A; Marcelli, G; Rovellini, P; Scattoni, V; Sciaraffia, G; Toia, G, 1996) |
| "Trans-urethral resection of the bladder cancer was performed in 8 patients, supported in two cases by immunotherapy with B." | ( Bernardini, P; D'Addezio, F; Del Nero, A; Dell'Orto, P; Mangiarotti, B; Pisani, E; Trinchieri, A, 1996) |
| "Since bladder cancer arises in the superficial lining of the urothelium, it is a likely candidate for site-directed administration of 5-iodo-2'-deoxyuridine radiolabeled with the Auger electron emitter 123I or 125I (*IUdR)." | ( Adelstein, SJ; Baranowska-Kortylewicz, J; Barclay, PD; Berman, RM; Kassis, AI; Richie, JP; Tutrone, RF; Van den Abbeele, AD, 1996) |
| "In patients with bladder cancer, little is known about diffusion in the tumor mass of 5-iodo-2'-deoxyuridine (IUdR) administered intraluminally, although previous studies based on external scanning have shown promising tumor-targeting properties of IUdR instilled intravesically." | ( Adelstein, SJ; Baldassarri, S; Baranowska-Kortylewicz, J; Buralli, S; Collecchi, P; Di Luca, L; Fontanini, G; Kassis, AI; Mariani, G, 1996) |
| "Although chemotherapy for advanced bladder cancer has historically been based on cisplatin-based combination regimens, the limitations of these regimens both in terms of efficacy and toxicity are now widely appreciated." | ( Roth, BJ, 1996) |
| "We treated 47 T2-4 N0 M0 bladder cancer patients with M-CAVI in a neoadjuvant phase II trial." | ( Albanell, J; Banus, JM; Bellmunt, J; Bermejo, B; Carulla, J; De Torres, JA; Lopez-Pacios, MA; Morote, J; Ribas, A; Rovirosa, A; Sole, LA; Vera, R, 1996) |
| "The decision to treat superficial bladder cancer with intravesical therapy should be predicated primarily on disease stage and grade as well as the patient's clinical history." | ( Huben, RP, 1996) |
| "Because bladder cancer has many transferrin (Tf) receptors and gallium has been reported to bind avidly with Tf receptors, gallium cytotoxicity and the possibility of intravesical instillation therapy with gallium nitrate were studied in vitro." | ( Aoyagi, T; Bander, NH, 1995) |
| "Ten patients with invasive bladder cancer and one with locally advanced renal pelvic cancer were treated with concurrent methotrexate, cisplatin and radiotherapy." | ( Himeno, Y; Igawa, M; Ishibe, T; Kadena, H; Kishi, H; Shiina, H; Shirakawa, H; Urakami, S; Usui, T, 1996) |
| "Nine patients with muscle-invasive bladder cancer were treated with intra-arterial THP and CDDP chemotherapy plus radiotherapy." | ( Hashine, K; Karashima, T; Kasahara, K; Sumiyoshi, Y, 1996) |
| "Advanced bilharzial bladder cancer is relatively sensitive to combination chemotherapy, but complete remission and prolonged survival is rare in this subgroup of patients with advanced disease." | ( Abu Rabia, A; el-Attar, I; el-Said, A; Gaafar, R; Gad el-Mawla, N; Hamza, MR; Khaled, HM; Magrath, I, 1996) |
| "Nineteen cases of invasive bladder cancer which had been subjected to two courses of neoadjuvant chemotherapy followed by radical cystectomy were analyzed." | ( Fujimoto, H; Kakizoe, T; Kume, H; Niwakawa, H; Tobisu, K; Tomita, K; Tsutsumi, M; Yuen, K, 1996) |
| "Eighty-five bladder cancers were treated at the Urology Clinic of Nancy and the Centre Alexis Vautrin from 1975 to 1992 with short course preoperative radiation therapy (3 x 3." | ( Guillemin, F; Hoffstetter, S; Hubert, J; Luporsi, E; Peiffert, D; Pernot, M; Six, A; Verhaeghe, J, 1996) |
| "Sixteen patients with invasive bladder cancer were received neoadjuvant methotrexate, vinblastine, pirarubicin and cisplatin chemotherapy on our planning protocol." | ( Horii, A; Ikemoto, S; Kawano, M; Kishimoto, T; Nakatani, T; Nishisaka, N; Sugimura, K; Tsujino, T; Wada, S; Yamamoto, K; Yasumoto, R, 1996) |
| "TNP-470 suppresses the development of bladder tumors when the treatment is started at an early stage of neoplasia." | ( Fujimoto, K; Kawamata, H; Oyasu, R; Tanaka, Y, 1997) |
| "We report three new cases of bladder cancer occurring in patients treated by cyclophosphamide (Endoxan): two patients had Waldenström disease and were treated during 7." | ( Alexandre, J; Bazarbachi, A; Delmer, A; Hunault, M; Lévy, V; Rio, B; Zittoun, R, 1996) |
| "Twelve patients with muscle-invading bladder cancer who were treated by concurrent radiotherapy and intra-arterial infusion of daily low dose of cisplatin using an implanted infusion port were included." | ( Akimoto, T; Mashimo, T; Matsumoto, M; Mitsuhashi, N; Niibe, H, 1997) |
| "The treatment of muscle-invasive bladder tumors currently consists of radical cystectomy with lymph node dissection." | ( Avances, C; Costa, P; Di Palma, M; Jardin, A; Misset, JL; Mottet, N, 1997) |
| "Nine patients with locally invasive bladder cancer received 1 to 4 courses of neoadjuvant intra-arterial chemotherapy, followed by radical cystectomy." | ( Aikawa, K; Ishibashi, K; Koseki, K; Ogihara, M; Shiraiwa, Y; Yamaguchi, O, 1997) |
| "A total of 46 patients with superficial bladder cancer underwent an initial 6-week course of intravesical BCG therapy after transurethral resection." | ( Hudson, MA; Rabinowitz, R; Smith, DS; Tiemann, DD, 1997) |
| "Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy." | ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "From 14 patients who had bladder cancer, clinical specimens were obtained before and after neoadjuvant intra-arterial chemotherapy." | ( Deguchi, T; Fujihiro, S; Kawada, Y; Kawamoto, S; Nezasa, S; Okano, M; Tamaki, M; Yamada, S, 1997) |
| "A total of 33 patients with invasive bladder cancer, clinical stages T2-4NxM0, were treated with aggressive transurethral resection (TUR) followed by three cycles of neoadjuvant methotrexate, cisplatin and vinblastine (MCV) chemotherapy and radiotherapy (60 Gy to the bladder)." | ( Arellano, R; Jiménez, U; López, M; Marín, A; Pérez Torrubia, A; Pinar, B; Zapatero, A, 1997) |
| "Presently, for muscle-invasive bladder cancer, radical cystectomy is considered to be the standard treatment." | ( Birkenhake, S; Kühn, R; Martus, P; Sauer, R; Schrott, KM; Wittekind, C, 1998) |
| "For the application of gene therapy to bladder cancer, we examined four in vivo gene transfer methods without viral vectors." | ( Harimoto, K; Kishimoto, T; Sugimura, K, 1997) |
| "Treatment of bladder cancer by TURB and RT/RCT is an alternative to primary cystectomy." | ( Birkenhake, S; Kühn, R; Martus, P; Sauer, R; Schrott, KM, 1998) |
| "These bladder tumors demonstrate a rapid progression of invasive disease and respond poorly to chemotherapy." | ( Edwards, WG; Gifford, RR; Wofford, JE, 1998) |
| "The majority of patients with invasive bladder tumors who achieve T0 status after neoadjuvant MVAC chemotherapy preserve their bladders for up to 10 years with bladder-sparing surgery." | ( Bajorin, DF; Herr, HW; Scher, HI, 1998) |
| "We define the risk of bladder cancer in multiple sclerosis related to the use of indwelling catheters and cyclophosphamide administered as an immunomodulating agent." | ( Baert, L; Carton, H; D'Hooghe, B; De Ridder, D; Demonty, L; Gonsette, R; van Poppel, H, 1998) |
| "Rats bearing orthotopic bladder tumors were treated either intravesically or intravenously with graded doses of 5-aminolevulinic acid (ALA) or PII." | ( Brown, KM; Lown, JW; McCallum, TJ; Miller, GG; Moore, RB; Tulip, J; Xiao, Z, 1998) |
| "Treatment of the T24 human bladder cancer cell line with anti-Fas mAb in combination with 5-fluorouracil, mitomycin C or methotrexate did not overcome resistance to these agents." | ( Bonavida, B; Mizutani, Y; Yoshida, O, 1998) |
| "Patients with superficial bladder cancer (pTa, pT1, pTis) were treated with intravesical MMC (30 mg, weekly for 4 weeks, and thereafter monthly for 5 months) or BCG (weekly for 6 weeks)." | ( Collette, L; Debruyne, FM; Sylvester, R; v d Meijden, AP; van Aubel, A; Witjes, JA; Witjes, WP, 1998) |
| "There were 11 deaths from bladder cancer (31% of the patients): 9 from distant metastase, one from local failure, and one from treatment." | ( Aref, I; Crook, J; Eapen, L; Futter, N; Grimard, L; Huan, S; Peterson, R; Rasuli, P; Stewart, D, 1998) |
| "The definitive treatment for advanced bladder cancer is considered to be systemic chemotherapy." | ( Hirao, Y; Ozono, S, 1998) |
| "But we really obtained superficial bladder tumors directly attached to the bladder surface with one of the two methods of tumor induction consisting in the abrasion of the bladder surface prior to the administration of the tumoral cells in the bladder cavity." | ( Bisson, JF; Guillemin, F; Labrude, P; Notter, D; Vigneron, C, 1999) |
| "Of 25 bladder cancer patients, 11 received 6 weeks of intravesical Bacille Calmette-Guerin (BCG), and 14 were treated weekly with intravesical dimethylsulfoxide (DMSO) for 4 weeks to further modulate biomarker expression." | ( Bonner, RB; Hemstreet, GP; Hurst, RE; Mellott, JE; Rao, J; Rooker, GM, 1999) |
| "Normal urothelial cells and bladder cancer cell lines MBT-2 and T24 show NOS activity, and cytokine treatment induces calcium-independent NOS activity." | ( Adolfsson, J; Jansson, OT; Kratz, G; Morcos, E; Wiklund, NP, 1999) |
| "In urinary bladder cancer, this technique results in improved local and nodal staging, in improved separation of transurethral granulation tissue and edema from malignant tumor, and in improved evaluation of the effect of chemotherapy." | ( Barentsz, JO; de LaRosette, J; Engelbrecht, M; Heerschap, A; Huisman, HJ; Jager, GJ; van Der Sanden, BP; Witjes, JA, 1999) |
| "In urinary bladder cancer, the combination chemotherapy with 5-FU and low-dose CDDP has been used as a radiosensitizer." | ( Fujinami, K; Kubota, Y, 1999) |
| "Treatment of ADR-resistant fresh bladder cancer cells with ADR at 0." | ( Miki, T; Mizutani, Y; Yoshida, O, 1999) |
| "Patients with bladder cancer who achieved complete or partial responses and those who had progression of the disease after systemic chemotherapy with methotrexate, vinblastine, epirubicin and cisplatin were compared according to the pretreatment values of the peripheral blood lymphocyte subsets." | ( Baltaci, S; Bedük, Y; Soygür, T; Tokgöz, G; Yaman, O, 1999) |
| "Intravesical therapy of superficial bladder cancer has been in routine use since the introduction of thiotepa in 1961." | ( Malmström, P, 2000) |
| "Eight patients with locally advanced bladder cancer who were not candidates for radical cystectomy or concurrent intra-arterial chemotherapy and radiotherapy were treated with combined platinum-based chemotherapy and radiation therapy." | ( Hashine, K; Nakatsuji, H; Sumiyoshi, Y; Yamashita, Y, 1999) |
| "One histopathologic stage of bladder cancer is CIS, for which BCG intravesical immunotherapy is the first-line therapy." | ( Erwin-Toth, P; Grossman, HB; Lamm, DL; Magar, R; Marchetti, A; Schellhammer, PF; Wang, L, 2000) |
| "Thirty patients with urinary bladder cancer and intractable bladder hemorrhage were treated with intraarterial (i." | ( Dölitzsch, C; Layer, G; Schild, HH; Strunk, H; Textor, HJ; Wilhelm, K, 2000) |
| "We report a case of invasive bladder cancer after cyclophosphamide administration for nephrotic syndrome, and briefly discuss the association of bladder cancer and cyclophosphamide." | ( Ikegami, Y; Kasaoka, Y; Nakamoto, T; Usui, T, 2000) |
| "Treatment of the T24 bladder cancer cells with the TZD PPARgamma agonist troglitazone, dramatically inhibited 3H-thymidine incorporation and induced cell death." | ( Breyer, MD; Breyer, RM; Davis, L; Guan, YF; Zhang, YH, 1999) |
| "In 28 patients with superficial bladder cancer treated with BCG IL-8 expression in the urine during the first 6 hours after the first BCG instillation was determined." | ( Cecchini, MG; Möhrle, K; Rentsch, C; Sermier, A; Studer, UE; Thalmann, GN, 2000) |
| "Of the control animals 66% developed bladder tumors and 55% of the animals treated with calcitriol early (3 weeks) after tumor induction developed bladder tumors." | ( Dhir, R; Getzenberg, RH; Hershberger, P; Johnson, CS; Konety, BR; Lavelle, JP; Meyers, SA; Nguyen, TS; Pirtskalaishvili, G; Shurin, MR; Trump, DL; Zeidel, ML, 2001) |
| "Surgical removal of metastases from bladder cancer refractory to systemic therapy has an impact on the quality of life of patients with symptomatic disease only." | ( Krege, S; Otto, T; Rübben, H; Suhr, J, 2001) |
| "Thirteen patients with invasive bladder cancer who had residual tumor after transurethral resections, were treated with consecutive intraarterial (IA) cisplatin (15 mg/d; total, 150 mg) and concurrent radiation (1." | ( Fukuda, K; Fukuda, Y; Ganaha, F; Irie, T; Ujita, M; Yamada, T, 2001) |
| "Eighteen patients with locally invasive bladder cancer were treated with 1 or 2 cycles of neoadjuvant chemotherapy consisting of methotrexate, epirubicin and cisplatin (MEC)." | ( Hosaka, M; Ikeda, I; Kawakami, S; Kubota, Y; Masuda, M; Noguchi, S; Ohuchi, H; Saito, K; Takase, K; Yao, M, 2001) |
| "We report a case of a bladder cancer occurring after a lag time of 20 years after oral therapy with cyclophosphamide for ovarian cancer." | ( Gnann, R; Kreienberg, R; Pfaff, P; Volm, T, 2001) |
| "Invasive bladder cancer is a chemotherapy-sensitive neoplasm." | ( Malkowicz, SB; Vaughn, DJ, 2001) |
| "On this basis, we treated bladder cancer patients in two trials using gemcitabine 1,000 mg/m(2) on days 1 and 8, and carboplatin (area under the curve 5) on day 1, every 21 days." | ( Carles, J; Nogué, M, 2001) |
| "The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone." | ( Glaholm, JG; Hussain, SA; James, ND; Moffitt, DD; Peake, D; Wallace, DM, 2001) |
| "Invasiveness of bladder cancer cells was greatly decreased in association with the great increase of GM3 synthesis induced by BFA treatment." | ( Hakomori, SI; Handa, K; Hoshi, S; Ito, A; Nojiri, H; Numahata, K; Ohyama, C; Saito, S; Satoh, M, 2001) |
| "In phase II trials in superficial bladder cancer, marker lesions have been used to test the ablative activity of intravesical chemo- or immunotherapy." | ( Bono, AV; Brausi, M; de Balincourt, C; Hall, R; Mack, D; Oosterlinck, W; Sylvester, R, 2001) |
| "Therapy of metastatic bladder cancer with doxorubicin-cisplatin was made more tolerable by this same circadian approach resulting in a 57% objective response rate." | ( Hrushesky, WJ; Kobayashi, M; Wood, PA, 2002) |
| "administration of CG8840 in RT4 human bladder cancer xenografts caused significant (P < 0." | ( Chen, Y; Dilley, J; Li, Y; Ramesh, N; Working, P; Yu, DC; Zhang, J, 2002) |
| "With regard to bladder cancer, advances in drug development and modern light delivery techniques mean that photodynamic therapy shows promise in the treatment of superficial bladder cancer resistant to conventional treatments." | ( Betts, CD; Briggs, C; Clarke, NW; Moore, JV; O'Flynn, KJ; Shackley, DC; Whitehurst, C, 2001) |
| "Patients with superficial bladder cancer refractory to intravesical bacillus Calmette-Guérin (BCG) therapy and refusing a cystectomy were considered eligible for the trial." | ( Bajorin, D; Dalbagni, G; dePalma, D; Donat, MS; Herr, HW; Mazumdar, M; Rabbani, F; Russo, P; Sheinfeld, J; Sogani, P; Tong, W, 2002) |
| "From weeks 97-104, urinary bladder tumors were observed in 8 of 31 and 12 of 31 rats in groups treated with 50 and 200 p." | ( Endo, G; Fukushima, S; Iwai, S; Morimura, K; Nakae, D; Wanibuchi, H; Wei, M; Yoshida, K, 2002) |
| "Treatment of bladder cancer requires an interdisdisciplinary approach, including urologist, medical oncologist and radiation oncologist." | ( Chrétien, Y; Durdux, C; Oudard, S, 2003) |
| "Although the incidence of bladder cancer has increased, responses to therapy have been limited." | ( Matsushima, M; Sato, D, 2003) |
| "We demonstrated in the orthotopic mouse bladder cancer model that successful inhibition of tumor cell growth could be obtained with cytokine gene therapy." | ( Esuvaranathan, K; Mahendran, R; Wu, Q, 2003) |
| "Human bladder cancer cells were treated with pathway specific inhibitors or were transfected with PI-3 kinase pathway components." | ( De Vere White, R; Highshaw, RA; Khan, Q; Obata, T; Sweeney, C; Wu, X, 2004) |
| "Superficial bladder cancer can be treated by transurethral resection and additional intravesical therapy." | ( Laan, A; Peters, GJ; Schalken, JA; van der Heijden, AG; Vriesema, JL; Witjes, JA, 2004) |
| "The recurrence rate for superficial bladder tumors treated with complete resection averages 88%." | ( Kamat, AM; Lamm, DL, 2004) |
| "Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall." | ( Colombo, R; Gofrit, ON; Leib, Z; Naspro, R; Nativ, O; Pode, D; Shapiro, A; Sidi, A; van der Heijden, AG; Witjes, JA, 2004) |
| "Of 149 consecutive patients treated for cancer of the bladder, 14 patients met eligibility criteria." | ( Goffin, JR; Rajan, R; Souhami, L, 2004) |
| "In this study, locally advanced bladder cancer was treated by radiation combined with cisplatin therapy and a retrospective analysis was conducted to predict the clinical response to chemoradiotherapy (CRT) based on the immunohistochemistry of apoptosis-related proteins." | ( Fukunaga, K; Matsumoto, H; Matsuyama, H; Naito, K; Wada, T; Yoshihiro, S, 2004) |
| "Two human bladder cancer cell lines were grown in culture using standard techniques and treated with Rofecoxib at doses ranging from 125 microg/well serially diluted down to 8." | ( Jackson, BJ; Kandzari, S; McFadden, D; Mohseni, H; Riggs, DR; Zaslau, S, 2004) |
| "Three of five human bladder cancer cell lines expressed LRAT mRNA independent of retinoid exposure, whereas in two cell lines LRAT mRNA expression was induced by retinoid treatment." | ( Bok, D; Boorjian, S; Gudas, LJ; Mongan, NP; Nanus, DM; Rando, RR; Scherr, DS; Tickoo, SK; Yu, H, 2004) |
| "Local control of HDR brachytherapy for bladder cancer was disappointing and late toxicity unexpectedly high." | ( Bartelink, H; Horenblas, S; Lebesque, J; Moonen, L; Pos, FJ; Schneider, C; Sminia, P, 2004) |
| "In all, 69 patients with Ta/T1 bladder cancer were randomly assigned to four intravesical administration protocols: A, delayed instillation (first instillation 7 days after TURBT) and low-dose (30 mg once every 2 weeks, six times): B, early instillation (three instillations before 7 days after TURBT) and low-dose; C, delayed and high-dose (30 mg once weekly 12 times) instillation; D, early and high-dose." | ( Akao, T; Habuchi, T; Kato, T; Li, Z; Mitsumori, K; Ohyama, C; Sato, K; Tsuchiya, N, 2004) |
| "Invasive bladder cancers have been treated by irradiation combined with cis-platinum (CDDP) as a bladder preservative option." | ( Fukunaga, K; Matsumoto, H; Matsuyama, H; Naito, K; Wada, T; Yoshihiro, S, 2004) |
| "We have demonstrated that bladder cancer exhibits a range of hypoxia, proliferation and vascular density which may be used to form the basis for patient selection for hypoxia modification, accelerated radiotherapy and vascular targeting agents." | ( Daley, FM; Hoskin, PJ; Saunders, MI; Sibtain, A; Wilson, GD, 2004) |
| "Combination treatment of T24 bladder cancer cells with JTE-522 and cis-diamminedichloroplatinum (II) (CDDP) resulted in a synergistic cytotoxic effect." | ( Kawauchi, A; Li, YN; Miki, T; Mizutani, Y; Nakanishi, H; Sato, N, 2004) |
| "The 4 bladder cancer cell lines UM-UC-6, UM-UC-9, UM-UC-10 and UM-UC-13 were treated with 2 retinoids, namely all-trans-retinoic acid (ATRA) and 9-cis retinoic acid (9cRA), as well as with IFN or with combinations of retinoids and IFN." | ( Grossman, HB; Liebert, M; Lotan, R; Qian, L; Ramakumar, S; Wang, J; Zang, R; Zou, C, 2005) |
| "A 77-year-old man with invasive bladder cancer and right ureter cancer had been treated with 3 courses M-VAC (methotrexate, vinblastine, epirubicin, cisplatin) chemotherapy." | ( Kawasaki, Y; Matsushita, M; Okada, Y, 2004) |
| "Neoadjuvant chemotherapy for invasive bladder cancer, involving a regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC), can improve the resectability of larger neoplasms for some patients and offer a better prognosis." | ( Fujioka, T; Kanehira, M; Katagiri, T; Kohri, K; Matsushita, Y; Miki, T; Nakamura, Y; Namiki, M; Shuin, T; Takata, R; Tsunoda, T, 2005) |
| "An earlier study in bladder cancer indicated that toxicity was an important determinant of treatment preference (Davey et al." | ( Aristides, M; Bhalla, S; Brown, A; Kielhorn, A; Roberts, T; Von Der Maase, H, 2005) |
| "Current therapies for bladder cancer are suboptimal and adenoviral gene therapy has been explored as an alternative treatment." | ( El-Zawahry, A; Lu, P; Voelkel-Johnson, C; White, SJ, 2006) |
| "Forty patients with advanced bladder cancer entered the study; 34 males/6 females, median age: 68 (range, 59-76), median PS (Karnovsky): 80, without receiving prior chemotherapy." | ( Alamanis, C; Bougas, D; Dimitrakopoulos, A; Giannopoulos, A; Kopterides, P; Kopteridis, P; Kosmas, C; Mitropoulos, D; Skopelitis, H; Stravodimos, K; Tsavaris, N, 2005) |
| "Superficial bladder cancer can be treated surgically, but patients are at high risk for recurrence." | ( Hale, K; Lamm, DL; McGee, WR, 2005) |
| "The CK was not detected in urine of bladder cancer patients showing response to radiotherapy." | ( Attallah, AM; El-Dosoky, I; El-Sharabasy, MM; Ibrahim, AS; Ismail, H; Ismail, MF; Sakr, HA, 2006) |
| "Twelve patients with known bladder cancer received a 2-hour administration of 50 mL of phosphate-buffered saline containing 4 mmol/L, 8 mmol/L or 16 mmol/L of hexylaminolevulinate." | ( Aymon, D; Collaud, S; Gurny, R; Jichlinski, P; Lange, N; Marti, A, 2006) |
| "A human bladder cancer cell line, BIU-87, was treated with different concentrations of TSA." | ( Chen, Z; Li, GC; Pan, TJ; Ye, ZQ; Zhang, X, 2006) |
| "Patients with superficial bladder cancer refractory or intolerant to intravesical BCG therapy and refusing a cystectomy were considered eligible for the trial." | ( Bajorin, D; Ben-Porat, L; Bochner, B; Dalbagni, G; Donat, MS; Herr, HW; Russo, P; Sheinfeld, J; Sogani, P, 2006) |
| "G3 Ta-1 bladder cancers and CIS showed a high risk of recurrence, and required aggressive treatment." | ( Chihara, Y; Fujimoto, K; Hirao, Y; Kondo, H, 2006) |
| "Superficial bladder cancer, where treatments are usually administered by vesical instillation, may represent such an indication." | ( Adorini, L; Daniel, KC; Penna, G, 2006) |
| "With the unraveling of bladder cancer biology and the discovery of novel agents targeting several carcinogenic pathways, the future of therapy for transitional cell carcinoma appears promising." | ( Berry, WR; Hutson, TE; Sonpavde, G, 2006) |
| "Human bladder cancer cell lines were treated with various AA metabolic enzymes inhibitors for lipoxygense (LOX) and cyclooxygenase (COX) pathways, and the growth suppression effects were examined." | ( Hayashi, T; Nishiyama, K; Shirahama, T, 2006) |
| "Nonmuscle-invasive bladder cancer is a common malignancy, standardly treated by transurethral resection and adjuvant intravesical instillations of chemotherapy or immunotherapy." | ( Hendricksen, K; Witjes, JA, 2006) |
| "Treatment of T24 bladder cancer cells with VP16 (50 microM) for 48 h induced phosphorylation of the EGFR and activation of the EGFR prevented the apoptosis induced by VP16." | ( Memon, AA; Munk, M; Nexo, E; Sorensen, BS, 2007) |
| "Human bladder cancer cell line T-24 was infected with oncolytic virus (ONYX-015) of different multiplicity of infection, or treated with MMC in addition to ONYX-015." | ( Tan, WL; Wu, YD; Xie, Y; Zhao, GZ; Zheng, SB; Zhu, WH, 2006) |
| "We report a case of bladder cancer with pelvic lymph node metastasis effectively treated by chemotherapy followed by radiotherapy." | ( Arai, Y; Hatano, K; Inoue, H; Kawashima, A; Miyagawa, Y; Miyake, O; Nishimura, K; Okuyama, A; Takaha, N, 2006) |
| "A 59-year-old woman with bladder cancer who was an HBV carrier developed severe liver dysfunction after 2 cycles of chemotherapy." | ( Chuma, M; Harabayashi, T; Higashiyama, H; Hige, S; Nonomura, K; Shinohara, N, 2007) |
| "Using the T24 human bladder cancer cell line, we found that EGCG treatment caused dose- and time-dependent inhibition of cellular proliferation and cell viability, and induced apoptosis." | ( Bai, Y; Dahiya, R; Li, LC; Qin, J; Shen, HF; Wang, YB; Xie, LP; Zheng, XY, 2007) |
| "Finally, we showed that treatment of bladder cancer cells with the methylation inhibitor, 5-aza-2'-deoxycytidine, alone or in combination with the histone deacetylase inhibitors MS-275 and 4-phenylbutyrate could strongly induce the expression of MAGE-A9." | ( Bergeron, A; Fradet, Y; Larue, H; Picard, V, 2007) |
| "To report a series of patients with bladder cancer treated with hypofractionated accelerated radiotherapy with amifostine cytoprotection, with or without concurrent liposomal doxorubicin." | ( Koukourakis, MI; Touloupidis, S; Tsolos, C, 2007) |
| "A total of 38 patients with invasive bladder cancer were treated with 15 consecutive fractions of 3." | ( Koukourakis, MI; Touloupidis, S; Tsolos, C, 2007) |
| "Seven bladder cancer cell lines were characterized for HER1/EGFR expression, then treated with erlotinib alone, IFNalpha alone, or IFNalpha plus erlotinib." | ( Brenner, PC; Goldstein, D; Hayes, VM; Qu, XJ; Russell, PJ; Yang, JL, 2007) |
| "Localized early-stage bladder cancer is treated with resection and intravesical cytokine therapy, whereas metastatic cancer is typically treated with various combinations of systemic chemotherapy." | ( Aggarwal, BB; Kamat, AM; Sethi, G, 2007) |
| "In patients with locally advanced bladder cancer, NED following chemotherapy alone or chemotherapy plus supplementary cystectomy or radiotherapy is essential to achieve long-term survival." | ( Als, AB; Sengelov, L; von der Maase, H, 2007) |
| "A 2-hours treatment of bladder cancer cells triggered a later, strong cytotoxic effect." | ( Eggenschwiler, J; Hunziker-Basler, N; Rist, L; Simões-Wüst, AP; Viviani, A; Zuzak, TJ, 2007) |
| "She had a history of superficial bladder tumors which were treated with transurethral resection (TURBT)." | ( Ao, T; Baba, S; Hirayama, T; Irie, A; Iwabuchi, K; Iwamura, M; Kudoh, O; Matsumoto, K; Uchida, T, 2007) |
| "We analyzed 59 patients with advanced bladder cancer who received MVAC chemotherapy at Sapporo Medical University hospital from January 1992 to September 2004." | ( Hirobe, M; Honma, I; Itoh, N; Maeda, T; Masumori, N; Takahashi, A; Tsukamoto, T, 2007) |
| "Murine bladder tumor-2 mouse bladder tumors exposed to intravesically administered RCR vectors exhibited 0%, 9." | ( Bochner, BH; Cordon-Cardo, C; Kasahara, N; Kikuchi, E; Logg, CR; Menendez, S; Ohori, M; Ozu, C, 2007) |
| "The high mortality rate in bladder cancer can be reduced by early treatment following pre-cancerous screening." | ( Chin, WW; Fu, CY; Lau, WK; Ng, BK; Olivo, M; Razul, SG; Tan, PH, 2007) |
| "Recommended treatment for stage Ta T1 bladder cancer is instillation of a chemotherapeutic agent within 6 hours of transurethral resection of bladder tumor based on recent review of literature." | ( McDonald, CE, 2007) |
| "Up to 50% of patients with bladder cancer cannot be treated with cisplatin because they are considered unfit due to poor renal function." | ( Albanell, J; Bellmunt, J; Berrocal, A; Carles, J; Climent, M; Esteban, E; Fabregat, X; Font, A; Garcia-Ribas, I; Gonzalez-Larriba, JL; Marfa, X, 2007) |
| "IHC of bladder tumors showed less cell proliferation and a higher expression of p21WAF1 in the belinostat-treated mice." | ( Ara, G; Bajorin, DF; Buckley, MT; Chiriboga, L; Liebes, L; Osman, I; Qian, X; Sun, TT; Wu, XR; Yee, H; Yoon, J, 2007) |
| "Furthermore, bladder cancer patients that expressed EPOR in tumor samples had a reduced survival in absence of rhEPO treatment." | ( Aguilera, A; Andreu, FB; Belda-Iniesta, C; Carpeño, Jde C; Casado, E; Cejas, P; de la Peña, J; Feliu, J; Ferreira, JA; González-Barón, M; Ibanez de Caceres, I; Madero, R; Manguan-García, C; Perez-Sánchez, E; Perona, R; Sanchez-Perez, I; Sereno, M, 2007) |
| "Treatment options for bladder cancer include surgery, combined with chemotherapy, radiation, and/or immunotherapy." | ( Dikmen, ZG; Gryaznov, SM; Shay, JW; Wright, WE, 2008) |
| "Selected patients with muscle-invasive bladder cancers may survive after transurethral resection and neoadjuvant chemotherapy, and tumor features can identify which patients responding completely to chemotherapy may survive without cystectomy." | ( Herr, HW, 2008) |
| "Various bladder cancer cell lines were treated with HTI-286 and mitomycin C (MMC) in vitro." | ( Adomat, H; Andersen, RJ; Fazli, L; Fradet, Y; Gleave, ME; Hadaschik, BA; So, AI, 2008) |
| "In patients with low-risk bladder tumors, the effectiveness of six weekly MMC instillations was determined and compared with the results of patients not receiving adjuvant treatment." | ( Budäus, L; Conrad, S; Friedrich, MG; Huland, H; Isbarn, H; Pichlmeier, U, 2008) |
| "The Bcl-2 expression in bladder cancer cells is decreased and caspase-3 expression increased after NaB treatment." | ( Li, S; Li, X; Tian, B; Tian, Y; Wang, D; Wang, Z, 2008) |
| "We administered UFT to 12 patients with bladder cancer." | ( Fujimoto, K; Hirao, Y; Okajima, E; Ozono, S; Tsujimoto, S, 2008) |
| "The system chemotherapy in invasive bladder tumors treatments is marked with accent." | ( Acimovic, M; Dzamic, Z; Hadzi-Djokic, J; Janicic, A; Radosevic-Jelic, Lj; Tulic, C, 2007) |
| "In vitro the 4 bladder cancer cell lines 253JB-V, UMUC-3, KU-7 and UMUC-13 were treated with gefitinib and vascular endothelial growth factor secretion was measured." | ( Adam, L; Bar-Eli, M; Black, PC; Brown, GA; Dinney, CP; Fisher, MB; Gallagher, D; Inamoto, T; Kassouf, W; Luongo, T; McConkey, DJ, 2008) |
| "Superficial bladder cancers are usually managed with transurethral resection followed by the intravesical administration of Bacillus Calmette-Guerin which requires major histocompatibility complex (MHC) class I expression on cancer cells." | ( Ashihara, E; Habuchi, T; Kimura, S; Maekawa, T; Maita, S; Sato, K; Takeuchi, M; Tsuchiya, N; Yuasa, T, 2009) |
| "In patients with solitary stage T1-T2 bladder cancer (< or = 5 cm) who refuse radical cystectomy or who are poor candidates for major surgical procedures, this modality is a valuable treatment alternative." | ( Battermann, JJ; Bosch, JL; Kok, ET; Oddens, JR; van Moorselaar, RJ; van Onna, IE, 2009) |
| "Twenty patients with a muscle-invasive bladder cancer were treated by TURBT followed by concurrent cisplatin (75 mg/m(2) day), administered on weeks 1 and 4 of radiotherapy." | ( Chung, J; Han, KS; Joung, JY; Kim, TS; Lee, KH; Seo, HK, 2008) |
| "The USC Department of Urology bladder cancer database was searched for subjects who received adjuvant chemotherapy following cystectomy for transitional cell carcinoma with extravesical and/or lymph node involvement, yielding 187 cases." | ( Dorff, TB; Miranda, G; Quinn, DI; Skinner, DG; Stein, JP; Tsao-Wei, D, 2009) |
| "For patients with invasive bladder cancer the usual recommended treatment is radical cystectomy, although transurethral resection of the tumor, systemic chemotherapy, and radiotherapy are each effective in some patients." | ( Gamal El-Deen, HS, 2007) |
| "Treatment of bladder cancer cells with Nurr1-active C-DIM resulted in decreased cell survival (MTT assay) and induction of cell death pathways, resulting in poly(ADP-ribose) polymerase cleavage and DNA fragmentation." | ( Chintharlapalli, S; Cho, SD; Inamoto, T; Kamat, AM; Papineni, S; Safe, S, 2008) |
| "The charts of patients with superficial bladder cancer treated with induction or maintenance intravesical therapy (IVT) were reviewed retrospectively." | ( Berry, A; Carroll, P; Konety, B; Whitson, J, 2009) |
| "Patients with stages T2-4aN0M0 bladder cancer suitable for cystectomy underwent radical transurethral resection and induction chemotherapy, followed by concurrent chemoradiotherapy (CCRT)." | ( Cheng, AL; Cheng, JC; Hsu, CH; Hsu, FM; Huang, CY; Huang, KH; Lin, CC; Pu, YS; Tsai, YC, 2009) |
| "High grade invasive bladder cancer is a leading cause of cancer deaths and treatment options are limited for this type of cancer." | ( Byun, SS; Khandrika, L; Kim, FJ; Koul, HK; Koul, S; Kumar, B; Wilson, S, 2009) |
| "The treatment of locally advanced bladder cancer with intra-arterial chemotherapy seems to be good for patients with less risk factor, but not so good for patients with more risk factors." | ( Hirai, M; Kobayashi, Y; Matsuura, K; Matsuzaki, A; Terauchi, F; Washino, S, 2009) |
| "Patients with non-muscle-invasive bladder cancer with an intermediate or high risk need adjuvant intravesical therapy after surgery." | ( Crawford, DE; Di Stasi, SM; Friedrich, M; Krege, S; Malmström, PU; Rintala, E; Solsona, E; Sylvester, RJ; Witjes, JA, 2009) |
| "About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy." | ( Agarwal, N; Hussain, M, 2009) |
| "The findings for bladder cancer should be treated with caution as they relate to a relatively early period of follow-up and are based on very small numbers." | ( Dost, A; Sorahan, T; Straughan, JK, 2009) |
| "T24 cells (human bladder cancer cell lines) were pre-coated with fibronectin, and treated with mitomycin C (MMC) and the specific phosphoinositide-3 kinase (PI3-K) inhibitor LY294002." | ( Pan, CW; Shao, Y; Shen, ZJ; Sun, J; Tang, XY; Wang, M; Wu, TT, 2009) |
| "Urinary biomarkers for the detection of bladder cancer have been developed, but no similar markers exist for prediction of clinical outcomes after receiving chemotherapy." | ( Baras, A; Moskaluk, C; Nitz, M; Pollard, C; Theodorescu, D; Williams, P, 2009) |
| "Low-grade RT-4 and high-grade UM-UC-3 bladder cancer cells were treated with 0-50 muM celecoxib." | ( Burmeister, CB; Gee, JR; Havighurst, TC; Kim, K, 2009) |
| "Chemotherapy for metastatic bladder cancer is rarely curative." | ( Cheon, S; Cho, H; Espina, V; Havaleshko, DM; Lee, JK; Liotta, LA; Owens, CR; Petricoin, EF; Smith, SC; Theodorescu, D; Wulfkuhle, JD, 2009) |
| "Using the rat model of bladder tumors, we found that bladder tumor burdens were significantly lower in the rats treated with BI-TK/GCV group than that treated with normal saline control group (p <0." | ( He, Y; Liu, G; Ma, Y; Tang, W; Zhou, S, 2009) |
| "Treatment of bladder cancer cells with resveratrol resulted in a significant decrease in cell viability." | ( Bai, Y; Mao, QQ; Qin, J; Shen, HF; Wang, YB; Xie, LP; Yang, K; Zheng, XY, 2010) |
| "Neoadjuvant chemotherapy for invasive bladder cancer, involving a regimen of M-VAC, can manage micrometastasis and improve the prognosis." | ( Fujioka, T; Obara, W; Takata, R, 2010) |
| "Previous reports suggested that bladder cancer patients who continue to smoke while receiving chemotherapy have poorer outcomes than their nonsmoking counterparts." | ( Chen, RJ; Guo, HR; Ho, YS; Wang, YJ, 2010) |
| "In studies using orthotopic mouse bladder cancer, the tumor loads in R-837-treated mice were significantly lower than those in vehicle-treated or non-treated mice." | ( Barberis, A; Carson, DA; Chan, M; Corr, M; Cottam, HB; Crain, B; Hayashi, T; Leoni, L; Maj, R, 2010) |
| "Patients with bone metastases from bladder cancer who were receiving palliative radiotherapy were randomized to placebo or zoledronic acid (4 mg intravenous monthly) for 6 months." | ( Boutrus, R; El-Attar, I; El-Hossieny, H; Kader, YA; Nazmy, M; Zaghloul, MS, 2010) |
| "Eighty-two bladder cancer patients were treated with hypofractionated/accelerated RT (14×2." | ( Giatromanolaki, A; Kalaitzis, C; Koukourakis, MI; Kyrgias, G; Panteliadou, M; Pistevou, K; Touloupidis, S; Tsoutsou, P, 2011) |
| "Human bladder cancer cell lines RT-4, 253J, 5637, BIU-87 and T24 were cultured and treated with 5-Aza-dC and(or) TSA." | ( Ai, X; Ju, ZH; Shi, TP; Wang, BJ; Wang, C; Ying, MG; Zhang, GX; Zhang, X, 2010) |
| "Human bladder cancer T24 and UMUC3 cells were pretreated with 1,25D3 followed by gemcitabine and cisplatin." | ( Johnson, CS; Ma, Y; Trump, DL; Yu, WD, 2010) |
| "The majority of bladder cancer deaths are due to unresectable lesions that are resistant to chemotherapy." | ( Chen, RJ; Ho, CT; Wang, YJ, 2010) |
| "The methylated bladder cancer cells were treated with 5-Aza- 2'-deoxycytidine (5-Aza-CdR), a demethylating agent." | ( Luo, C; Pan, C; Pu, J; Shen, S; Wang, C; Wu, X; Yang, S, 2010) |
| "A total of 48 patients with superficial bladder cancer, initially treated with bladder sparing approach between 1990 and 1992, were available for long-term follow-up ranging between 10 and 15 years; the remaining patients were lost to follow-up." | ( Das, SK; Dwivedi, US; Kumar, A; Pandey, AK; Samir Swain, HB; Sharma, GK; Singh, PB; Trivedi, S, 2010) |
| "The study group comprised of 101 bladder cancer patients treated with platinum-based CRT, and seven polymorphisms in XPC (Lys939Gln, rs2228001), XPD (Lys751Gln, rs13181), XPG (Asp1104His, rs17655), XRCC1 (Arg399Gln, rs25487), XRCC3 (Thr241Met, rs861539), TP53 (Arg72Pro, rs1042522) and MDM2 (SNP309, T>G, rs2279744) were genotyped." | ( Eguchi, S; Hara, T; Hinoda, Y; Kawai, Y; Matsumoto, H; Matsuyama, H; Nagao, K; Naito, K; Sakano, S; Sasaki, M; Shinohara, A; Wada, T, 2010) |
| "Superficial bladder cancer occurs in the urothelial layer of the bladder and is usually treated by transurethral resection and chemotherapy." | ( Burt, H; Jackson, J; Tsallas, A, 2011) |
| "Human bladder cancer cell lines TCCSUP and 253J were treated with VPA and mRNA expression of natural killer group 2D (NKG2D) ligands was determined." | ( Acharya, B; Gotoh, A; Naoe, M; Okamura, H; Suzuki, T; Terao, S; Yamamoto, S, 2010) |
| "Synergism was observed when the bladder cancer cell line 5637 cells were treated with gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine." | ( Cheng, L; Evans, C; Pan, CX; Wang, S; Zhang, H, 2010) |
| "Treatment of NTUB1, a human bladder cancer cell, with 1 or 1 cotreated with cisplatin for 24 h resulted in a decreased viability of cells." | ( Hour, TC; Huang, AM; Lee, LY; Lin, CN; Lin, KW; Pu, YS; Tu, HY; Wu, CC; Yang, SC, 2011) |
| "The treatment and prognosis of bladder cancer are based on the depth of primary tumour invasion and the presence of metastases." | ( Bouchelouche, K; Gerke, O; Holt, P; Jensen, TK; Marcussen, N; Riehmann, M; Svolgaard, B, 2011) |
| "In an orthotopic bladder cancer mouse model, intravesical treatment with survivin or PLK1 UsiRNA in DiLA(2) liposomes at 1." | ( Adami, R; Bell, S; Brown, T; Charmley, P; Chen, F; Chen, Y; Fam, R; Farber, K; Fosnaugh, K; Harvie, P; Houston, ME; Johns, R; Kwang, E; Liu, Y; Maciagiewicz, I; Matsui, Y; McCutcheon, M; Polisky, B; Seth, S; Severson, G; So, A; Takagi, A; Templin, MV; Vaish, N; Zhu, T, 2011) |
| "In the treatment of localised invasive bladder cancer (BCa), the standard treatment remains radical surgical removal of the bladder within standard limits, including as-yet-unspecified regional lymph nodes." | ( Cowan, NC; De Santis, M; Kuczyk, MA; Merseburger, AS; Ribal, MJ; Sherif, A; Stenzl, A; Witjes, JA, 2011) |
| "We examined locally invasive bladder cancer in 32 patients (30 men, 2 women; mean age at treatment 68." | ( Abe, T; Itatani, H; Mori, N; Sato, M; Sekii, K; Yoshioka, T, 2011) |
| "Chemoradiation therapy for invasive bladder cancer can achieve survival rates similar to those in patients treated with radical cystectomy, with successful bladder preservation." | ( Abe, T; Itatani, H; Mori, N; Sato, M; Sekii, K; Yoshioka, T, 2011) |
| "Using human bladder cancer cells HTB3, HT1376, J82, RT4, CRL1749, T24, Sup, and HTB9, the treatment effect of pazopanib and cytotoxic chemotherapy was assessed using a tetrazolium-based assay." | ( Flaig, TW; Li, Y; Su, LJ; Yang, X, 2011) |
| "The superficial bladder cancer cell line BIU-87 and invasive T24 bladder cancer cells were treated with different concentrations of berberine." | ( Fan, Y; Feng, J; Hou, L; Liu, C; Liu, Z; Xu, Z; Yan, K; Yan, L; Zhang, C; Zheng, B; Zhou, Z, 2011) |
| "Exact pathological staging of bladder cancer is crucial for determination of further treatment." | ( Bach, T; Becker, JU; Burchardt, M; Christgen, M; Gross, AJ; Herrmann, TR; Imkamp, F; Kramer, MW; Kuczyk, MA; Merseburger, AS; Nagele, U; Wolters, M, 2011) |
| "Between 1994 and 2009, 82 patients with bladder cancer (clinical stage T2-N0M0) without concurrent upper urinary tract urothelial cancer were treated with CRT." | ( Hara, T; Matsuyama, H; Miyachika, Y; Nishijima, J; Sakano, S; Yamamoto, Y, 2011) |
| "The incidence of invasive bladder cancer in animals treated with sirolimus was statistically lower (20%) than in animals not treated (54%) (p=0." | ( Colaço, A; Lopes, C; Oliveira, PA; Palomino, LF; Santos, L; Vala, H; Vasconcelos-Nóbrega, C, 2011) |
| "Following cystectomy for bladder cancer, a 73-year-old woman undergoing HD developed lung metastasis and received combination chemotherapy with almost the same doses of GP as those in patients with normal renal function." | ( Hoshino, K; Ide, H; Masuda, T; Satou, A; Tasaka, Y; Uchida, Y; Yasumizu, Y, 2011) |
| "Improved outcomes in localized bladder cancer requires an integrated approach including better identification of high-risk disease, earlier use of cystectomy, broader use of chemotherapy and the availability of a dedicated multidisciplinary team." | ( Blais, N, 2011) |
| "The present gold standard for bladder cancer is Mycobacterium bovis bacillus Calmette-Guérin (BCG) immunotherapy, but serious side-effects are common." | ( Akaza, H; Harashima, H; Joraku, A; Kawai, K; Kohama, H; Miyazaki, J; Nakamura, T; Nakaya, A; Nishiyama, H; Yano, I, 2011) |
| "RT-4, TCCSUP, UMUC-3, and RT-112 bladder cancer cells were treated with VPA (0." | ( Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Tsaur, I; Vallo, S; Wiesner, C; Xi, W, 2011) |
| "Treatment of bladder cancer cells with parthenolide resulted in a significant decrease in cell viability." | ( Cheng, G; Xie, L, 2011) |
| "Thus, high priorities for bladder cancer research include identification of (1) biomarkers that will enable the identification of high grade T1 tumors that pose the most threat and require the most aggressive treatment; (2) biomarkers that predict the likelihood that a low grade, American Joint Committee on Cancer stage pTa bladder tumor will progress into an invasive carcinoma with metastatic potential; (3) biomarkers that indicate which pTa tumors are most likely to recur, thus enabling clinicians to prospectively identify patients who require aggressive treatment; and (4) how these markers might contribute to biological processes that underlie tumor progression and metastasis, potentially through loss of terminal differentiation." | ( Adam, RM; Cates, JM; Clark, PE; DeGraff, DJ; Matusik, RJ; Mauney, JR, 2013) |
| "For metastatic bladder cancer patients, systemic cisplatin (CDDP)-based combination chemotherapy is the first-line choice of treatment." | ( Fujii, Y; Kawakami, S; Kihara, K; Koga, F; Neckers, L; Tatokoro, M; Yoshida, S, 2012) |
| "Eleven bladder tumors from control rats, seven tumors from rats treated with Iressa, and seven normal bladder epithelia were profiled by the Affymetrix Rat Exon 1." | ( Grubbs, CJ; James, M; Liu, P; Lu, Y; Lubet, RA; Van den Bergh, F; Wen, W; You, M; Zellmer, V, 2012) |
| "Treatment of HTB5 and HTB9 bladder cancer cells for 24 to 72 hours with valproic acid and mitomycin C resulted in concentration and time dependent decreases in viability and proliferation." | ( Deb, AA; Koul, HK; Koul, S; Kumar, B; Lim, DD; Meacham, RB; Rove, KO; Wilson, SS, 2011) |
| "When bladder cancer cell lines were treated with SB plus CDDP, Western blotting showed increased expression of p21 but not p27 in T24 cells, whereas both p21 and p27 increased in 253J and UMUC3 cells." | ( Maruyama, T; Nojima, M; Qiu, J; Shima, H; Suzuki, T; Ueda, Y; Yamamoto, S, 2012) |
| "We show here that treatment of human bladder cancer UM-UC-3 cells or rat bladder cancer AY-27 cells with NAC-AITC at 15 μM results in significant inhibition of cell growth and proliferation, together with cell cycle arrest and apoptosis." | ( Bhattacharya, A; Geng, F; Li, Y; Munday, R; Zhang, Y, 2012) |
| "Three human bladder cancer cell lines (T24, HT1376, and 5637) were treated using a range of RAD001 concentrations." | ( Arantes-Rodrigues, R; Brochado, P; Cardoso, ML; Colaço, A; Ferreira, R; Guedes-Teixeira, CI; Lopes, C; Oliveira, PA; Palmeira, C; Palomino, LF; Pinto-Leite, R; Salvador, A; Santos, L; Vasconcelos-Nóbrega, C, 2013) |
| "We obtained bladder cancer specimens from 10 patients before and after chemotherapy and measured AKR1B10 mRNA levels using real-time PCR." | ( Hashimoto, Y; Hatakeyama, S; Imanishi, K; Kamimura, N; Koie, T; Ohyama, C; Okamoto, A; Okamoto, T; Tokui, N; Yoneyama, T, 2013) |
| "Invasive bladder cancer is a lethal disease for which effective prognostic markers as well as potential therapy targets are still lacking." | ( Chen, K; Li, J; Li, Y; Liao, W; Liu, L; Liu, Z; Song, L; Wu, Y; Yu, C; Zhang, Z; Zhao, X; Zhong, Y; Zhou, F, 2012) |
| "Most of the chemotherapy treatments for bladder cancer aim to kill the cancer cells, but a high recurrence rate after medical treatments is still occurred." | ( Chang, SJ; Chen, PY; Chiou, SM; Chueh, FS; Chung, JG; Fan, MJ; Huang, WW; Kuo, HM; Pai, SJ; Tsuzuki, M; Wu, PP; Yang, JS; Yeh, CC, 2012) |
| "Given that bladder cancer is characterized by initial localized presentation in the vast majority of cases, the paradigm of neoadjuvant therapy may expedite the development of novel systemic agents." | ( Sonpavde, G; Sternberg, CN, 2012) |
| "Forty three patients with T2b-T4N0M0 bladder cancer underwent maximal TURBT followed by neoadjuvant chemotherapy cisplatinum 75 mg/m[2] D1+ gemcitabine 1000 mg/m[2] D1, D8 & D15 repeated every 28 days for three cycles followed by concurrent radiation 65Gy and weekly cisplatinum 30 mg/m[2] or gemcitabine 100 mg/m[2]." | ( Hashmi, A; Masood, R; Qayyum, A; Rafi, M; Tunio, MA, 2011) |
| "Incident cases of bladder cancer were identified by a discharge diagnosis of bladder cancer combined with specific aggressive treatment." | ( Alla, F; Allemand, H; Fagot, JP; Neumann, A; Ricordeau, P; Weill, A, 2012) |
| "cisplatin) capsule for chemotherapy of bladder cancer T24 cells." | ( Hu, M; Lian, HY; Liu, CH; Wu, KC; Yamauchi, Y, 2012) |
| "The infiltrating bladder cancer cells T24 were cultured, and then treated by a proper dosage of drug." | ( Li, J; Liu, T; Wang, E; Yang, G; Zhong, S, 2012) |
| "KK47 and RT4 human bladder cancer cells were sensitive to the Ad-REIC treatment for apoptosis induction, but some human bladder cancer cell lines (T24, J82 and TccSup) were resistant." | ( Hirata, T; Huh, NH; Kaku, H; Kobayashi, Y; Kumon, H; Nasu, Y; Sakaguchi, M; Takei, K; Watanabe, M; Yamada, H, 2012) |
| "No relation between pioglitazone and bladder cancer was found for duration of therapy <12 months and cumulative dose <28,000 mg." | ( Lu, Y; Shen, Z; Xu, C; Zhong, S; Zhu, Z, 2012) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "In patients with bladder cancer who had received BCG treatment iNOS-like immunoreactivity was found in the urothelial cells but also in macrophages in the submucosa." | ( de Verdier, PJ; Ehrén, I; Koskela, LR; Poljakovic, M; Wiklund, NP, 2012) |
| "Only approximately 50% of patients with bladder cancer respond to chemotherapy." | ( Agerbæk, M; Birkenkamp-Demtroder, K; Borre, M; Dyrskjøt, L; Hartmann, A; Nordentoft, I; Ostenfeld, MS; Theodorescu, D; Ørntoft, TF, 2012) |
| "In this study, a panel of five bladder cancer cell lines representing a variety of disease stage and grades were treated with the antiestrogens 4-hydroxytamoxifen, raloxifene, or the pure antagonist ICI 182,780." | ( Hoffman, KL; Lerner, SP; Smith, CL, 2013) |
| "In patients with advanced bladder cancer, glucocorticoids are frequently given to reduce acute toxicity, particularly hyperemesis, during chemotherapy, as well as to improve cachectic conditions." | ( Ishiguro, H; Izumi, K; Li, Y; Miyamoto, H; Zheng, Y, 2012) |
| "Given the promising control of bladder cancer achieved by combined chemotherapy/radiotherapy with selective transurethral resection, obstacles remain to the treatment of unresectable bladder cancer." | ( Cheng, AL; Cheng, JC; Ho, PY; Pu, YS; Tsai, YC; Tuan, TF; Tzen, KY; Yeh, CH, 2013) |
| "Cell-free extracts of muscle-invasive bladder tumors are defective in nonhomologous end-joining (NHEJ), and this phenotype may be used clinically by combining radiotherapy with a radiosensitizing drug that targets homologous recombination, thereby sparing normal tissues with intact NHEJ." | ( Bristow, RG; Groselj, B; Kerr, M; Kiltie, AE; Knowles, MA; Phillips, RM; Qiao, B; Teo, MT, 2013) |
| "Despite more than 70,000 new cases of bladder cancer in the United States annually, patients with advanced disease have a poor prognosis due to limited treatment modalities." | ( Almasan, A; Dreicer, R; Ecsedy, JA; Hansel, DE; Lindner, D; Mir, MC; Parker, Y; Singh, K; Teh, BT; Zhang, Z; Zhou, N, 2013) |
| "In hypoxic human bladder cancer cells (T24), treatment with magnolol inhibited hypoxia-stimulated H2O2 formation, HIF-1α induction including mRNA, protein expression, and transcriptional activity as well as VEGF secretion." | ( Chen, MC; Chou, TC; Huang, WH; Lee, CF, 2013) |
| "T24 human bladder cancer cells were treated with ursolic acid at final concentrations of 12." | ( Cai, N; Gai, L; Kong, X; Wang, L; Xu, X, 2013) |
| "This led to changes of bladder cancer treatment in another four of 96 patients (4." | ( Fioole-Bruining, A; Horenblas, S; Mertens, LS; van Rhijn, BW; Vegt, E; Vogel, WV, 2013) |
| "However, there is no report about bladder cancer therapy of urolithins." | ( Jin, L; Liu, L; Liu, Y; Qin, C; Qiu, Z; Xie, S; Yu, H; Zhou, B; Zhu, F, 2013) |
| "TCCSUP and RT-112 bladder cancer cells were treated with VPA (0." | ( Bartsch, G; Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Makarevic, J; Meyer dos Santos, S; Schneider, T; Wiesner, C, 2013) |
| "Human bladder cancer cell lines and normal human urothelial cell cultures were treated with emetine and/or cisplatin." | ( Foreman, KE; Gupta, GN; Jesse, JN; Kuo, PC, 2014) |
| "Three bladder cancer cell lines, T24, HT1376, and UM-UC-3, were analyzed for cell proliferation after treatment with mTORc1/c2 inhibitors OSI-027 or PP242." | ( Becker, MN; Copland, JA; Kreinest, PA; Marlow, LA; Vonroemeling, CA; Williams, CR; Wu, KJ, 2014) |
| "Orthotopic bladder cancer model was established in nude mice, and the inhibitory efficacy of intravesical instillation therapy with AxdAdB-3 or/and gemcitabine was assessed." | ( Chen, GP; Li, DC; Li, FY; Liu, Z; Wang, H; Wang, ZP; Zhao, Y, 2013) |
| "In vivo, the mean weight of the bladder tumors in mice treated with intravesical instillation of AxCAlacZ, gemcitabine, AxdAdB-3, and AxdAdB-3 + gemcitabine were 400." | ( Chen, GP; Li, DC; Li, FY; Liu, Z; Wang, H; Wang, ZP; Zhao, Y, 2013) |
| "The drugs used in the treatment of bladder cancer are represented by the products referred to diagnosis (hexyl aminolevulinate), the intravesical instillations for the treatment of tumors not infiltrating the muscle and the infiltrating tumor chemotherapy (neo-adjuvant treatment or metastatic tumors)." | ( Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H, 2013) |
| "A 66-year-old man with superficial bladder cancer was treated with transurethral resection (TURBT) in October 2011." | ( Fukawa, T; Fukumori, T; Izaki, H; Kagawa, J; Kanayama, HO; Komori, M; Oi, H; Oyama, T; Sasaki, Y; Senzaki, T; Takahashi, H; Takahashi, M; Takemura, M; Yamaguchi, K; Yamamoto, Y, 2013) |
| "Low AR level of T24 bladder cancer cells treated with dehydrotestosterone (DHT) decreased expression of E-cadherin, β-catenin and N-cadherin expression, indicating a strong sensitivity to the EMT and In cells with low AR content, TGF-β induced down-regulation of E-cadherin and β-catenin." | ( Jianming, W; Jinchen, H; Jitao, W; Lei, S; Li, C; Qingzuo, L; Zhenli, G, 2014) |
| "A 67-year-old man with bladder cancer who was treated with transurethral resection of bladder tumour(TUR-Bt)and chemotherapy at the age of 59 years was diagnosed as having urothelial cancer by biopsy 8 years later." | ( Fukuoka, M; Nishizawa, Y; Omura, N; Tachibana, S; Tatara, T; Tatsumi, Y; Yoshida, T; Yoshimura, H, 2013) |
| "As for sex differences of urinary bladder tumors, the BrdU labeling index for epithelial cells of the urinary bladder by 5-week oral treatment with topiroxostat at 10 mg/kg to F344 rats was increased in males only, showing consistency with histopathological findings." | ( Ashizawa, N; Iwanaga, T; Matsumoto, K; Moto, M; Saito, K; Shimo, T, 2014) |
| "However, bladder cancer cells often develop drug resistance to these therapies, and ~ 50% of patients with advanced bladder cancer do not respond to chemotherapy." | ( Fan, Y; Liu, Y; Mu, X; Qin, Y; Shen, B; Tan, M; Zhang, F, 2014) |
| "Whether metformin therapy affects bladder cancer risk in patients with type 2 diabetes mellitus (T2DM) has not been extensively investigated." | ( Tseng, CH, 2014) |
| "Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy." | ( Baggerly, K; Bondaruk, J; Cheng, T; Choi, W; Czerniak, B; Dinney, CP; Hoffman-Censits, J; Kim, S; Lee, IL; Majewski, T; McConkey, DJ; Melquist, J; Plimack, ER; Porten, S; Pretzsch, S; Roth, B; Siefker-Radtke, A; Tran, M; Willis, D; Zhang, S, 2014) |
| "The data of primary non-muscle invasive bladder cancer patients treated by either KTP laser vaporization (PVB group) or TURBT were analyzed retrospectively." | ( Liu, X; Shan, Y; Xue, B; Yang, D; Zang, Y; Zhou, Y; Zhu, J, 2014) |
| "Urine samples from 58 patients with bladder cancer were centrifuged, and urine sediments were then treated with ALA." | ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2014) |
| "Human bladder cancer is an aggressive tumor which frequently resists chemotherapy." | ( Li, X; Zhao, B, 2014) |
| "He had been treated for bladder cancer 2 years ago." | ( Beyan, C; Kaptan, K, 2014) |
| "Forty-seven patients with advanced bladder cancer (33 men and 14 women) and treated at our hospital between August 2004 and December 2011 were enrolled." | ( Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T, 2015) |
| "Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival; however, their efficacy and safety remain unclear." | ( Hayashi, N; Matsuo, T; Miyata, Y; Nomata, K; Ohba, K; Sakai, H; Sakamoto, I; Uetani, M, 2015) |
| "Cell proliferation levels in bladder cancer cells, renal cell carcinoma, and prostate cancer cells treated with GSK3β inhibitor (SB216763) were detected by WST-1 reagent." | ( Bilen, CY; Konac, E; Varol, N, 2015) |
| "Non-muscle invasive bladder cancer is treated with intravesical chemotherapy (IVC) after transurethral resection (TUR) to reduce the probability of recurrence." | ( Endo, H; Inoue, M; Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, H; Yoshida, T, 2015) |
| "In patients with muscle-invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) confers a survival benefit compared to radical cystectomy (RC) alone." | ( Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T, 2015) |
| "Treatment of human bladder cancer T24 cells with mapatumumab in combination with mitomycin C, vinblastine or gemcitabine did not overcome resistance to these agents." | ( Ahmed, SM; Jin, X; Kakehi, Y; Kanematsu, A; Li, Y; Nojima, M; Sugimoto, M; Suzuki, T; Togo, Y; Wu, X; Yamamoto, S; Zhang, X, 2015) |
| "This led to changes of bladder cancer treatment in another four of 96 patients (4." | ( See, WA, 2014) |
| "Using bladder cancer as a paradigm, this study was designed to identify the novel molecular basis underlying the antiangiogenic activities of JA and its potential in cancer therapy." | ( Chang, TY; Cheng, HL; Chow, NH; Chuang, JJ; Lee, CT; Liu, HS; Tsai, HW; Tzai, TS; Wang, YW; Won, SJ, 2015) |
| "Recurrent TaT1 non-muscle-invasive bladder cancer (NMIBC) patients should be treated with immediate instillation of chemotherapy after transurethral resection of bladder tumour followed by instillation therapy." | ( Aaltomaa, S; Boström, PJ; Järvinen, R; Kaasinen, E; Kallio, J; Liukkonen, T; Marttila, T; Puolakka, VM; Rintala, E; Seppänen, M; Tuhkanen, K; Vaarala, M; Viitanen, J, 2015) |
| "Treatment of bladder cancer cell lines (T24, 5637) with the PKC-α or Dicer knockdown and the PKC inhibitors (Calphostin C and Gö 6976) can promote the apoptosis." | ( Chen, X; Jiang, Z; Kong, C; Zhang, Y; Zhang, Z; Zhu, Y, 2015) |
| "In an advanced bladder cancer model, intravesical CS/IL-12 immunotherapy controlled simultaneous orthotopic and subcutaneous tumors in 70 % of treated mice." | ( Katz, MD; Koppolu, BP; Kurtz, SL; Ravindranathan, S; Smith, SG; Yang, L; Zaharoff, DA, 2015) |
| "OH-BBN-treated rats, 96% developed urinary bladder cancers." | ( Bode, A; Boring, DL; Grubbs, CJ; Juliana, MM; Lubet, RA; Minasian, L; Scheiman, JM; Steele, VE; White, J, 2015) |
| "An early diagnosis of urinary bladder cancer is crucial for early treatment and management." | ( Chen, C; Kang, Q; Lu, J; Wang, L; Xing, W; Zhang, H, 2015) |
| "Cisplatin- and gemcitabine-resistant bladder cancer cells exhibit enhanced basal and drug-induced autophagosome formation and lysosomal activity which is accompanied by an attenuated apoptotic cell death after treatment with both (-)-gossypol and ABT-737, a Bcl-2 inhibitor which spares Mcl-1, in comparison to parental cells." | ( Antonietti, P; Bartsch, G; Blaheta, R; Cinatl, J; Gessler, F; Haferkamp, A; Kögel, D; Mani, J; Michaelis, M; Rakel, S; Vallo, S, 2015) |
| "A model of intra-arterial bladder cancer treatment was successfully established in BALB/c-nu mice." | ( Li, Q; Li, Y; Liu, H; Liu, R; Shen, X; Wang, W; Yu, G, 2015) |
| "In an orthotopic MBT-2 bladder cancer model, the effect of intravesical administration of PTX-30W was compared with that of paclitaxel solubilized with Cremophor (PTX-CrEL)." | ( Ishihara, K; Kikuchi, E; Konno, T; Matsumoto, K; Miyajima, A; Oya, M; Tamura, K, 2015) |
| "In the orthotopic bladder cancer model, intravesical administration of PTX-30W resulted in a significant reduction of bladder wet weight compared with that of PTX-CrEL." | ( Ishihara, K; Kikuchi, E; Konno, T; Matsumoto, K; Miyajima, A; Oya, M; Tamura, K, 2015) |
| "Treatment of human bladder cancer cells with cantharidin significantly decreased cell viability." | ( Fang, KM; Huang, CF; Huang, KT; Lai, CH; Lee, KI; Liu, SH; Lu, TH; Su, CC; Su, YC; Wu, CC; Yen, CC, 2015) |
| "Their selectivity for bladder cancer tissue and capacity to carry tracers or drugs make NT4 peptides candidate tumor targeting agents for tracing cancer cells and for personalized therapy of human bladder cancer." | ( Bracci, L; Brunetti, J; Carini, M; Depau, L; Falciani, C; Lelli, B; Menichetti, S; Minervini, A; Pini, A; Ravenni, N; Siena, G; Tenori, E, 2015) |
| "Systemic therapy for advanced bladder cancer has not changed substantially in more than 2 decades and mortality rates remain high." | ( Awrey, S; Black, PC; Dejima, T; Fazli, L; Hayashi, T; Jäger, W; Li, N; Matsubara, A; Moskalev, I; Oo, HZ; Seiler, R; Todenhöfer, T, 2015) |
| "Patients with superficial bladder cancer can be definitively cured by one single transurethral resection (TUR) with additional intravesical chemotherapy; however, up to 75 % of cases display frequent and multiple recurrences." | ( Chang, LS; Chen, Y; Gao, Y; Guo, P; He, D; Li, L; Shi, Q; Wang, X; Wu, K; Zeng, J; Zhu, G, 2016) |
| "Treatment of bladder cancer cells with phenformin resulted in growth inhibition that was frequently accompanied by increased glucose uptake and acidification of the medium that was blocked by co-incubation with 3PO." | ( Altayyar, M; desBordes, C; Lea, MA, 2015) |
| "The treatment of metastasized bladder cancer has been evolving during recent years." | ( Ecke, TH, 2015) |
| "Treatment of bladder cancer cells with Z-VAD-FMK + hepaCAM significantly downregulated procaspase 3/8/9 and PARP and induced cellular apoptosis, compared with that using Z-VAD-FMK alone." | ( Chen, E; Luo, C; Quan, Z; Tang, M; Wang, X; Wang, Y; Wu, X; Yang, X, 2016) |
| "Non-muscle-invasive bladder cancer (NMIBC) may progress to muscle-invasive disease, but no effective preventive treatments are available." | ( Bruno, S; Campora, S; Curotto, A; DeCensi, A; Defferrari, C; Garrone, E; Johansson, H; Petrera, M; Puntoni, M; Torrisi, R, 2016) |
| "Patients with non-muscle-invasive bladder cancer (NMIBC) belonging to the intermediate-risk group should be treated with intravesical instillations to prevent recurrence and progression." | ( Aaltomaa, S; Boström, P; Hellström, P; Järvinen, R; Kaasinen, E; Leskinen, M; Liukkonen, T; Marttila, T; Raitanen, M; Rintala, E; Seppänen, M; Tammela, T, 2016) |
| "In an orthotopic bladder cancer model, the group treated using PTT presented significant differences in tumor development." | ( Chen, CH; Chen, JJ; Wu, YJ, 2016) |
| "Currently, clinical treatment of bladder cancer mainly utilizes partial or total cystectomy, supplemented by conventional chemotherapy." | ( Che, X; Chen, F; Chen, X; Li, X; Song, X; Wang, J; Wang, L; Wang, Q; Wang, X; Yang, D; Zhang, Z; Zheng, W, 2016) |
| "For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy." | ( Choi, W; Efstathiou, JA; Guo, CC; Hahn, NM; Kamat, AM; Kassouf, W; Lerner, SP; Lotan, Y; Malmström, PU, 2016) |
| "Muscle invasive bladder cancer (MIBC) is recognized as a lethal disease due to its poor response to traditional chemotherapy." | ( Chen, H; Chen, W; Ding, C; Ding, Y; He, D; Hernandez, E; Hsieh, JT; Huang, J; Lin, H; Sagalowsky, A; Santoyo, J; Wang, B; Wu, K; Yun, EJ; Zhou, J, 2016) |
| "The overall prognosis of bladder cancer has not been improved over the last 30 years and therefore, there is a great medical need to develop novel diagnosis and therapy approaches for bladder cancer." | ( Airhart, S; Chen, JL; deVere White, R; Ferrara, KW; Lac, D; Lam, KS; Li, T; Li, Y; Lin, TY; Liu, Q; Pan, CX; Wachsmann-Hogiu, S; Zhang, H, 2016) |
| "The current intravesical treatment of bladder cancer (BC) is limited to a few chemotherapeutics that show imperfect effectiveness and are associated with some serious complications." | ( Gabig, TG; Romanov, V; Waltzer, WC; Whyard, T, 2016) |
| "A 70-year-old man with urothelial cancer of the bladder (UBC) metastatic to the pelvic and retroperitoneal lymph nodes was treated with gemcitabine plus cisplatin, but after two cycles neutropenic sepsis developed, which required a prolonged intensive care unit admission." | ( Domingo-Domenech, J; Ferket, BS; Galsky, MD; Sfakianos, JP, 2016) |
| "Resistance of bladder cancer to cisplatin is a major obstacle to successful treatment." | ( Choi, HY; Jeon, HG; Jeon, SS; Jeong, BC; Lee, HM; Lim, JE; Park, BH; Seo, SI, 2016) |
| "Cisplatin-resistant bladder cancer cells were treated with decitabine to investigate epigenetic sensitization of resistant cell lines." | ( Clozel, T; Elemento, O; Erdem, Z; Hassler, MR; Krzywinski, M; Robinson, BD; Shariat, SF; Xylinas, E; Zhuang, D, 2016) |
| "To examine whether AMPK regulates bladder cancer cell growth, HTB2 and HT1376 bladder cells were treated with an AMPK activator, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)." | ( Claffey, KP; Garg, I; Kopsiaftis, S; Sullivan, KL; Taylor, JA, 2016) |
| "A 90-year-old man with bladder cancer refractory to bacillius Calmette-Guérin was diagnosed with deep vein thrombosis (DVT) and started on warfarin one month before starting treatment with intravesical gemcitabine 2 g (one dose per week for six weeks)." | ( Feuz, L; Gee, ME; Krajewski, KC; Kurtzhalts, K, 2016) |
| "About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy." | ( Bastaros, JM; Carles, J; de Castro, AM; Maldonado, X; Morales-Barrera, R; Morote, J; Racca, F; Suárez, C; Valverde, C, 2016) |
| "Advanced bladder cancer is treated mainly with gemcitabine and cisplatin, but most patients eventually become resistance." | ( Deguchi, T; Fujita, Y; Horie, K; Ito, M; Kameyama, K; Kato, T; Kawakami, K; Kojima, T; Miyazaki, T; Mizutani, K, 2017) |
| "Should patients with T1G3 bladder cancer have an immediate radical cystectomy or should they receive intravesical bacillus Calmette-Guérin-preserving bladder? Gemcitabine and cisplatin (GC) adjuvant chemotherapy may help to strike a balance between intravesical and early cystectomy." | ( Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH, 2017) |
| "Patients with T1G3 bladder cancer with concomitant CIS should be treated more aggressively because of the high risk of progression." | ( Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH, 2017) |
| "We studied 52 patients with metastatic bladder cancer treated with the gemcitabine and cisplatin regimen by evaluating the relationship between the expression of two biomarkers, ribonucleotide reductase subunit M1 and excision repair cross complementing 1, by immunohistochemistry and clinical outcomes." | ( Hara, I; Iba, A; Kikkawa, K; Kodama, Y; Kohjimoto, Y; Matsumura, N; Nakamura, Y; Nishizawa, S, 2017) |
| "However, even after resection of bladder tumors and intravesical chemotherapy, half of them will recur and progress." | ( Chen, JF; Cheng, Y; Lv, XY; Ma, L; Ma, Q; Yu, BX; Yu, R, 2017) |
| "Muscle-invasive bladder cancer (MIBC) generally responds poorly to treatment and tends to exhibit significant mortality." | ( Abate-Shen, C; Al-Ahmadie, HA; Iyer, G; Kobayashi, T; Owczarek, TB; Puzio-Kuter, AM; Ramirez, R; Rong, L; Sánchez-Vega, F; Schultz, N; Solit, DB; Teo, MY; Wang, J; Zheng, T, 2017) |
| "Palliative chemotherapy for advanced bladder cancer is recommended in clinical practice guidelines because of the results achieved in clinical trials." | ( Booth, CM; Mackillop, WJ; Robinson, AG; Vera-Badillo, FE; Wei, X, 2017) |
| "In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy." | ( Choudhury, A; Denley, H; Hall, E; Hendron, C; Huddart, R; Hussain, SA; James, N; Lewis, R; Porta, N; West, CM, 2017) |
| "Nude mice bearing bladder cancer were treated with Kae for 31 days." | ( Lin, J; Qiu, W; Su, M; Tian, Y; Zeng, L; Zhang, J; Zhu, Y, 2017) |
| "Ninety mice bearing orthotopic bladder cancer induced by BBN were randomly divided into six groups and treated with chemotherapeutic agents once a week for four weeks." | ( Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2017) |
| "Cisplatin-resistant bladder cancer overexpresses particular sugar chains compared with chemotherapy-naïve bladder cancer." | ( Agerbæk, MØ; Al-Nakouzi, N; Babcook, JS; Battsogt, D; Black, PC; Clausen, TM; Crabb, SJ; Daugaard, M; Davicioni, E; Douglas, J; Esfandnia, S; Fazli, L; Gustavsson, T; Kiss, B; Kumar, G; Lallous, N; Lee, SS; Moskalev, I; Nordmaj, MA; Oo, HZ; Pereira, MA; Rennie, PS; Rich, JR; Salanti, A; Seiler, R; Thalmann, GN; Todenhöfer, T; Tortora, D; Wang, CK; Ørum-Madsen, MS, 2017) |
| "Non-muscle invasive bladder cancers (NMIBC) are typically treated by transurethral resection with intravesical chemotherapy." | ( Chen, L; Cui, XG; Gao, Y; Huang, H; Pan, XW; Wang, LH; Xu, DF; Yang, QW, 2017) |
| "Human bladder cancer cell lines T24 and BIU87 were treated with GEM in vitro." | ( Dong, XY; Gou, X; He, WY; Huang, XL; Lin, Y; Xie, XY; Yang, XY; Yin, HB; Zhang, H, 2017) |
| "As human bladder cancer tumor exhibits high basal level of autophagic activities, we detected the autophagic flux in cells treated with CQ and HCQ, showing an alternation in LC3 flux in CQ- or HCQ-treated cells." | ( Chen, HE; Chou, KY; Hwang, TI; Lin, JF; Lin, YC; Tsai, TF; Wen, SI; Yang, SC, 2017) |
| "Non-muscle invasive bladder cancer (NMIBC) is usually treated with local therapy including transurethral resection of the bladder tumor and intravesical therapy depending on the stage of the tumor." | ( Daste, A; Dousset, V; Gross-Goupil, M; Hoepffner, JL; Ravaud, A; Teyssonneau, D, 2017) |
| "To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas." | ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018) |
| "In addition, bladder cancer cell lines T24 and 5637 cells were treated with different concentrations of curcumin." | ( Gao, Y; Jia, Z; Shi, J; Wang, Y; Yao, Y; Zhao, C, 2017) |
| "The therapy for bladder cancer is so far not satisfactory." | ( Cao, HL; Chang, Z; Liu, ZJ, 2017) |
| "The effect of the combined treatment on bladder cancer cells was verified in T24 cells." | ( Cao, JY; Han, X; Li, HS; Yin, HS; Yu, XQ, 2017) |
| "We constructed a bladder cancer-specific oncolytic adenovirus and provided new combination treatment strategies for bladder cancer." | ( Cao, W; Gao, Y; Li, C; Liu, X; Lu, J; Rodriguez, R; Svatek, RS; Tian, J; Wang, Y; Wang, Z, 2017) |
| "Patients with invasive bladder cancer (clinical T3-4aN0M0) who were treated between March 2003 and March 2015 with 2 or 3 cycles of neoadjuvant chemotherapy followed by radical cystectomy were retrospectively evaluated." | ( Fujimoto, N; Kubo, T; Minato, A, 2017) |
| "The treatment of non muscle-invasive bladder cancer (NMIBC) encompasses a range of different procedures." | ( Bassi, PF; De Pascalis, I; Emilio, S; Larocca, LM; Lopez-Beltran, A; Marques, RC; Pierconti, F; Straccia, P; Volavsek, M, 2017) |
| "We treated T24 and 5637 bladder cancer cell lines with Fcn in vitro." | ( Fan, B; Ma, Y; Zhang, A; Zhang, X, 2017) |
| "Non-muscle invasive bladder cancer (NMIBC) has still chances of recurrence and progression in spite of surgery and adjuvant treatments." | ( Caramés Masana, F; de Reijke, TM, 2017) |
| "Non-muscle invasive bladder cancer (NMIBC) is a highly recurrent disease with potential progression to muscle invasive disease despite the standard bladder instillations with mitomycin C (MMC) or Bacille Calmette-Guérin immunotherapy." | ( Arends, TJH; Falke, J; Lammers, RJM; Oosterwijk, E; van der Heijden, AG; van Valenberg, FJP; Witjes, JA, 2018) |
| "In advanced bladder cancer, cisplatin-based chemotherapy has been the standard treatment for many years, but there are many problems in terms of side-effects." | ( Aono, Y; Horinaka, M; Miki, T; Sakai, T; Sowa, Y; Takamura, T; Toriyama, S; Ukimura, O; Yasuda, S, 2018) |
| "The effect of BP in bladder cancer treatment is still unclear and worth for further investigate." | ( Chang, SF; Chen, SP; Chiu, SC; Chiu, TL; Hsieh, TF; Huang, SY; Pang, CY, 2017) |
| "Human bladder cancer EJ cells were cultured and then treated with sodium bisulfide (NaHS) (100 μmol/L for low dosage, 200 μmol/L for moderate dosage, 400 μmol/L for high dosage)." | ( Chang, J; Hou, J; Li, Y; Liu, H; Zhao, Z, 2017) |
| "NSG mice bearing bladder cancer patient-derived xenografts were treated with vehicle, PTUPB, cisplatin, GC, or combinations thereof." | ( Airhart, S; de Vere White, RW; Hammock, BD; Henderson, PT; Hwang, SH; Lin, TY; Ma, AH; Malfatti, M; Pan, CX; Turteltaub, KW; Wang, F; Yang, J; Yu, W; Yuan, J; Zhang, H; Zhu, D; Zimmermann, M, 2018) |
| "Conservative treatment for invasive bladder cancer (BC) involves a complete transurethral tumor resection combined with chemotherapy (CT) and radiotherapy (RT)." | ( Balarino, N; Belgorosky, D; Eiján, AM; Langle, Y; Prack Mc Cormick, B; Sandes, E; Vanzulli, S, 2018) |
| "Herein, we found that treatment of bladder cancer (BC) cells with ISO resulted in a significant upregulation of p27, which was also observed in ISO-treated mouse BCs that were induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)." | ( Huang, C; Huang, H; Jiang, G; Jin, H; Li, J; Li, Y; Wang, J; Xie, F; Zhu, J, 2018) |
| "A total of 238 patients with T2-T4 bladder cancer enrolled into two prior randomized trials comparing neoadjuvant cisplatin-based chemotherapy (NAC) plus cystectomy with cystectomy only (no-NAC) were used as discovery and validation cohorts." | ( Hemdan, T; Malmström, PU; Segersten, U; Turker, P, 2018) |
| "Overcoming the chemoresistance of bladder cancer is a pivotal obstacle in clinical treatments." | ( He, W; Li, X; Tong, H; Wang, Q; Yang, X; Yin, H; Zeng, Y; Zhang, Y, 2018) |
| "The treatment of non muscle invasive bladder cancer (NMIBC) continues to be a challenge." | ( Alvarez Casal, M; Domínguez, JL; León-Mata, J; Piñeiro Vázquez, E; Redorta, JP; Sousa Escandón, A; Sousa González, D, 2018) |
| "In this aggressive bladder cancer model, a lower number of tumor-positive rats after treatment with TLR-7 agonists indicates activity for the treatment of non-muscle invasive bladder cancer." | ( Falke, J; Hulsbergen-van de Kaa, CA; Maj, R; Oosterwijk, E; Witjes, JA, 2018) |
| "Should patients with T1G3 bladder cancer have an immediate radical cystectomy or should they receive intravesical bacillus Calmette-Guérin preserving bladder? Gemcitabine and cisplatin (GC) adjuvant chemotherapy may help to strike a balance between intravesical and early cystectomy." | ( Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH, 2018) |
| "Patients with T1G3 bladder cancer with concomitant CIS should be treated more aggressively because of the high risk of progression." | ( Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH, 2018) |
| "With limited success achieved in bladder cancer patient management, novel agents are in urgent need for the purpose of therapy and prevention." | ( Chen, Y; Li, W; Tang, Y; Zeng, Z, 2018) |
| "Despite this, lymphadenectomy for bladder cancer is still underutilized and even where performed, controversies exist in regard to what defines an adequate dissection and whether or not the indications for lymphadenectomy have changed now that we are firmly entrenched in the neoadjuvant chemotherapy era." | ( Daneshmand, S; Ghodoussipour, S, 2019) |
| "In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients." | ( Abbosh, PH; Bajorin, D; Bell, A; Bellmunt, J; D'Andrea, AD; Damish, AW; Frazier, Z; Gao, SP; Iyer, G; Jordan, EJ; Kamburov, A; Lazaro, JB; Li, Q; Liu, D; Ma, J; Mouw, KW; Plimack, ER; Reznichenko, E; Riaz, N; Rosenberg, JE; Solit, DB; Van Allen, EM; Zhao, H, 2019) |
| "The mainstay of treatment for advanced bladder cancer (BC) is cisplatin (CDDP)-based systematic chemotherapy." | ( Du, YH; Hu, XJ; Hui, PY; Ni, F; Yan, CY; Yu, J; Zhang, ZG; Zheng, L; Zhou, S, 2018) |
| "Gemcitabine (GEM) effectively inhibits bladder cancer progression in the clinic, but novel combination treatments using multiple drugs are needed." | ( Bai, XG; Ding, M; Jin, ZL; Xu, HJ; Yang, Y; Zhang, LJ, 2018) |
| "The use of traditional agents for bladder cancer therapy is constrained by their toxicity and limited efficacy." | ( Cao, J; Lu, Q; Tan, SL; Wang, K; Wang, YH; Wu, SQ; Xu, R; Zhao, XK; Zhong, ZH, 2018) |
| "This study did not show a difference in bladder cancer outcomes between microwave-heated chemotherapy and standard of care treatment." | ( Bhatt, R; Billingham, LJ; Buckley, L; Cresswell, J; Datta, SN; Devall, AJ; Feneley, MR; Griffiths, TRL; Hodgson, D; Issa, R; Kelly, JD; Loubière, LS; Madaan, S; McGrath, J; Mostafid, H; Page, T; Panchal, A; Pope, AM; Sangar, V; Tan, WS, 2019) |
| "Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy." | ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| "Although the association between bladder cancer pathology and circRNAs remains undetermined, circRNAs signatures may be useful as prognostic and predictive factors and clinical tools for assessing disease state, treatment response and outcome." | ( Bi, S; Chi, BJ; Gui, SL; Liu, L; Qin, WB; Wang, FF; Wang, SQ; Wu, DM; Yin, XZ; Zhao, DM; Zhou, SB, 2019) |
| "The vast majority of bladder cancer is non-muscle invasive with transurethral resection (TURBT) as the gold standard for surgical treatment." | ( Bobrow, A; Bukavina, L; Buzzy, C; Fish, ML; Mahran, A; Mishra, K; Ponsky, L, 2018) |
| "Thirty‑six C57BL/6J mice bearing bladder cancer were randomly divided into six treatment groups as follows: control, BCG, MMC, ADM, MMC‑BCG and ADM‑BCG." | ( Fujimoto, K; Gotoh, D; Hori, S; Iida, K; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, K; Onishi, S; Tanaka, N; Tatsumi, Y, 2019) |
| "The prognosis for patients with bladder cancer (BCa) with lymph node (LN) metastasis is poor, and it is not improved by current treatments." | ( Chen, X; Chen, Z; Dong, W; Han, J; Huang, J; Huang, M; Li, H; Lin, T; Xie, R; Zhang, J; Zhou, Q, 2019) |
| "Advanced bladder cancer is a common disease characterized by a frequent onset of resistance to cisplatin-based therapy." | ( Barrera, G; Cavalli, R; Cucci, MA; Daga, M; Dianzani, C; Ferrara, B; Grattarola, M; Pizzimenti, S; Scariot, V; Trotta, F, 2019) |
| "Human bladder cancer TSGH 8301 cells were treated with regorafenib, NF-κB, AKT, or mitogen-activated protein kinase (MAPK) inhibitors for different time." | ( Chiang, CH; Chung, JG; Hsu, FT, 2019) |
| "To understand the impact of PC on bladder cancer progression, human bladder cancer TSGH8301 cells were treated PC with various concentration (25-100 μM)." | ( Chang, HR; Hsu, YH; Huang, HP, 2019) |
| "Cultured bladder cancer cell lines EJ and UMUC3 were treated with triptolide (TPL) and/or HCPT." | ( Ding, Y; Gao, W; Li, D; Sun, Y; Wang, T; Wang, Z; Wei, J; Yang, Y, 2019) |
| "Radiotherapy is the primary option for bladder cancer patients, but it does not have obvious curative effects." | ( Li, H; Lu, Q; Qu, J; Wu, S; Xu, R; Yuan, H; Zhou, Y, 2019) |
| "Topical therapy of nonmuscle-invasive bladder cancer (NMIBC) is based on immunotherapy with Bacillus Calmette-Guerin and chemotherapy administered by passive instillation, but an active drug administration achieves a better concentration of the drugs in the bladder." | ( Carando, R; Cotrufo, S; Ludovico, GM; Zazzara, M, 2019) |
| "The new classification system of bladder cancer based on molecular characteristics is expected to helpful tool for the establishment of personalized treatment strategies and associated prediction of therapeutic responses." | ( Jeong, CW; Kim, HH; Ku, JH; Kwak, C; Moon, KC; Yuk, HD, 2019) |
| "Treatment of muscle-invasive bladder cancer remains a major clinical challenge." | ( Domany, E; Eichhorn, PJA; Ha, HK; Haviv-Shapira, L; Iyengar, PV; Jaynes, PW; Kappei, D; Kumar, AP; Lama, D; Lui, SKL; Ng, HC; Radulescu, C; Rouanne, M; Saei, A; Sim, WJ; Tan, TZ; Ten Dijke, P; Thiery, JP; Verma, CS, 2019) |
| "BACKGROUND Bladder cancer is a very common urological cancer globally, and cisplatin- or gemcitabine-based chemotherapy is essential for advanced bladder cancer patients." | ( He, W; Hu, X; Li, Y; Wang, L; Zu, X, 2019) |
| "Despite the recent advances in bladder cancer therapy which include the use of checkpoint inhibitors, the treatment options for patients with locally advanced and metastatic BC remain limited." | ( Degoricija, M; Haupt, B; Ivanisevic, T; Karaman, I; Korac-Prlic, J; Palada, V; Petkovic, M; Terzic, J; Vilovic, K, 2019) |
| "In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin-based neoadjuvant chemotherapy (NAC) before radical cystectomy improves overall survival." | ( Galsky, MD; Garzon, N; Gschwend, JE; Gupta, S; Ibrahim, M; Liaw, D; Necchi, A; Raybold, B; Rutstein, M; Sonpavde, G; Steinberg, GD; Van Der Heijden, MS, 2020) |
| "Although bladder cancer is commonly chemosensitive to standard first-line therapy, the acquisition of the resistance to cisplatin (DDP)-based therapeutic regimens remains a huge challenge." | ( Cao, L; Chen, J; Li, Y; Li, Z, 2020) |
| "The ability to detect and diagnose bladder cancer early and precisely is crucial for effective treatment." | ( Aebisher, D; Bochynek, K; Cieślar, G; Gasiorek, M; Kawczyk-Krupka, A, 2020) |
| "O-GlcNAcylation levels in bladder cancer cells were altered through pharmacological or genetic manipulations: treating with 6-diazo-5-oxo-norleucine (DON) or thiamet-G (TG) or up- and downregulation of O-GlcNAc transferase (OGT) or O-GlcNAcase (OGA)." | ( Dai, G; Jin, L; Liu, X; Shan, Y; Wang, L; Xiang, H; Xue, B; Yao, Q; Yuan, F, 2020) |
| "nZnO were characterized and bladder cancer T24 cells were treated with nZnO for 48 hrs at different exposure concentrations." | ( Chen, Y; Cheng, J; Du, E; Liu, Y; Qi, S; Xu, Y; Zhang, T; Zhang, Z, 2020) |
| "Patients aged ≥ 18 with muscle-invasive bladder cancer (≥ cT2) and who had received either GC or ddMVAC as neoadjuvant chemotherapy followed by cystectomy were retrospectively evaluated using the electronic medical record." | ( Montgomery, RB; Ruplin, AT; Spengler, AMZ; Wright, JL, 2020) |
| "Therapeutic options for metastatic bladder cancer (BC) have seen minimal evolution over the past 30 years, with platinum-based chemotherapy remaining the mainstay of standard of care for metastatic BC." | ( Carles, J; González, M; Maldonado, X; Mateo, J; Morales-Barrera, R; Morote, J; Raventos, C; Serra, E; Suárez, C; Valverde, C, 2020) |
| "Pretreatment of bladder cancer cells with ROS scavengers abolished NRF2 expression and nuclear translocation, indicating that miconazole activates the noncanonical p62-KEAP1-NRF2 pathway, which is regulated by ROS production." | ( Chen, HE; Chen, PC; Chou, KY; Ho, CY; Hwang, TI; Lin, JF; Lin, YC; Tsai, TF, 2020) |
| "The viability of human bladder cancer cells with epirubicin and/or BCG treatments was examined by Cell Counting Kit-8 (CCK-8) assay." | ( Dong, B; Fu, X; Han, B; Luo, Y; Men, H; Meng, M; Tian, S; Yuan, L; Zhang, F; Zhang, S, 2020) |
| "The viability of human bladder cancer with epirubicin or BCG treatment was decreased and the viability with epirubicin combined with BCG treatment was decreased more, which were determined by CCK-8 assay." | ( Dong, B; Fu, X; Han, B; Luo, Y; Men, H; Meng, M; Tian, S; Yuan, L; Zhang, F; Zhang, S, 2020) |
| "The first-line therapy of metastatic bladder cancer (urothelial carcinoma, UC) depends on whether a patient is cisplatin-fit or not." | ( Grüllich, C; Zacharis, A, 2020) |
| "Syngeneic mouse bladder cancer model BBN963 was used to assess whether palbociclib could potentiate anti-PD1 immunotherapy." | ( Cao, Z; de Vere White, R; Guo, J; Lin, TY; Long, Q; Ma, AH; Pan, CX; Sonpavde, GP; Xia, R; Zhang, H, 2020) |
| "Progressive bladder cancer growth is associated with abnormal activation of the mammalian target of the rapamycin (mTOR) pathway, but treatment with an mTOR inhibitor has not been as effective as expected." | ( Blaheta, RA; Chun, FK; Juengel, E; Justin, S; Maxeiner, S; Rutz, J, 2020) |
| "Currently, treatment for bladder cancer is limited." | ( Cheng, L; Huang, H; Lin, J; Wang, H; Wang, Z; Zhuo, D, 2020) |
| "A 47-year-old man with bladder cancer was treated surgically and received BCG intravesical therapy." | ( Berthier, C; Lellouch, AG; Lupon, E; Mansat, P; Martin-Blondel, G; Pollon, T, 2020) |
| "Apoptosis was induced by bergenin in bladder cancer cells, as evidenced by increased Bax and cleaved caspase 3 protein levels and decreased Bcl-2 level in bergenin-treated cells." | ( Gu, S; Li, S; Liu, J; Wang, G; Xiao, H; Yu, C; Zhang, P; Zhang, Y, 2021) |
| "Mouse advanced bladder cancer models were treated with vehicle control, intravesical xenogeneic urothelial cells, cisplatin + gemcitabine, or the combination and assessed for tumor responses to treatments." | ( Huang, CP; Shyr, CR; Wu, CC, 2021) |
| "Locally advanced or metastatic bladder cancer chemotherapy was initially introduced for metastasis management." | ( Loizaga Iriarte, A; Martín Bazaco, J; Rabade Ferreiro, A; Senarriaga Ruiz de la Illa, N; Unda Urzaiz, M; Zubiaur Libano, C, 2020) |
| "The human bladder cancer T24 cells and mouse bladder cancer MB49 cells were treated with naltrexone." | ( Pan, Z; Shi, Y; So, EC; Tang, D; Tian, J; Wang, X; Wu, T; Wu, X; Yu, W; Zhang, R; Zhou, X, 2021) |
| "First, we administered PD to the bladder cancer cell lines T24 and 5637 and the human uroepithelial cell line SV-HUC-1." | ( Chen, D; Chen, T; Dong, L; Guo, Y; Lu, C; Wang, C, 2021) |
| "Signaling pathways that drive bladder cancer (BC) progression may be promising and specific targets for systemic therapy." | ( Börding, T; Elezkurtaj, S; Elmasry, M; Horst, D; Karl, A; Kirchner, T; Schmidt, EM; Schulz, GB; Stief, CG, 2021) |
| "Many muscle-invasive bladder cancers are hypoxic, which limits the efficacy of radiation therapy." | ( Choudhury, A; Hoskin, PJ; Irlam, J; Lane, B; Mistry, H; Song, YP; Valentine, H; West, C; Yang, L, 2021) |
| "The thulium laser resection of bladder tumors (TmLRBT) was increasingly used in the treatment of non-muscle-invasive bladder cancer (NMIBC) recently, and here we report the relevant outcomes of our institution to evaluate its efficacy and safety." | ( Chen, Z; Guan, W; Hu, H; Hu, Z; Li, F; Li, H; Liu, Z; Long, G; Ouyang, W; Sun, G; Wang, S; Wang, Z; Xu, H; Yang, J; Yu, X; Zhang, Y, 2022) |
| "Identification of novel agents for bladder cancer treatment is highly desirable due to the high incidence of tumor recurrence and the risk of progression to muscle-invasive disease." | ( Aden, S; Anderluh, G; Bedina Zavec, A; Kisovec, M; Kreft, ME; Podobnik, M; Resnik, N; Tratnjek, L; Veranič, P, 2021) |
| "Muscle invasive bladder cancer (MIBC) remains amongst the deadliest genitourinary malignancies due to treatment failure and extensive molecular heterogeneity, delaying effective targeted therapeutics." | ( Azevedo, R; Cotton, S; Fernandes, E; Ferreira, D; Ferreira, JA; Freitas, R; Gaiteiro, C; Lima, L; Martins, G; Oliveira, MJ; Palmeira, C; Paulo, P; Peixoto, A; Relvas-Santos, M; Santos, LL; Silva, AMN; Soares, J; Teixeira, B, 2021) |
| "For muscle-invasive bladder cancer (MIBC), treatment includes radical cystectomy, radiotherapy, and chemotherapy; however, the outcome is generally poor." | ( Allison, SJ; Burns, JE; Hurst, CD; Knowles, MA; Phillips, RM, 2021) |
| "The incidence of bladder cancer increases with age, and elderly patients with muscle invasive bladder cancer (MIBC) are significantly undertreated." | ( Anzela, A; Azzopardi, M; Barrett, S; Buddle, N; Hooshmand, R; Knesl, M; Min, M; Notman, A; Vignarajah, DD; Wilson, J; Woolls, H, 2021) |
| "The growing prevalence of bladder cancer worldwide has become a major concern for researchers, and the side effects of chemotherapy drugs have always been a major problem in cancer treatment." | ( Abbasalipourkabir, R; Aminzadeh, Z; Ziamajidi, N, 2022) |
| "Treatment of muscle-invasive bladder cancer (MIBC) remains challenging, especially for elderly and/or comorbid patients." | ( Arnold, CR; Ganswindt, U; Horninger, W; Kouvaiou, O; Lindner, AK; Lukas, P; Maffei, M; Mangesius, J; Pichler, R; Schachtner, G; Skvortsov, S; Tulchiner, G; Tulchiner, N, 2022) |
| "The treatment of bladder cancer remains a challenge in clinical practice." | ( Almeida, TC; da Silva, GN; de Medeiros Teixeira, LF; Lima, APB; Melo, AS; Soares, LBM, 2022) |
| "Our study confirmed the contribution of bladder cancer derived exosomes on the establishment of immunosuppressive TME and provided a potential therapeutic target for bladder cancer treatment." | ( Jia, Z; Jiang, Z; Yang, J; Zhang, Y; Zhang, Z, 2021) |
| "The position of the bladder cancer at different locations along the bladder wall lining can potentially affect the treatment efficacy since laser is irradiated externally from the skin surface." | ( Alchera, E; Alfano, M; Armanetti, P; Cheong, JK; Chiew, YS; Franchini, MC; Locatelli, I; Maturi, M; Menichetti, L; Ooi, EH; Popov, V, 2021) |
| "Eighty-three patients with bladder cancer treated with chemotherapy were reviewed." | ( Chen, M; Chen, S; Liu, C; Lu, K; Qu, H; Wang, Y; Wu, J; Xu, B, 2023) |
| "Thus, we showed that in patients with bladder cancer who received chemotherapy, the higher clinical response rate is associated with low FOXA1 expression, low M2 TAM infiltration, and high CTL infiltration." | ( Chen, M; Chen, S; Liu, C; Lu, K; Qu, H; Wang, Y; Wu, J; Xu, B, 2023) |
| "Improving urinary bladder cancer diagnosis, follow-up, and therapy tools to overcome existing limitations and increase survival rates is a highly desirable goal." | ( Abdelaziz, G; El-Kawy, OA, 2022) |
| "For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available for clinical use to predict response to neoadjuvant chemotherapy." | ( Abrahamsson, J; Bernardo, C; Chebil, G; Eriksson, P; Höglund, M; Holmsten, K; Johansson, I; Kollberg, P; Liedberg, F; Lindh, C; Lövgren, K; Marzouka, NA; Olsson, H; Sjödahl, G; Ullén, A, 2022) |
| "In urothelial cancer of the bladder, the introduction of immunotherapy with immune checkpoint inhibitors represents progress in the management of the disease's early and advanced stages." | ( Luciani, A; Perego, G; Petrelli, F; Vavassori, I, 2022) |
| "The treatment landscape of advanced bladder cancer continues to evolve with novel therapeutics approved in recent years and many in the pipeline." | ( Boudreau, J; Bulin, J; Hanna, KS; Larson, S; Nguyen, J; Rolf, M, 2022) |
| "Patients with advanced bladder cancer often first receive platinum-based therapy, while immune checkpoint inhibitors offer a maintenance option following cytotoxic chemotherapy or a second-line option." | ( Boudreau, J; Bulin, J; Hanna, KS; Larson, S; Nguyen, J; Rolf, M, 2022) |
| "These findings identify a bladder cancer-specific aptamer that can be used for targeted delivery of chemotherapy, potentially reducing toxicity and enhancing therapeutic efficacy." | ( Guo, J; Huang, Q; Huo, F; Jia, R; Li, PC; Theodorescu, D; Wang, J; Wang, Y; Yan, C; Yang, J; Yu, H; Zhang, Y, 2022) |
| "Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance." | ( Enokida, H; Fukumoto, W; Kawakami, I; Nakagawa, M; Okamura, S; Osako, Y; Sakaguchi, T; Sugita, S; Tamai, M; Tatarano, S; Yamada, Y; Yonemori, M; Yoshino, H, 2022) |
| "In selected patients with bladder cancer, partial cystectomy is an alternative treatment for bladder preservation with fair oncologic result." | ( Cho, HJ; Choi, YS; Kim, KS; Kim, SH; Sur, HJ, 2022) |
| "Most of the bladder cancers are treated with transurethral resection." | ( Özler, S; Pazarci, P, 2022) |
| "Management of bladder cancer (BLCA) has not changed significantly in the past few decades, with platinum agent chemotherapy being used in most cases." | ( Bhattacharjee, S; Demagall, A; Hendrix, AS; Nadiminty, N; Petros, FG; Sindhwani, P; Sullivan, MJ; Wynn, RR, 2022) |
| "We showed that bladder cancer patients receiving immunotherapy followed by cystectomy have good long-term outcomes." | ( Aleshin, A; Assaf, ZJ; Banchereau, R; Castellano, D; Crabb, SJ; Daelemans, S; Duran, I; Gravis, G; Herranz, UA; Kockx, M; Linch, M; Maillet, D; Mariathasan, S; Mendez, MJ; Mousa, K; Pous, AF; Powles, T; Prendergast, A; Protheroe, A; Ravaud, A; Rodriguez-Vida, A; Rombouts, M; Sharma, S; Stanoeva, D; Suarez, C; Szabados, B; Tea, JS; Tyson, C; van Dam, PJ; Van Der Heijden, MS, 2022) |
| "The patient was diagnosed as having bladder cancer (cT3bN1M0) and received two cycles of chemotherapy with gemcitabine and cisplatin." | ( Hirayama, Y; Kato, M; Kuratsukuri, K; Masuda, H; Otoshi, T; Uchida, J; Yamasaki, T; Yoshiuchi, H; Yukimatsu, N, 2022) |
| "Urothelial bladder cancer is rapidly spreading across Western countries, and therapy has shown little-to-moderate effects on bladder cancer." | ( Annseles Rajula, S; Bharath Kumar, V; Chen, MC; Chen, RJ; Day, CH; Hsu, CH; Huang, CY; Li, CC; Viswanadha, VP; Wang, TF, 2022) |
| "Intravesical treatment of bladder cancer is preferred over systemic administration." | ( Alm, M; Andersen, TE; Hjelmager, JS; Stærk, K; Thomsen, P, 2022) |
| "Raman spectra of treated and untreated bladder cancer organoids were compared using multivariate data analysis to monitor the impact of drugs on subcellular structures such as nuclei and mitochondria based on shifts and intensity changes of specific molecular vibrations." | ( Aicher, WK; Becker, L; Fischer, F; Fleck, JL; Harland, N; Herkommer, A; Marzi, J; Schenke-Layland, K; Stenzl, A, 2022) |
| "Molecular subtypes of bladder cancer differ markedly regarding sensitivity to cisplatin-based chemotherapy and harbor FGFR treatment targets to various content." | ( Barski, D; Ecke, TH; Eidt, S; Friedersdorff, F; Hake, R; Hallmann, S; Heidenreich, A; Kastner, L; Koch, S; Linden, F; Otto, T; Rabien, A; Rieger, C; Roggisch, J; Schlomm, T; Veltrup, E; Voß, PC; Waldner, M; Wirtz, RM, 2022) |
| "Although bladder cancer (BLCA) is the 10th most common tumor worldwide, particularly practical markers and prognostic models that might guide therapy are needed." | ( Bi, J; Wang, L; Wang, Y, 2022) |
| "This study confirmed that patients with bladder cancer with a mutation in the ERCC2 gene often respond to chemotherapy." | ( Alcaraz, A; Black, PC; Boormans, J; Braaf, L; Broeks, A; Contreras-Sanz, A; Gil-Jimenez, A; Kerkhoven, R; Mengual, L; Ribal, MJ; Seiler, R; van der Heijden, MS; van der Vos, K; van Dorp, J; van Kessel, KEM; van Rhijn, BWG; Vis, DJ; Wessels, LFA; Wright, JL, 2023) |
| "However, in bladder cancer, the link between cuproptosis and clinical outcome, tumor microenvironment (TME) modification, and immunotherapy is unknown." | ( Fu, W; Shu, F; Song, Q; Zhou, R, 2022) |
| "The proteomic analysis of a bladder cancer cell line before and after treatment with functional unit (FU) βc-HlH-h using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and mass spectrometry revealed differences in the expression of some proteins." | ( Antonova, O; Dolashka, P; Dolashki, A; Kaynarov, D; Velkova, L; Voelter, W, 2022) |
| "This makes bladder cancer a "silent killer" and it needs appropriate treatment planning." | ( Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP, 2022) |
| "In nonmuscle invasive bladder cancer (NMIBC) patients who fail standard intravesical treatment and are unfit or unwilling to undergo a radical cystectomy, radiofrequency (RF)-induced hyperthermia combined with intravesical chemotherapy (RF-CHT) has shown promising results." | ( Brummelhuis, ISG; Crezee, J; Witjes, JA, 2023) |
| "We showed that bladder cancer cells display an intrinsic resistance to nintedanib treatment in vitro, independently of their FGFR3 status." | ( Corral, S; Del Pozo, N; Hilberg, F; Marqués, M; Martínez de Villarreal, J; Real, FX; Sánchez-Díaz, M; Schweifer, N; Zagorac, I, 2023) |
| "Patients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease have limited treatment options." | ( Degraff, DJ; Drabick, J; Emamekhoo, H; Gartrel, B; Hauke, R; Holder, SL; Joshi, M; Kaag, M; Kilari, D; Liao, J; Merrill, S; Sankin, A; Schell, T; Stein, M; Tuanquin, L; Walter, V; Warrick, J; Zakharia, Y; Zheng, H; Zhu, J, 2023) |
| "Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination." | ( Ambite, I; Babjuk, M; Cavalera, M; Chaudhuri, A; Esmaeili, P; Hien, TT; Sabari, S; Svanborg, C; Wan, MLY, 2023) |
| "Muscle-invasive bladder cancer remains a challenging disease associated with significant morbidity and mortality; however, increasing options in systemic therapy and an increasingly personalized approach to cancer treatment suggest continued future improvements in patient care." | ( Cockrell, DC; Rose, TL, 2023) |
| "During the BCG drug shortage, eligible bladder cancer patients were less likely to receive gold standard intravesical BCG with a large variation in treatment patterns between US states." | ( Chun, B; Davies, BJ; Gabriel, N; He, M; Hernandez, I; Jacobs, BL; Jones, C; Vasan, R, 2023) |
| "Half of patients with muscle-invasive bladder cancer worldwide may not receive curative-intent therapy." | ( Chau, A; Cutie, CJ; Dickstein, RJ; Guerrero-Ramos, F; Hafron, JM; Keegan, KA; Maffeo, JC; Messing, EM; Mir, MC; Morris, D; Palou, J; Raybold, B; Rodriguez, O; Scarpato, KR; Stromberg, KA; Tyson, MD, 2023) |
| "Local treatment of bladder cancer faces several limitations such as short residence time or low permeation through urothelium tissue." | ( Alvarez-Lorenzo, C; de Freitas, LF; de Lima, CSA; Ferreira, AH; Kadłubowski, S; Lugão, AB; Pereira-da-Mota, AF; Rial-Hermida, MI; Varca, GHC; Vivero-Lopez, M, 2023) |
| "The model can predict the prognosis of bladder cancer patients and their immune infiltration status, which may also provide a reference for tumor immunotherapy." | ( Chen, A; Cui, B; Mao, C; Xu, C, 2023) |
| "The treatment of muscle-invasive bladder cancer is moving toward the individualization of treatment options based on specific tumor and patient characteristics and away from the one-size-fits-all approach that has dominated this space for the last couple of decades." | ( Koshkin, VS; Osbourne, AS; Singh, A, 2023) |
| "Patients with non-muscle invasive bladder cancer (NMIBC) that are unresponsive to Bacillus Calmette-Guérin (BCG) have historically had limited treatment options." | ( Brum Reis, I; Cardoso de Arruda Camargo, G; Cristina Dias, Q; Durán, N; José Fávaro, W; Oliveira, G; Ribeiro de Souza, B, 2023) |
| "Most patients with muscle-invasive bladder cancer (MIBC) are not cured with platinum chemotherapy." | ( Bastos, MMSM; Batista da Costa, J; Bianchi-Frias, D; Black, PC; Carvalho, H; Chatterjee, P; Colaço, B; Coleman, IM; Faustino-Rocha, A; Ferreira, R; Ferreirinha, P; Gil da Costa, RM; Lam, HM; Levesque, C; Lopes, C; Mendes, J; Moreira-Pais, A; Nelson, PS; Neto, T; Oliveira, PA; Pinto da Cunha, N; Santos, C; Sweeney, CJ; Vilanova, M; Wright, JL, 2023) |
| "Trans-Urethral Resection of Bladder Tumors (TURBT) is a critical step in diagnosis, staging and treatment of bladder tumors." | ( Abdelwahed, M; Assem, A; Kassem, A; Lotfi, A; Sherif, M, 2023) |
| "Systemic therapy for muscle-invasive bladder cancer (BC) remains dominated by cisplatin-based chemotherapy." | ( Chen, C; Fan, G; Gao, D; Gong, Y; Lu, J; Ma, J; Niu, Q; Tao, Y; Wang, R; Wang, Z; Yang, E; Yu, X, 2023) |
| "A group of patients with urothelial bladder cancer, presenting for the first time for definitive treatment, were prospectively enrolled from 2013 to 2017." | ( Abeygunasekara, A; Dissanayake, V; Ediriweera, D; Goonewardena, S; Jayasekara, R; Lokuhetty, D; Malalasekera, AP; Perera, N; Wettasinghe, K, 2022) |
| "In muscle-invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) combined with radical cystectomy (RC) is critical in reducing disease recurrence, with GC (gemcitabine and cisplatin) being one of the most commonly used NACs." | ( Chen, C; Cheng, H; Ding, H; Lu, L; Tian, J; Wang, H; Wang, Z, 2023) |